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Abstract 
Lead-oriented synthesis (LOS) is a concept that seeks to underscore the usefulness of 
developing new methodologies suitable for making a diverse library of highly three-dimensional 
small organic molecules with controlled molecular properties that qualify them to most likely 
serve as lead compounds or be in the 'lead-like' space. The 'top down' approach to LOS seeks to 
gain rapid access to complex polycyclic assemblies which can then be deconstructed or 
modified through ring addition, cleavage and expansion to generate multiple, diverse lead-like 
scaffolds. This strategy hopes to solve the problem of high attrition rates in drug discovery. 14 
diverse sp3-rich scaffolds have been synthesized through this means from relatively cheap and 
simple materials using a novel oxidative dearomatisation reaction as the complexity-generating 
step. The scaffolds have been decorated along different vectors with exemplar medicinal 
chemistry capping groups to generate 52 final compounds, with their molecular properties 
assessed by LLAMA (Lead-likeness and Molecular Analysis) prior to the decoration, and shall be 
tested for biological activity against a wide range of targets. 
Chapter 1 discusses the the general overview to small molecule drug discovery. Some of the 
issues touched are the high attrition rates of drug discovery, factors linked to such attrition 
rates and the importance of synthetic chemistry in the drug discovery process.  
Chapter 2 discusses the key scaffold synthesis and the application of the ‘top down’ approach 
to generate complex and diverse molecular scaffolds.  
Chapter 3 discusses the functionalisation of the diverse scaffolds along different vectors to 
generate final compounds for biological screening, as well as the LLAMA analysis of such 
compounds. 
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Abbreviations 
1D  One-dimensional 
1H-1H COSY Proton-proton correlation spectroscopy 
2D  Two-dimensional 
3D  Three-dimensional 
ADMET Absorption, distribution, metabolism, excretion and toxicity 
All  Allyl 
AlogP  Atom-based computed value of the logarithm of partition coefficient 
ATP  Adenosine triphosphate 
BCR  Benzoyl CoA reductase 
BINAP  [2,2’-bis(diphenylphosphino)-1,1’-binaphthyl] 
Bn  Benzyl 
br.d  Broad doublet 
br.s  Broad singlet 
CAN  Cerium ammonium nitrate 
Cbz  Benzyloxycarbonyl 
clogP  Fragment-based computed value of the logarithm of partition coefficient 
d  Doublet 
Da  Dalton 
DCM  Dichloromethane 
dd  Doublet of doublet 
ddd  Doublet of doublet of doublet 
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dddd  Doublet of doublet of doublet of doublet 
ddt  Doublet of doublet of triplet 
DIBAL  Diisobutylaluminium hydride 
DIPEA  N,N-Diisopropylethylamine 
DMAP  4-Dimethylaminopyridine 
DMF  Dimethylformamide 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
DOS  Diversity-oriented synthesis 
dr  Diastereomeric ratio 
dt  Doublet of triplet 
dtd  Doublet of triplet of doublet 
EDC  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
Et3N  Triethylamine 
FBDD  Fragment based drug discovery 
FDA  Food and Drug Adminstration 
Fsp3  Fraction of sp3 carbon atoms 
hept  Heptet 
HFIP  Hexafluoroisopropanol 
HMBC  Heteronuclear multiple bond correlation 
HMQC  Heteronuclear multiple quantum coherence 
HOBT  1-Hydroxybenzotriazole 
7 
 
HRMS  High resolution mass spectrometry 
HTS  High throughput screening 
IND  Investigational New Drug 
i-Pr  Isopropyl 
IR  Infrared 
J  Coupling constant 
LCMS  Liquid chromatography-mass spectrometry 
LLAMA  Lead-likeness and Molecular Analysis 
LOS  Lead-oriented synthesis 
m  Multiplet 
Ms  Methanesulfonyl 
NaDPH  Nicotine adenine dinucleotide phosphate 
NDA  New Drug Application 
NMR  Nuclear magnetic resonance 
NOE  Nuclear overhauser effect 
NOESY  Nuclear overhauser enhancement spectroscopy 
PAINS  Pan assay interference compounds 
PIFA  Phenyliodine bis(trifluoroacetate) 
PMI  Principal moment of inertia 
PMP  Para-Methoxyphenyl 
PPA  Polyphosphoric acid 
ppm  parts per million 
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q  Quartet 
qd  Quartet of doublet 
quint  Quintet 
Rf  Retention factor 
RO3  Rule of three 
rt  Room temperature 
s  Singlet 
SBDD  Structure-based drug discovery 
sext  Sextet 
SNAr  Nucleophilic aromatic substitution 
SPR  Surface plasmon resonance 
t  Triplet 
TBA  Tetrabutylammonium 
TBS  tert-Butyldimethylsilyl 
tBu  tert-Butyl 
td  Triplet of doublet 
tdd  Triplet of doublet of doublet 
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran 
TLC  Thin layer chromatography 
TMS  Trimethylsilyl 
TosMIC Toluenesulfonylmethyl isocyanide 
Ts  p-Toluenesulfonyl 
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tt  Triplet of triplet 
Z-Gly-OH N-Carbobenzyloxy glycine 
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1.0 Introduction 
1.1 A general overview of small molecule drug discovery 
Drug discovery is a multidisciplinary and complex process which can take 12-15 years to 
complete and can cost in excess of $1 billion for the development of a new drug. The process 
usually begins as a result of a clinical condition with no suitable chemotherapy and this 
motivates researchers to seek a solution. The first step in a drug discovery program is the 
identification of a target to be modulated. The term target applies to a range of biological 
entities such as proteins, DNA and RNA. A good target has to be druggable, efficacious, safe 
and, meet both clinical and commercial needs. Once the target is identified, a hypothesis can be 
put forward predicting a therapeutic effect upon the inhibition or activation of the target. The 
target is then validated using a range of techniques from in vitro tools and using whole animal 
models, to the modulation of a desired target in patients of interest. Despite the fact that each 
target-validation technique may be right in its own context, a multi-validation approach of 
targets significantly increases the credibility of the observed outcome.1 
After target identification and validation, the hit and lead discovery phase commences. It is at 
this stage that compound screening methodologies are developed. A hit can be defined as a 
molecule with a desired activity and whose activity can be confirmed after retesting. Different 
screening protocols exist for hit identification. An example is high throughput screening (HTS) 
which involves the screening of an entire compound library (which could be of the order of 1 
million samples)2 directly against the target; or in a more complex protocol, such as a cell-based 
assay, whose activity is dependent upon the target but which would require the confirmation of 
the site of action through secondary assays. Other screening paradigms which may be chosen 
from include focused screen, fragment screen, structure-aided drug design, virtual screening, 
physiological screening and NMR screening.1,3 Apart from de novo and HTS methods of sourcing 
hits, scientists also turn to nature and biotechnology for biologics that may be progressed into 
vaccines and monoclonal antibodies.4,5 
The next stage is the hit-to-lead phase where structure-activity relationship (SAR) investigations 
are carried out on each hit to measure the activity and selectivity of each compound. The aim is 
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to refine the hits to produce more potent and selective, but less toxic compounds. New binding 
sites on the target may be discovered in the process. Subsequently, absorption, distribution, 
metabolism, excretion and toxicological (ADMET) tests are carried out on the lead compounds 
to determine their pharmacokinetics. The final phase of drug discovery is the lead optimization 
phase. This is to increase the therapeutic index of the lead compound, maintaining its 
favourable properties and improving on undesirable features in its structure.1,4 
An Investigational New Drug (IND) application is filed with the Food and Drug Administration 
(FDA) for the optimized lead compound(s) prior to clinical development. Clinical development is 
divided into phase I to phase IV clinical trials which will determine whether the drug candidate 
should be approved for the market or not.5 Below is a diagrammatic representation of a typical 
small molecule drug discovery paradigm. 
 
 
 
 
 
Years     3            3                   6    1.5 
Figure 1. Drug discovery process and the corresponding timescale for each stage. IND, 
Investigational New Drug; NDA, New Drug Application; FDA, Food and Drug Administration. 
Adapted from source.1 
1.2 Attrition rate in drug discovery 
Although there has been a surge in the number of biologics approved as drug candidates in 
recent times by the FDA, small molecules are known to dominate the science of drug 
discovery.6 However, the success rate of new chemical entity (NCE) drug discovery, from first-
in-man clinical trial to approval by the FDA is very low (11% for all disease types). So, there is an 
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89% chance that a drug candidate will fail during clinical development. Some of the factors 
responsible for the undesirably high attrition rate are poor pharmacokinetic properties, lack of 
efficacy and safety considerations.7 The conclusion above is drawn from a study that was 
carried out, for candidates subjected to clinical development from 1991 to 2000 by 10 big 
pharmaceutical companies in Europe and the United States. Even till 2019, drug discovery 
success rate is still not impressive considering the fact that only 32 small molecules were 
approved by the FDA in the same year.8 
 
Figure 2. Drug discovery success rate from phase I clinical trial to registration. Adapted from 
source.7 
1.2.1 Factors linked to attrition in drug discovery 
Right from the time of Lipinski’s introduction of the ‘rule of five’, synthetic chemists have 
become more aware of the importance of physicochemical properties in drug discovery. Some 
of the properties deemed to be important in this context are lipophilicity, number of aromatic 
rings, molecular weight, saturation and the number of chiral centres present in a drug 
candidate.9–12 
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Safety of candidates is very important in drug discovery. Therefore, toxicity related issues are a 
major cause of attrition at the preclinical stage. It has been observed that less polar or more 
lipophilic compounds have a higher probability of exhibiting increased toxicity.10 Also, aromatic 
ring count is another factor that has been observed to be important in early stage drug 
discovery. Increasing the number of aromatic rings in a molecule leads to increased binding on 
biological targets. However, more than three aromatic rings in a molecule correlates with poor 
developabilty, decreased aqueous solubility and increased lipophilicity; and hence can increase 
the risk of attrition.11 
On the other hand, an increase in the complexity of drug candidates has been observed to 
correlate well with success. It results in a better biological target/candidate complementarity 
which may lead to additional interactions inaccessible to flat molecules, and hence improving 
potency and selectivity. This is also supported by the fact that many drugs are offshoots of 
complex and diverse natural products. An attempt has been made to measure complexity using 
the carbon bond saturation and the number of chiral centres present in a molecule. Saturation 
can be measured as a fraction of sp3 (Fsp3) carbons present in a molecule with respect to the 
total carbon count. Increasing the Fsp3 and number of chiral centres in a drug molecule 
increases its chances of success.12 
1.3 The importance of synthesis in drug research and development 
Small organic molecules play crucial roles in drug discovery. Of the 6000 potential drug targets 
in the human genome, only about 300 have been targeted by approved drugs. There are still 
many diseases with limited or no treatment options. Nevertheless, the impact of approved 
drugs on public health is outstanding.13 
A number of approaches have been used to access complex and diverse scaffolds with the 
potential of targeting biologically relevant chemical space. A few of such approaches will be 
reviewed in this report. Below is a diagram that depicts the pharma space relevant to this 
project. 
16 
 
 
Figure 3. A graph indicating lead-like space and optimal drug-like space. Adapted from source.14 
1.3.1 Diversity-oriented synthesis 
In a study in 2008, it was discovered that 0.25% of molecular frameworks were found in 50% of 
known cyclic organic compounds.15 It therefore means chemists tend to synthesise compounds 
based on already known frameworks. Diversity-oriented synthesis (DOS) – a term first 
introduced by Schreiber16 - was intended to solve an important problem in chemical biology 
which is the design and synthesis of libraries that can modulate a wide range of biologically- 
relevant chemical space. The aim of DOS is to provide access to structurally complex and 
diverse molecules which combinatorial chemistry fails to achieve. In DOS, structural complexity 
is desired because many small molecules known to modulate protein-protein interactions are 
complex natural products. Equally, structural diversity is desired because diverse scaffolds are 
more likely to be successful in chemical genetic-like phenotypic screens which are cell- or 
organism based. DOS is therefore different from target-oriented synthesis where a preselected 
protein target is used for screens of structurally similar compound libraries.15–18 Three different 
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pathways to diversity-oriented synthesis have been reviewed in the past and are discussed 
below.19,20 
Appendage or substitutional diversity: This has been termed the simplest process for 
generating molecular diversity. It involves the functionalization of vectors inherent in a scaffold 
with different building blocks. In this way, many diverse compounds can be synthesized 
depending on the number of functional groups the molecular skeleton carries.19 Shair and co-
workers21 demonstrated a biomimetic, solid-phase synthesis of a complex scaffold via oxidative 
dearomatization as shown below. 
 
Scheme 1. Natural product inspired complexity-generating oxidative cyclisation.19,21 
The product 2 has six different points of possible orthogonal attachment to different building 
blocks, thereby having the potential to generate diversity. 
Sterochemical diversity: Increasing the stereochemical diversity of a biologically active 
molecule increases its chance of modulating the target at different orientations. Therefore, 
methodologies that impart diastereo- or enantioselectivity on products of reactions are 
valuable in drug discovery.19 An example is shown below in the work of Jacobsen and Chavez22 
using chiral catalysis to override substrate bias in a Diels-Alder reaction. 
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Scheme 2. Demonstrating stereochemical diversity through chiral catalysis.19,22 
Using the catalyst (1R,2S)-7, the product 5 was obtained. This is also consistent with the 
stereochemical bias imparted on the reaction by the methyl group on the chiral centre of 3. 
However, such bias can be overridden by using the enantiomer (1S,2R)-7 instead, thereby 
yielding compound 6 as product.19,22 
Skeletal diversity: Pathways that lead to diverse molecular skeletons are important in diversity-
oriented synthesis. Three approaches have been described to achieve this objective. Therefore, 
skeletal diversity can be achieved by: one, reacting the same part of a molecule with different 
reagents to generate diverse scaffolds; two, using a molecule that is densely functionalized by 
orthogonally pairing the different functional groups present in the molecule to generate diverse 
scaffolds; and finally using different substrates - pre-encoded with different structural features 
subjected to the same type of reactions – to generate diverse scaffolds.19,20 
Illustrating the first approach, Schreiber and co-workers23 reacted the same part of the triene 8 
with different dienophiles to generate diverse scaffolds as shown in Scheme 3 below. Less 
reactive tri- and tetrasubstituted dienophiles such as 13 and 15 gave monocyclization products. 
However, using halogenated quinones such as 15, led to products that spontaneously 
underwent dehydrohalogenation and aromatization to give benzene derivatives. 
19 
 
 
Scheme 3. Syntheses of diverse scaffolds by reacting the same part of a molecule with different 
reagents.19 
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For the second approach, Porco and co-workers24 demonstrated the syntheses of diverse 
scaffolds by orthogonally pairing the different functional groups of a densely functionalised 
molecule as shown below. 
 
Scheme 4. Syntheses of diverse scaffolds through the orthogonal pairing of functional groups on 
the same substrate.20,24 
A classical example of the third approach to skeletal diversity is the work done by Oguri and 
Schreiber25 inspired by the Mejia-Oneto and Padwa’s26 synthesis of indole alkaloids through the 
[3+2] cycloaddition of a carbonyl ylide with a pre-encoded indole ring on different substrates. 
Distinct molecular skeletons were therefore obtained as illustrated below. 
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Scheme 5. Illustrating skeletal diversity using different substrates with pre-encoded structural 
features.27 
The Rh(II) catalyst interacts with the diazo groups of 23, 24 and 25 to form the respective Rh 
carbenoids. Each of the carbenoids then interacts with the neighbouring carbonyl group to 
form the ylide that undergoes a [3+2] cycloaddition with the 2,3-double bond of the indole ring 
to form the products.25 
1.3.2 Lead-oriented synthesis 
Lead-oriented synthesis14 (LOS) is a concept that underscores the usefulness of developing new 
methodologies suitable for making small molecules in the ‘lead-like space’, thereby enhancing 
optimisation. It has been observed that there is an unintentional bias towards the synthesis of 
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non-lead-like small molecules due to the deficiencies of current synthetic methodologies. With 
respect to Figure 3, the lead-like space gives room for the optimisation of small molecules 
thereby improving the therapeutic indices of the final drug candidates.  
As mentioned earlier, the Lipinski ‘rule of five’ for orally bioavailable drugs and other studies 
have continually stressed the importance of physicochemical descriptors to drug discovery.9,14 
The key descriptors that correlate strongly with success are molecular weight, lipophilicity and 
the fraction of sp3-hybridised carbon.28 The lead-like space has been defined as -1 < clog P < 3 
for lipophilicity and 14 ≤ heavy atoms ≤ 26 for molecular size (or a molecular weight range of 
250 – 350 Da). Factors to consider in a lead-oriented synthesis programme include lipophilicity, 
molecular size and complexity, molecular shape and substructural considerations.14 
Lipophilicity is probably the most important of the factors listed above. A high logP usually 
favours the binding of small molecules to biological targets thereby enhancing potency. 
However, of concern is the resultant poor aqueous solubility and promiscuous binding to 
undesired targets which may lead to toxicity and side effects, and consequently, attrition. The 
advantage of starting a drug discovery programme with small molecules is that they more 
efficiently sample biologically relevant chemical space than bigger molecules and they have 
more utility for optimisation. The three-dimensional shape and aromatic character of small 
molecules are also becoming increasingly important. Increasing the number of aromatic rings 
decreases aqueous solubility, as well as the observation that highly aromatic molecules have 
high rates of attrition. Finally, there are undesirable functional groups and substructures that 
are problematic to drug discovery due to their ability to make a molecule unstable, electrophilic 
or have a potential for redox chemistry which should be avoided.14 
The Marsden and Nelson groups have made significant strides towards making small molecules 
that fall within the lead-like space of which a few will be touched in this review. The groups 
have developed two approaches towards accessing lead-like scaffolds. They are the bottom-up 
and top-down approaches discussed below. 
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1.3.2.1 The bottom-up approach to lead-oriented synthesis 
The bottom-up approach to LOS is a strategy developed in the Marsden and Nelson groups to 
make specific classes of small polyfunctionalised substrates that can be cyclised to afford 
complex and diverse molecular scaffolds using orthogonal reaction toolkits.29 
Drawing inspiration from the work of Licini30, Marsden and co-workers31 demonstrated the 
bottom-up approach by using α-allyl α-amino acid derivatives as substrates. The amino end was 
armed with functional groups that can be tuned for cyclisation with either the adjacent ester or 
alkene functionality. Diversity was also introduced by the choice of the skeletal framework of 
the amino acid derivative itself. From four amino acids and six pairing reactions, 22 distinct 
scaffolds were synthesized. A typical example is illustrated below. 
 
Scheme 6. Illustrating the bottom-up approach to lead-oriented synthesis.31 
1.3.2.2 The top-down approach to lead-oriented synthesis 
The top-down approach to LOS, also developed in the Marsden and Nelson groups, seeks to 
gain access to complex polycyclic assemblies which can then be broken apart or modified using 
a toolkit of synthetic methodologies to produce multiple diverse lead-like scaffolds. The 
complex polycyclic assembly is designed in such a way that it possesses bonds that can be 
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selectively cleaved and modified. The complexity-generating reaction also has to take place in a 
single step.29 
 
 
Figure 4. An overview of the proposed strategy to make a complex polycyclic assembly and the 
complexity generating illustrations29 
Drawing inspiration from the work done by Mascarenas and co-workers32; Nelson, Marsden and 
co-workers33 made β-alkoxy-γ-pyrones from kojic acid. The β-alkoxy-γ-pyrones were made to 
undergo [5+2] cycloaddition reactions to generate the scaffold to be used to demonstrate the 
top down approach to LOS.29 This is illustrated in the scheme below.  
Scheme 7. Preparation of β-alkoxy-γ-pyrones as starting materials for generating scaffolds to 
demonstrate the top-down approach to LOS.33 
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As stated earlier, the intramolecular [5+2] cycloaddition of the β-alkoxy-γ-pyrones generated 
the scaffolds in good yields as shown in the scheme below. 
 
Scheme 8. Synthesis of scaffolds for the demonstration of the top-down approach to LOS33 
Demonstrating the top down approach on synthesised scaffolds via ring addition, cleavage and 
expansion; 52 fragments were made for biological screening.33 An example of each class of 
scaffold elaboration is shown in the scheme below. 
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Scheme 9. Illustrating the top-down approach using the ring addition, cleavage and expansion 
strategies33 
1.3.3 Fragment based drug discovery 
Fragment-based drug discovery (FBDD) is an approach that makes use of lower molecular 
weight (typically 120-250 Da) screening libraries as compared to HTS compound libraries 
(probably from 250–600 Da).34 Hits from fragment-based approaches are primarily detected by 
biophysical methods such as surface plasmon resonance (SPR), protein crystallography and 
NMR among others, rather than bioassays because of the typically weak inhibition (10 µM–
mM) of such hits. Fragment hits are highly suitable for optimisation into drug-like compounds 
because they possess high ligand efficiency. However, compared to HTS hits, they are simpler, 
less functionalised and possess lower affinity.34 
Theoretically, a high quality fragment library samples by far a greater proportion of biologically 
relevant chemical space than a high quality HTS library as there is an inverse relationship 
between the molecular complexity of a compound and its probability of possessing good 
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complementarity with a target protein.35,36 Therefore fragments in a library will have a high 
likelihood to sample chemical space as thoroughly as possible thereby forming high quality 
interactions with the target even if the binding affinity is low. Due to the extensive exploration 
of chemical space, hit-rates from fragments can be used to determine the chemical tractability 
of a target.37 Structure-based drug design (SBDD) is often used in conjunction to help in the 
design and synthesis of fragments with desirable properties. It also guides the control of 
molecular properties as fragments are grown into leads.38,39 
Congreve and co-workers in 2003 proposed that on average, fragment hits obey a ‘rule of three 
(RO3)’ which are: molecular weight ≤ 300 Da, the number of hydrogen bond donors and 
acceptors ≤ 3 respectively and cLogP ≤ 3.40 The RO3 is still very relevant today. However, other 
factors have come into play and these are to ensure that fragment libraries: contain 
pharmacophores that induce binding to biologically relevant chemical space; have appropriate 
size and shape distribution; contain synthetic handles or growth vectors to aid optimisation; 
and do not contain groups that are highly reactive or aggregate in solution, examples of which 
are, pan assay interference compounds (PAINS) and aggregators that constitute problems at 
high concentrations, during assays.41–46 
A more elaborate guideline for the chemical characteristics of good fragments was published by 
Rees and Murray in 2016.47 The properties highlighted are discussed below. 
Molecular recognition: Fragments should contain diverse, usually polar groups, for binding to 
the target protein. It is desirable to express a given binding pharmacophore in different 
chemotypes. It is also important for fragments to possess multiple synthetically accessible 
vectors for fragment growth in three dimensions in order to investigate new binding 
interactions.47 
Physicochemical properties: The molecular weight of fragments should be between 140 – 230 
gmol-1, the non-hydrogen atoms should be between 10 – 16 and the lipophilicity (clogP) should 
be between 0.0 – 2.0. They also have to possess properties required for biophysical screening at 
high concentrations – the aqueous solubility should preferably be more than or equal to 5 mM 
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in 5% DMSO, or other screening co-solvents and should not possess highly reactive groups or 
groups that can aggregate in solution.47 
Synthetic tractability and shape: Fragments should be synthetically tractable at 50 – 100 mg 
scale and can be made in not more than 4 steps from commercially available reagents. They 
should possess a variety of 3-dimensional shapes for each scaffold and pharmacophore; the 
number of freely rotatable bonds should be between 0 and 3 and the number of chiral centres 
should be between 0 and 1, sometimes 2.47 
As a result of the size range of HTS hits, the hit-rates are often low and many of the hits do not 
progress to optimisation.48,49 In the same vein, some of the initial drug-like properties of HTS 
hits may be lost or reduced when optimized, thereby reducing the scope of developability.50–52 
FBDD aims to solve the problem of poor hit-rates from HTS campaigns as well as improving 
optimisation to drug-like compounds. More than 26 protein targets have been investigated by 
fragments.53,54 A typical example of the usefulness of FBDD is discussed below. 
HTS screens to identify compounds that bind to the ATP site of the bacterial enzyme DNA 
gyrase proved unsuccessful.55 However, over a dozen fragments were identified as needle-hits 
(or fragment hits) binding to the same target by using a high concentration bioassay screening 
technique. The screening methodology was validated by biophysical methods such as NMR, SPR 
and X-ray crystallography. Indazole, highlighted in blue in Figure 5, was one of the fragment 
hits. Selected needle hits binding to the same target were used to obtain 3-D structural 
information which proved to be a useful optimisation guide that gave the lead compound 46 
that is more than 10,000 times as active as the indazole fragment.34 
 
Figure 5. Lead compound obtained from fragment-based methods with the starting fragment in 
blue 
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 In recent times, it has been stated that FBDD has been used less systematically in academia. 
Therefore a call has been made for a deeper collaboration between players in industry and 
academia so that industrial discoveries will not be reinvented.41 
1.4 Aim and objectives of the project 
The aim of the project was to prepare and decorate complex and diverse molecular scaffolds 
for hit identification and optimisation through the top-down approach to lead-oriented 
synthesis. 
The objectives of the project were: 
i. To make the complex polycyclic assembly (primary scaffold) to be used as a starting 
point for the implementation of the top-down strategy to lead-oriented synthesis. 
The primary scaffold was to be made from a multistep sequence of which the final 
step is illustrated below. Also, some of the points of diversification for a potential 
demonstration of the top down approach to LOS are illustrated with the blue arrow. 
 
Scheme 10. Synthetic route for scaffold to be used to demonstrate the top-down approach to 
LOS 
ii. To modify the complex polycyclic assembly to generate multiple diverse lead-like 
scaffolds. The primary scaffold was to be used to generate secondary scaffolds 
through ring addition, cleavage and expansion as shown below. 
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Figure 6. Potential diversification reactions for demonstrating the top-down approach to LOS 
iii. To decorate the lead-like scaffolds prepared in (ii) with exemplar medicinal 
chemistry capping groups to give about 50 final compounds for biological screening. 
Some of the decoration reactions are alkylation, reductive amination and amidation 
among others.The molecular properties of these compounds will be assessed by 
LLAMA, a lead-likeness computational software developed within the Marsden and 
Nelson groups56, to ensure they are in the lead-like space. Two examples are 
illustrated in the scheme below. 
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Scheme 11. Exemplar decoration reactions for secondary scaffolds generated from the top-
down approach to LOS 
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2.0 Results and discussion 1 
2.1 Dearomatisation 
Enzymatic dearomatisation reactions are known in nature. They can either proceed via 
oxidative mechanism (by the use of oxygenases) or reductive mechanism (by the use of 
reductases).57–60 However, there are chemoenzymatic61 or completely chemical means of 
making arenes or their derivatives lose aromaticity.57 
An example of a biocatalysed (regio- and stereoselective) oxidative dearomatisation by the use 
of the enzyme TropB is shown below. This step is important in the biosynthesis of the 
tropolone-based stipitatonic acid.62–64 
 
Scheme 12. Enzymatic oxidative dearomatisation towards the biosynthesis of stipitatonic acid62 
Also, under anaerobic conditions, benzoyl CoA redutase (BCR) found in the bacteria T. 
aromatica is known to catalyse the Birch-like dearomatisation of benzoyl CoA 60 to cyclohexa-
1,5-diene-1-carbonyl-CoA 61. Ferredoxin serves as the donor of the two electrons that are 
transferred to the aromatic ring as shown below.65 
 
Scheme 13. Enzymatic reductive dearomatisation of benzoyl CoA65 
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Dearomatisation leads to highly reactive intermediates which can spontaneously form carbon-
carbon and carbon-heteroatom bonds; or result in cascade reactions, and cycloadditions.57 
Therefore, it is a powerful tool for accessing complexity and diversity from relatively simple 
aromatics or heteroaromatics. It has been recognised as a bridge between rich sources of 
aromatic hydrocarbons and the alicyclic skeletons frequently found in bioactives.66–71 Two 
examples demonstrating the use of dearomatisation as a complexity-generating step in total 
synthesis are discussed below. 
Subjecting the phenol 62 to deprotonation, Corey and co-workers72 synthesised cedrene 64, via 
alkylative dearomatization as a key complexity-generating step as shown in Scheme 14. 
 
Scheme 14. Illustration of dearomatisation towards the synthesis of cedrene57 
Schulte and co-workers73 took advantage of the same concept in their synthesis of morphine 
68. Hydrozirconation of the alkyne followed by addition to the aldehyde 65, and subsequent 
protection of the resulting alcohol, gave the silyl ether 66 which was then subjected to a crucial 
dearomatisation reaction (via an intramolecular 4+2 cycloaddition) to give the teracyclic 
compound 67 that was pertinent to the synthesis of the target molecule. 
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Scheme 15. Illustration of dearomatisation towards the synthesis of morphine57 
Oxidative dearomatization, via a hypervalent iodine reagent, was employed for the complexity-
generating step in the synthesis of the key scaffold used in this project to demonstrate the top-
down approach to lead-oriented synthesis as shown in Scheme 10. 
2.2 Complexity-generating reactions for the key scaffold for LOS 
The primary scaffold used to demonstrate the top-down approach to lead-oriented synthesis in 
this work was made in the Marsden and Nelson groups and added to the European Lead 
Factory Joint Compound Library.74 The route used to access the scaffold is shown below. 
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Scheme 16. Discovery route for scaffold to be used to demonstrate the top-down approach to 
LOS 
Ammonolysis of the ester 69 gave the amide 70 which was then reduced with lithium 
aluminium hydride, protected and hydrogenated to afford the key amine 71 relevant to the 
synthesis of the scaffold. The amine 71 was reacted with different isocyanates to give ureas 
that were utilised in making variants of the scaffold (75-77) upon treatment with PIFA, as 
shown in the proposed mechanism below. 
Scheme 17. Proposed mechanism for the synthesis of key scaffold 
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Some of the decorations that had been carried out on the scaffold (with the decoration points 
indicated in red) are shown below (unpublished results). 
 
Figure 7. Decorations carried out on the scaffold obtained via oxidative dearomatisation 
The scaffold has two fused rings, two spirocyclic rings, a cyclic urea, an enone functionality and 
two stereocentres. Hence, it is a starting point of good quality for lead-oriented synthesis. 
Accessing the key precursor of the scaffold in large amounts is crucial to the project. Therefore, 
we had to develop an alternative route to the key amine 71 via a key aldehyde 80. Compound 
80 was obtained through the Heck reaction of the aryl iodide 79 with allyl alcohol. We 
envisioned transforming 80 to 71 to avoid the risk of using lithium aluminium hydride in the 
synthesis of 71 on a large scale (see Scheme 16). The opted route to the amine 71 and the 
scaffold is depicted below. 
 
Scheme 18. Optimised synthesis of scaffold through a key Heck reaction 
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Heck reaction75 is a typical cross-coupling reaction that can allow the formation of carbon-
carbon bonds between alkenes and; aryl, benzyl and styryl halides via palladium(0) catalysis. It 
works well with a wide range of substrates and it is known to give aldehydes and ketones as 
products when aryl halides are reacted with allyl alcohols under suitable conditions.76,77 A 
known drawback of intermolecular Heck reactions is that it requires high temperatures (about 
100 °C) to take place. Therefore, Jeffery developed a set of conditions77,78 that would enable 
the formation of products at milder temperatures (room temperature to 30 °C), using 
tetrabutylammonium chloride as a solid-solution phase transfer agent. This extends the scope 
of the reaction to substrates that are thermally unstable such as methyl vinyl ketone and 
acrolein. 
In their development of a catalyst system for alkyne metathesis and its application to the 
synthesis of natural products, Furstner and co-workers79 took advantage of the ‘Jeffery 
conditions’ to make the aldehyde 85 after performing a Heck reaction between 4-iodoanisole 
84 and allyl alcohol as shown below. 
 
Scheme 19. Heck reaction of 4-iodoanisole with allyl alcohol79 
Based on the precedent above (Scheme 19), 4-iodophenol 78 and 4-bromophenol 86 were 
benzylated to give the ethers 79 and 87 respectively in preparation for Heck reaction with allyl 
alcohol. 
 
Scheme 20. Benzylation of 4-iodophenol and 4-bromophenol 
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Attempts to make the key aldehyde 80 using the protected halophenols 79 and 87 are 
summarized in the table below. 
 
Entry Compound Reaction conditions Outcome 
1 87 AllOH (1.5 eq.), 1% Pd(OAc)2, Bu4NCl (1.0 eq.), 
NaHCO3 (2.0 eq.), DMF, 50 - 90°C, 43.5 h 
No reaction. Starting 
material detected by TLC 
and proton NMR of the 
crude reaction mixture 
2 87 AllOH (1.1 eq.), 5% Pd(OAc)2, 10% P-(o-Tol)3, 
Et3N, 110 °C, 17 h 
Unknown mixture 
monitored by TLC and 
proton NMR 
3 79 AllOH (1.1 eq.), 5% Pd(OAc)2, 10% P-(o-Tol)3, 
Et3N, 110 °C, 17 h 
Unknown mixture 
monitored by TLC and 
proton NMR  
4 79 AllOH (1.5 eq.), 1% Pd(OAc)2, Bu4NCl (1.0 eq.), 
NaHCO3 (2.0 eq.), DMF, 90 °C, 21 h 
Unknown mixture as 
monitored by TLC and 
proton NMR 
5 79 AllOH (1.5 eq.), 1% Pd(OAc)2, Bu4NCl (1.0 eq.), 
NaHCO3 (2.0 eq.), DMF, 50 °C, 20 h 
20:1 molar ratio of desired 
product to its branched 
isomer respectively as 
deduced from the proton 
NMR of the crude mixture. 
The aldehyde 80 was 
isolated in 82% yield. 
Table 2. A table showing the results of the Pd-coupling between allyl alcohol and, compounds 
87and 79respectively under different conditions 
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The proposed mechanism for the Heck reaction between the protected 4-iodophenol and allyl 
alcohol under ‘Jeffery conditions’ is shown below. 
Scheme 21. Proposed mechanism for the Heck reaction between the aryl iodide 79 and allyl 
alcohol 
The palladium (0) undergoes oxidative addition to the aryl iodide 79 to form the σ-
arylpalladium (II) complex 88 in the first step. The complex 88 then coordinates with the double 
bond of allyl alcohol for syn-insertion into the alkene to generate the σ-alkylpalladium(II) 
complex 89.The complex 89 then undergoes β-hydride elimination to give either the allylic 
product 90 or the enol 91 in the third step. The enol 91 once formed, tautomerises to the more 
thermodynamically stable aldehyde 80.80–82 
Selectivity in this case can be determined by the hydricity of HA and HB (see Scheme 21). Since 
HA is in principle more hydridic than HB, the major product obtained via β-hydride elimination, 
is expected to be the aryl-substituted allylic alcohol 90. However, the β-hydride elimination 
step is a reversible process which can lead to the re-insertion of the eliminated H-PdII-I species 
into the allylic double bond of 90, thereby enhancing isomerisation to the enol 91. Another 
factor that favours the formation of the enol 91 is the fact that the lone pairs on the oxygen 
atom of the alcohol 89 stabilise the consequent partial positive charge on the neighbouring 
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carbon atom when HB is eliminated. Sodium bicarbonate is used for the reductive elimination of 
the H-PdII-I species in order to turn over the catalyst.80,81 
However, Jeffery developed another set of conditions83 to achieve selectivity in obtaining the 
substituted allylic alcohol such as 90 as the major product instead of the aldehyde. This involves 
the use of silver carbonate or silver acetate instead of sodium bicarbonate for the reductive 
elimination step. Palladium acetate and triphenylphosphine are also needed in catalytic 
amounts. The silver ion (Ag+) is known to be a good trap for hydrohalic acids.84–87 Therefore, 
silver salts prevent the re-insertion of H-PdII-X (where X is a halogen) into an alkene such as 90 
and this in turn prevents isomerisation. 
Also, from the proton NMR of the crude product, the molar ratio of the aldehyde 80 and its 
branched isomer 96 is 20:1 respectively. This supports the alkene isomerisation mechanism and 
also shows that the migratory insertion step can pose problems to selectivity as shown below. 
The aldehyde 96 was isolated and characterized by both proton and carbon-13 NMR. Neither 
the allylic alcohol 90 nor 93 was detected in the proton NMR of the crude product. 
 
Scheme 22. Proposed mechanism for the formation of the contaminant aldehyde 96 in the Heck 
reaction between the aryl iodide 79 and allyl alcohol 
Reductive amination of the aldehyde 80 with benzylamine to give the secondary amine 81 was 
facile as shown below. 
41 
 
 
Scheme 23. Synthesis of the precursor to the key amine 71 
Subjecting 81 to double debenzylation via hydrogenation to give the key amine 71 using Pd/C as 
catalyst was sluggish. Only the mass of the mono-debenzylated product was detected by LCMS, 
even after adding acetic acid to the reaction system to prevent catalyst poisoning by the amino 
group.88 Using Pd(OH)2/C as catalyst instead of Pd/C in the presence of AcOH, the desired 
product was obtained (see Scheme 18). As stated earlier, accessing the key amine 71 in large 
amounts was crucial to the project. However, the hydrogenation of the secondary amine 81 on 
an 800 mg to 3.8 g scale took two days to reach completion but it took five days on a 13 g scale 
when telescoped from 80 without purification of the intermediate 81. This problem was solved 
by carrying out the hydrogenation step under pressure at 15 bar and 40 °C as shown below. The 
double debenzylation of 15 g of 81 was then accomplished in 24 h. 
 
Scheme 24. Accelerated synthesis of the key amine 71 
The primary amine 71 was then reacted with different isocyanates to give the different ureas 
82a-c (see Scheme 18). 
Other methods to synthesise key precursors of the primary scaffold were also investigated. One 
of such was the attempted reductive alkylation of carbamates and subsequent deprotection, as 
demonstrated by Dube and Scholte.89 Benzyl carbamate was reacted with the aldehyde 80 as 
illustrated in the scheme below. The mass of the intended product 97 was detected by LCMS 
but was not successfully isolated. 
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Scheme 25. Attempted alkylation of benzyl carbamate with the key aldehyde 80. 
Another method considered was the synthesis of primary amines from one-pot reductive 
amination of aldehydes via oximes as demonstrated by Delmas and co-workers90 As shown in 
Scheme 26 below, oximation of the aldehyde 80 with hydroxylamine followed by metal-in-acid 
reduction afforded the amine 98 in 44% yield. 
 
Scheme 26. Synthesis of an alternative primary amine as a key precursor of the primary scaffold 
The amine 98 was then reacted with isopropyl isocyanate towards the synthesis of the urea 82a 
as shown below. 
 
Scheme 27. Alternative route to the synthesis of the urea 82a 
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The ureas 82a-c were then used for the oxidative dearomatisation step to make variants of the 
primary scaffold 83a-c (see Scheme18). In an attempt to optimise scaffold synthesis, PIFA 
dearomatisation was carried out with the urea 82a at -78 °C. Only the mass of the starting 
material was observed by LCMS. However, upon allowing the reaction to warm up to room 
temperature for 1 h, both the scaffold 83a and the intermediate 100 were isolated in 15% and 
20% yields respectively. This supports the mechanism mentioned earlier (see Scheme 17). 
 
Scheme 28. Attempted optimisation of primary scaffold synthesis 
The expected stereochemical outcome for the primary scaffold is the cis-ring fusion based on 
previous work74 and the likely energetic preference for this over a trans-fused 6,5-ring system. 
We confirmed this in the case of the tosyl derivative of the scaffold by x-ray crystallography as 
shown in Figure 7. 
 
Figure 7. X-ray crystal structure of the tosyl variant of the primary scaffold 
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Comparatively, the PMP and isopropyl derivatives of the primary scaffold were obtained in 
higher yields than the tosyl derivative. This is presumably because amines are more nucleophilic 
than sulfonamides and therefore will serve as better Michael donors in the PIFA 
dearomatisation step (see Scheme 17). 
In order to determine the solution conformation of the variants of the primary scaffold, J values 
were looked at as depicted in table 1 below. However, the values are not consistent with truly 
axial/axial and axial/equatorial couplings, and therefore cannot be used to deduce the solution 
conformation of the variants of the primary scaffold. 
 
Entry Multiplicity/Jvalues 
in Hz for proton 6a 
Multiplicity/Jvalues 
in Hz for proton 7-HA 
Multiplicity/Jvalues 
in Hz for proton 7-HB 
R = i-Pr dd, J = 6.9, 5.3 dd, J = 16.1, 5.2 dd, J = 16.1, 6.9 
R = PMP t, J = 5.1 dd, J = 16.6, 5.0 dd, J = 16.6, 5.2 
R = Ts dd, J = 8.8, 5.8 dd, J = 15.9, 5.7 dd, J = 15.9, 8.8 
Table 1. Multiplicities and coupling constants for key protons of the primary scaffolds for LOS 
2.3 Double bond reduction ofenone scaffolds 
Reducing the double bonds of the scaffolds 83a-c to the corresponding saturated ketones is 
desirable because they can either be utilised in making secondary scaffolds with distinct 
molecular skeletons, or making final compounds for biological screening.  
Hydrogenation of the isopropyl derivative of the scaffold 83a in methanol using Pd(OH)2/C as 
catalyst gave a mixture of the ketone 101a and the acetal 102a as shown below. Carrying out 
the same reaction in ethyl acetate instead of methanol, only the mass of the starting material 
was observed by LCMS. 
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Scheme 18. Hydrogenation of the isopropyl variant of the primary scaffold 
However, performing a metal-catalysed hydrosilylation and subsequently hydrolysing the 
resulting silyl enol ether 103 with 1M HCl afforded the ketone 101a in 85% yield over two steps. 
The silyl enol ether 103 was isolated in 85% yield and characterised. However, in all cases, the 
reaction was telescoped, without further purification, to the ketone 101a. 
 
Scheme 19. Synthesis of the ketone of the isopropyl variant of the primary scaffold via 
hydrosilylation 
In the same vein, hydrogenation of the tosyl variant of the primary scaffold 83c in methanol 
gave a mixture of both the ketone 101c and the acetal 102c as deduced from the analysis of the 
proton NMR of the crude product. Subjecting the crude product to acid hydrolysis in THF gave 
the ketone 101c in 72% yield over two steps. The crystal structure of 101c is shown in Figure 8. 
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Scheme 20. Synthesis of the ketone of the tosyl variant of the primary scaffold 
 
Figure 8. X-ray crystal structure of theketone 101c 
The chair conformation is known to be more energetically stable for cyclohexane and 
cyclohexanone rings than the boat form. However, the carbonyl group in cyclohexanone rings is 
known to considerably lower the energy of the boat conformer with respect to the chair 
conformer.91–94 In the crystalline state, the cyclohexanone ring of 101c prefers the boat 
conformation as shown above. 
Also, it was observed that hydrogenation of the PMP variant of the scaffold 83b and the tosyl 
variant of the scaffold 83c in ethyl acetate using Pd(OH)2/C as catalyst gave the corresponding 
ketones in 69% and 83% yields respectively. As stated earlier, hydrogenating the isopropyl 
variant of the scaffold 83a under the same conditions was not successful. It could be that 83a is 
not soluble enough in ethyl acetate to be hydrogenated in the same medium. 
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Scheme 21. Hydrogenation of the PMP and Ts variants of the primary scaffold in ethyl acetate 
2.4 Attempted deprotection of the ketone of the tosyl and PMP variants of 
the primary scaffold 
The ketones 101b and 101c were sought to be deprotected (removal of the –R group) to afford 
the secondary urea nitrogen for functionalization with exemplar medicinal chemistry capping 
groups. 
Inspired by the work of Ankner and Hilmersson95, 101c was subjected to radical deprotection by 
exposing it to SmI2 in the presence of triethylamine and water. Only the mass of the starting 
material was observed by LCMS. 
 
Scheme 22. Deprotection of the ketone of the tosyl variant of the key scaffold 
However, exposing 101b to CAN gave the desired product 104 although there were difficulties 
with respect to reproducibility in terms of yield (14 – 95%) on a scale of 13 – 20 mg. The crystal 
structure of 104 is shown in Figure 9. The cyclohexanone ring of 104 adopts the boat 
conformation similar to that adopted by the cyclohexanone ring of 101c (see Figures 8 and 9). 
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Scheme 23. Deprotection of the ketone of the PMP variant of the key scaffold  
 
Figure 9. X-ray crystal structure of deprotected PMP ketone of key scaffold 
2.5 Generationof secondary scaffolds via ring addition 
Ring addition or fusion to the 6-membered ring of the derivatives of the primary scaffold (83a-
c) was one of the strategies used to generate secondary scaffolds. 
2.5.1 Ring fusion to the enone functionality of the primary scaffold 
The enone functionality of the variants of the primary scaffold was utilized to generate 
secondary scaffolds by the addition of rings as discussed below. 
Van Leusen reaction96 was used to append a pyrrole to the double bond of the isopropyl 
derivative of the key scaffold 83a as shown below. 
49 
 
 
Scheme 24. Pyrrole synthesis via Van Leusen reaction 
Also, Corey-Chaykovsky cyclopropanation97 was carried out on the double bond of the isopropyl 
derivative of the primary scaffold 83a to give 106a in 71% yield. The same reaction was carried 
out on the PMP derivative of the key scaffold 83b to give 106b in 64% yield. From the proton 
NMR of the crude reaction mixtures, the diastereomeric ratio for the product of the 
cyclopropanation of 83a is 13:2 while that of 83b is 3:1. However, the products 106a and 106b 
were isolated as single diastereomers respectively. An attempt to determine the 
stereochemistry of 106a by NOESY correlations was unsuccessful but this was solved by 
obtaining its x-ray crystal structure. For 106b, the stereochemistry was assigned by knowledge 
of that of its derivative 191 (see Scheme 88). 
 
Scheme 25. Cyclopropanation of the isopropyl and PMP variants of the primary scaffold 
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Selectivity in this case can be adduced to the fact that the ylide generated from 
trimethylsulfoxonium chloride is bulky. It therefore attacks from the face of the electrophilic 
double bond that is anti to the hindered pyrrolidine ring. The proposed mechanism is shown 
below. 
 
Scheme 26. Proposed mechanism for the Corey-Chaykovsky cyclopropanation of the primary 
scaffold 
It is known that desoxybenzoin and Δ4-cholestenone are substrates that seem to be resistant to 
the Corey-Chaykovsky reaction probably because of an enhanced ability to transfer protons to 
the dimethylsulfoxonium methylide 108 via enolisation.97 When the tosyl derivative of the 
primary scaffold 83c was subjected to the same reaction, only the mass of the starting material 
was observed by LCMS. The tosyl group is electron withdrawing and could enhance the acidity 
of the enolisable protons of the primary scaffold 83c. 
The last ring addition strategy to the enone functionality was demonstrated via the syntheses 
of pyrrolidines as described by Fray and co-workers.98 This ensued through the [3+2] 
cycloaddition of the derivatives of the primary scaffold 83a-c to an azomethine ylide. From the 
proton NMR of the crude reaction mixture, the diastereomeric ratio for the products of the 
reaction of 83b was 2:1. The two diastereomeric products (107 and 108) were isolated cleanly. 
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Deducing the diastereomeric ratios for the products of the reactions of 83a and 83c from the 
proton NMR of their respective crude mixtures proved difficult because of extensive signal 
overlap. However, single diastereomers (109 and 110) were isolated from each reaction after 
column chromatography. The stereochemistry of 107 was deduced from the NOESY correlation 
of the proton at position 6a (6a-H) and those at positions 8a and 11a (8a-H and 11a-H) while 
that of 109 was determined by the NOESY correlation between its 8a-H and 1-H as shown 
below. The stereochemistry of 110 was determined by the NOESY correlations of the derived 
alcohol 181 (see Scheme 72). 
 
 
Scheme 27. Synthesis of pyrrolidines via 1,3-dipolar cycloaddition of the variants of the primary 
scaffold to an azomethine ylide 
52 
 
In principle, it was expected that the major diastereomers formed in the 1,3-dipolar 
cycloaddition reactions will have the pyrrolidine ring syn to the urea ring for the same reason as 
in the case of the Corey-Chaykovsky reaction shown in Scheme 26. 
2.5.2 Pyridine synthesis 
Arcadi and co-workers99 developed a method for the synthesis of pyridines from ketones or 
aldehydes and propargylamine via gold catalysis. Therefore, refluxing the ketone 101c with 
propargylamine in the presence of sodium tetrachloroaurate (III) dihydrate gave regiomeric 
pyridines (1:2 isomeric ratio from the proton NMR of the crude product) that were not 
separated cleanly. 
 
Scheme 28. Pyridine synthesis from the ketone of the tosyl variant of the primary scaffold 
Therefore, the tosyl derivative of the primary scaffold 83c was used for the same reaction to 
see if it would allow for regiocontrol. However, only the mass of the imine 113 was observed by 
LCMS. 
 
Scheme 29. Attempted pyridine synthesis from the tosyl derivative of the primary scaffold 
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Using the cyclopropanes 106a and 106b for the same reaction, product formation was observed 
by both LCMS and the proton NMR of the crude reaction mixture. However, only the PMP 
variant 115b could be isolated cleanly. 
 
Scheme 30. Pyridine synthesis from the cyclopropane-fused scaffolds 
An attempt was made to synthesize a substituted pyridine from the cyclopropane 106a by using 
a substituted propargylamine. Therefore, 106a was refluxed with 3-phenylpropargylamine 
hydrochloride under the same conditions but in the presence of DIPEA to release the free 
amine for condensation with the ketone, followed by cyclization and then aromatisation. 
Product formation was observed by both LCMS and the proton NMR of the crude reaction 
mixture. However, the product 116 was not isolated cleanly. It was obtained with an unknown 
impurity after column chromatography. 
 
Scheme 31. Attempted synthesis of a substituted pyridine  
2.5.3 Attempted Indole synthesis 
Attempts were also made to use the cyclopropane 106a to synthesise the indole 118 via the 
Fischer method100 or via the annulation of o-iodoanilines to ketones developed by Chen and co-
workers.101 However, neither approach was successful. For the Fischer indole method, only the 
masses of the intermediate cyclopropane 106a and the phenylhydrazone 117 were observed by 
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LCMS. Also, for the o-iodoaniline annulation method, the masses of the intermediate 
cyclopropane 106a and the imine 119 (or its tautomeric enamine 120) were detected by LCMS 
but not the product. 
 
 
Scheme 32. Attempted indole synthesis via the Fischer method, and the annulation of o-
iodoaniline to the cyclopropane 106a 
2.6 Secondary scaffolds generated via ring cleavage 
Urea cleavage of 101a-c and the cleavage of the double bond of the enone 83a were 
investigated to generate ring-cleaved secondary scaffolds. 
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2.6.1 Urea cleavage of ketones of the primary scaffold 
Attempts to cleave the urea functionality of 101c under the conditions tabulated below were 
unsuccessful.  
 
Entry Compound Condition Outcome 
1 101c K2CO3, MeOH, 70 °C, 5 h Only the starting material was 
detected by LCMS 
2 101c Ba(OH)2.8H2O, EtOH/H2O, 100 °C, 6 h Only the starting material was 
detected by LCMS 
3 101c NaOMe, PhMe, 80 °C, 1 h Only the starting material was 
detected by LCMS 
4 101c NaOMe, PhMe, 80 °C, 4 h Only the starting material was 
detected by LCMS 
5 101c NaOMe, PhMe/MeOH, 80 °C, 1 h Only the starting material was 
detected by LCMS 
Table 3. Attempted cleavage of the urea functional group of the ketone of the tosyl variant of 
the primary scaffold 
However, cyclic ureas are known to be deoxygenated by lithium aluminum hydride to form 
aminals which can then be subjected to acidic cleavage to afford diamines as demonstrated by 
Keyserlingk and Martens.102 Carrying out the reaction with the tosyl-substituted urea 101c, it 
was noticed that the second step was not needed because the compound had already 
spontaneously undergone a reductive cleavage with concomitant reduction of the ketone. This 
is presumably due to the toluenesulfonamide group acting as a nucleofugal leaving group after 
the formation of the aminal 121c as shown below. 
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Scheme 33. Urea cleavage via deoxygenation by lithium aluminium hydride 
 
Subjecting the isopropyl- and PMP-substituted ureas 101a and 101b to the same reaction did 
not result in spontaneous reductive cleavage. Instead, the intermediate aminals (121a and 
121b) were formed which were then used crude for the cleavage step. Cleaving the aminal 
121a with HCl proved difficult even at reflux. However, aminals are also known to be cleaved by 
hydroxylamine hydrochloride to give diamines as demonstrated by Trost and Fandrick.103 
Therefore subjecting 121a and 121b to cleavage by hydroxylamine hydrochloride afforded the 
diamines 123a and 123b in 64% and 84% yields respectively.The diamine 123b can be of great 
synthetic utility for ring-swap reactions with different reagents. Therefore, the original urea ring 
can be swapped for other rings of the same size or larger. This is because 123b has a secondary 
pyrrolidine, which in principle, will be more reactive than its secondary aniline. The 
stereochemistry of 122 and 123b were determined by the NOE correlation between the 6-H 
and 8-H of the respective compounds. This was confirmed by x-ray crystallography. However, 
attempts to determine the stereochemistry of 123a by NOE correlations were not successful 
but it was determined by the coupling constant analysis of its 6-H (t, J = 3.2 Hz) and 8-H (quint, 
J= 2.4 Hz) protons. Both protons are equatorial and therefore have to be on the same face of 
the cyclohexanol ring. 
In an instant, after the cleavage step, residual PMP-substituted aminal 121b was also isolated, 
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characterised and its structure confirmed by x-ray crystallography. 
 
Figure 10. X-ray crystal structures of PMP-substituted aminal 121b, PMP-substituted diamine 
123b and tosyl-substituted diamine 122 
2.6.2 Cleavage of the double bond of the isopropyl derivative of the primary scaffold 
The double bond functionality of the enone 83a was investigated for oxidative cleavage. 
However 83a itself was not used because enones are difficult to cleave oxidatively since they 
are electrophilic in character and most of the oxidising agents used to cleave alkenes are 
themselves electrophilic. Therefore, 83a was reduced to the allylic alcohol 124 in 92% yield 
under Luche conditions.104 The diastereomeric ratio from the proton NMR of the crude product 
is 13:1 but it was isolated as a single diastereomer. Protection of the alcohol functionality of 
124 with TBSCl did not reach completion after 3 days. Proton NMR of the crude reaction 
mixture indicated a mixture of the allylic alcohol 124 and the product 125 in about 1:1 ratio 
from which the product 125 was isolated in 55% yield as shown below. 
 
Scheme 34. Synthesis of protected allylic alcohol for oxidative cleavage 
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Figure 11. NOE correlation and x-ray crystal structure of the allylic alcohol 124 
Using TBSOTf instead of TBSCl for the protection led to complete conversion of 124 to 125 in 
96% yield over two steps. 
 
Scheme 35. Alternative synthesis of protected allylic alcohol for oxidative cleavage 
Dihydroxylation of the double bond of 125 with potassium osmate and NMO prior to a 
proposed oxidative cleavage with sodium periodate was not successful. After two weeks, only 
the starting material was observed from the proton NMR of the crude reaction mixture. 
 
Scheme 36. Attempted dihydroxylation of the double bond of the protected allylic alcohol 126 
Therefore 125 was subjected to ozonolysis followed by reduction and TBAF deprotection to give 
the triol 129 (isolated with 4% TBAF contamination) as shown below. 
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Scheme 37. Synthesis of triol 102 via oxidative cleavage 
2.7 Secondary scaffolds generated via ring expansion 
The strategies investigated for the generation of secondary scaffolds via ring expansion are: 
i. Post-ozonolysis nitrogen insertion into the 6-membered ring of the primary scaffold 
ii. Cyclopropane ring opening 
iii. A ring swap reaction of the 6,3-fused ring of 106a for a cyclohexanol ring 
iv. Ring swap reactions with the PMP-substituted diamine 123b 
v. Beckmann rearrangement 
2.7.1 Attempted azepane synthesis 
The dialdehyde 127 could be detected by LCMS after ozonolysis but it was not purified due to 
concerns about its stability. It was therefore subjected crude to double reductive amination 
with benzylamine in the presence of sodium triacetoxyborohydride (at room temperature) in an 
attempt to make the azepane 130 as shown below. However, only the masses of both the 
dialdehyde 127 and the imine from condensation with one equivalent of benzylamine were 
observed by LCMS, even upon heating.  
 
Scheme 38. Attempted ring expansion by post-ozonolysis nitrogen insertion via double reductive 
amination 
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Therefore, a different approach to the desired azepane was investigated based upon 
nucleophilic substitution. The crude diol 128 was mesylated and subjected crude to a double 
SN2 reaction with benzylamine in an attempt to make the azepane 130. The mass of the the 
dimesylated compound 131 was observed by LCMS but not that of the desired azepane. 
 
Scheme 39. Attempted ring expansion by post-ozonolysis nitrogen insertion via a double SN2 
reaction 
2.7.2 Attempted cyclopropane ring opening 
Two approaches towards ring expansion were investigated via a proposed opening of the 
cyclopropane ring of 106a. The first approach investigated was an attempted radical-induced 
cyclopropane ring opening while the second was an attempt to open the cyclopropane ring via 
hydrogenation. 
2.7.2.1 Attempted radical-induced cyclopropane ring opening 
The cyclopropane 106a was subjected to radical ring opening using samarium iodide in THF at 
room temperature in an attempt to make the cycloheptanone 132 as shown below. 
 
Scheme 40. Attempted radical-induced cyclopropane ring opening 
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Instead of the desired product 132, the secondary and tertiary alcohols 133a and 134 were 
formed in 27% and 15% yields respectively. Both 133a and 134 were obtained as single 
diastereomers. The stereochemistry of 133a was determined by comparison with an identical 
compound obtained from the sodium borohydride reduction of 106a (see Scheme 43). The 
stereochemistry of 134 was not determined. The tertiary alcohol 134 may have been formed 
from a bis(iodomethyl)samarium contaminant which was most probably present in the 
commercial samarium iodide used. 
 
Scheme 41. Samarium iodide reduction of the cyclopropane 106a 
Using tributyltin hydride and AIBN to open the cyclopropane ring of 106a resulted in a complex 
mixture. 
2.7.2.2 Attempted cyclopropane ring opening via hydogenation 
The cyclopropane ring is known to possess the characteristics of a double bond.105 Therefore, 
an attempt was made to open the cyclopropane ring of 106a via hydrogenation to give the 
cycloheptanone 132. This led to the partial conversion of 106a to the alcohol 133a as 
monitored by proton NMR.  
 
Scheme 42. Attempted cyclopropane ring opening via hydrogenation 
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2.7.3 Attempted swap of the 6,3-fused ring of 106a for a cycloheptanol ring 
Compound 106a was reduced to the alcohol 133a in an attempt to subsequently swap its 6,3-
fused ring for a cycloheptanol ring as shown below. DIBAL gave a 1:2 mixture of diastereomers 
as deduced from the proton NMR of the crude reaction mixture, and the product was isolated 
in the same ratio in 29% yield. The major diastereomer is identical to the alcohol obtained from 
the samarium iodide/sodium borohydride reduction. Reduction of 106a with sodium 
borohydride gave the corresponding alcohol isolated as a single diastereomer (dr from the 
proton NMR of the crude product is 92:8). The stereochemistry of the product 133a was 
determined by the NOE correlation between its 6a-H and 8-H. 
 
Scheme 43. Cyclopropanation and subsequent reduction  
The alcohol 133a was hydrogenated in an attempt to obtain the ring-expanded cycloheptanol 
135. However, only the mass of the starting material was detected by LCMS. 
 
Scheme 44. Attempted swap of the 6,3-fused ring of 106a for a cycloheptanol ring 
2.7.4 Urea ring swap for isomeric piperazinone rings 
As stated earlier, the PMP-substituted diamine 123b can be of great synthetic utility for 
swapping the urea ring in 101b for other ring forms. This is because the secondary pyrrolidine 
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of 123b is expected to be more nucleophilic than its aniline. Therefore, the diamine 123b was 
selectively alkylated with methyl bromoacetate 136 followed by base-mediated intramolecular 
amidation to swap the original urea ring of 101b for a piperazinone ring. The regiochemistry of 
both the intermediate and final product were determined by NOE correlations. Telescoping the 
intermediate 137 without purification, the piperazinone 138 was isolated in 90% yield (over two 
steps). 
 
Scheme 45. Urea ring swap for a piperazinone via the diamine 123b 
 
Figure 12. Determination of regiochemistry through NOESY correlations 
The regioisomeric piperazinone 139 could be accessed by using bromoacetyl bromide as the 
electrophile, leading to the acylation of the more nucleophilic aliphatic amine, followed by 
internal nucleophilic substitution to give the desired product. For this reaction, a complex 
mixture was obtained even though the mass of the desired product was detected by LCMS. 
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Scheme 46. Attempted ring swap reaction for the synthesis of the regioisomer of 138 
However, using chloroacetyl chloride and DIPEA, the desired product was obtained in one pot 
in 61% yield. The acylation of the hydroxyl group to give the chloromethyl ester was also 
observed, but this could be easily hydrolysed by 2M KOH. 
 
Scheme 47. Urea ring swap reaction for the synthesis of the regioisomer of 138 
2.7.5 Beckmann rearrangement 
The last ring expansion strategy investigated was Beckmann rearrangement.106–108 It involves 
the protic acid- or lewis acid-mediated rearrangement of aldoximes or ketoximes to give the 
corresponding amides or lactams. The mechanism of the reaction is shown below. 
 
Scheme 48. Mechanism for Beckmann rearrangement108 
For strong orbital overlap, only the group anti to the hydroxyl group of the oxime migrates to 
the nitrogen atom in Beckmann rearrangement. Therefore, when unsymmetrical cyclic ketones 
are subjected to this reaction, a mixture of isomeric lactams will be expected since ketoximes 
exhibit geometrical isomerism. However, when a branched migratory group competes with an 
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unbranched one, more of the oxime with the hydroxyl group anti to the branched group will be 
formed. This therefore determines regioselectivity.108 
 
Scheme 49. Depiction of selectivity in Beckmann rearrangement108 
In addition, when single isomers of unsymmetrical ketoximes are tosylated (as in the case of 
145) and rearranged in the presence of protic acids, they are known to convert to their 
corresponding geometric isomers, followed by equilibriation and rearrangement. An example is 
shown in Scheme 50 below. Therefore, for 145, either the n-propyl group or the methyl group 
can migrate to the nitrogen atom to make the corresponding amides after treatment with 
toluenesulfonic acid. However, the product formed will be determined by electronic factors. In 
the example below,the n-propyl group migrates faster under equilibrating conditions because it 
stabilises a positive charge better than the methyl group.108 
Rearrangement of 145 with alumina however results in the methyl group migrating because a 
Lewis acid does not permit isomeric interconversion.108 
 
Scheme 50. Comparison of Beckmann rearrangement under oxime-equilibriating and non-
equilibriating conditions108 
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2.7.5.1 Beckmann rearrangement of the isopropyl derivative of the primary 
scaffold 
Attempts were made, albeit unsuccessfully, to expand the enone ring of 83a by Beckmann 
rearrangement. The oxime synthesis was successful as monitored by LCMS but treatment of the 
crude with either polyphosphoric acid, phosphorus (V) oxychloride or phosphorus 
pentachloride failed to give the desired product. The crude oxime was observed by TLC. 
 
Scheme 51. Attempted Beckmann rearrangement of the isopropyl variant of the primary 
scaffold 
2.7.5.2 Beckmann rearrangement of the isopropyl, PMP and tosyl variants of 
the ketone of the primary scaffold 
The ketone 101a was then chosen to investigate Beckmann rearrangement. Oxime synthesis as 
in Scheme 51 was successful as monitored by LCMS. The crude oxime was then tosylated to 
improve selectivity via equilibriation upon treatment with protic acids (see Scheme 52). 
Therefore, treating the crude tosylated oxime with acetic acid at room temperature or reflux, 
only the mass of the tosylated oxime and the ketone 101a could be detected by LCMS. 
However, using sulphuric acid instead of acetic acid surprisingly afforded the lactam 152a in a 
highly regioselective manner as shown below. The isomeric ratio from the proton NMR of the 
crude reaction mixture is 93:7 but after purification by column chromatography, only 152a was 
isolated cleanly. Although the reaction was expected to be regioselective, 152a was not 
expected to be the major product under equilibriating conditions. This is because the carbon 
atom at position 9 (C-9) of the oximes (150 and 151) was expected to migrate faster than the 
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one at position 7 (C-7) since the primary alkyl group terminating at C-9 is expected to stabilise a 
positive charge better than the one terminating at C-7. The lactam 152a may have been formed 
predominantly because the oxime 151 persisted as the major isomer in solution to avoid steric 
clashes between the tosylate and isopropyl groups. Hence C-7 of 151 migrated to the nitrogen 
atom preferentially. The structure of the isolated product 152a was determined from the 1H-1H 
COSY NMR correlation between its N-H proton and the two diasterotopic 5-H protons. This was 
confirmed by x-ray crystallography. 
 
Scheme 52. Beckmann rearrangement of the ketone 101a to give the lactam 152a 
 
Figure 13. X-ray crystal structure of the lactam 152a 
A similar observation was made for the PMP variant of the ketone of the primary scaffold 101b 
as well as the tosyl variant 101c when subjected to Beckmann rearrangement under the same 
conditions as 101a. From the proton NMR of the crude reaction mixtures, the isomeric ratio for 
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the lactams obtained from the reaction of 101b (isolated as a 93:7 mixture) is 3:1 while that for 
the lactams obtained from the reaction of 101c (isolated as a 90:10 mixture) is 2:1. 
Regiochemistry was determined by the 1H-1H COSY NMR correlations between the N-H protons 
and the diastereotopic 5-H protons of the major products 152b and 152c respectively. 
 
Scheme 53. Beckmann rearrangement of the PMP and tosyl variants of the ketone of the 
primary scaffold 
2.7.5.3 Beckmann rearrangement of the isopropyl and PMP variants of the 6,3-
fused cyclopropane scaffolds 
The isopropyl variant of the cyclopropane scaffold 106a was subjected to Beckmann 
rearrangement under oxime-equillibriating conditions. This was to see if more of the tosyl 
oxime 155 with the tosylate group anti to C-3 will persist in solution as compared to the 
reaction of 101a discussed in Section 2.7.5.2 (see Scheme 52). From the proton NMR of the 
crude mixture for the reaction of 106a, the isomeric ratio of the formed lactams is 60:40 as 
compared to 93:7 for the reaction of 101a. The lactams 156a and 157a were isolated in 23% 
and 21% yields respectively as shown below. The regiochemistry of 156a was determined by 
the 1H-1H COSY NMR between the N-H proton and the diastereotopic 3-H protons. This was 
confirmed by the x-ray crystal structure of both 156a and 157a. 
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Scheme 54.Beckmann rearrangement of the isopropyl variant of the cyclopropane scaffold 106a 
 
Figure 14. X-ray crystal structures of the lactams from the Beckmann rearrangement of 106a 
The PMP variant of the cyclopropane scaffold 106b was then subjected to the same 
rearrangement reaction conditions as 106a. From the proton NMR of the crude reaction 
70 
 
mixture, the isomeric ratio of the lactams formed is difficult to deduce. However, the product 
was isolated as a 78:22 mixture of the isomeric lactams 156b and 157b respectively. The 
regiochemistry of the major product 156b was determined by the 1H-1H COSY NMR correlation 
between its N-H proton and the diastereotopic 3-H protons. 
 
Scheme 55. Beckmann rearrangement of the PMP variant of the cyclopropane scaffold 106b 
2.8 Attempted PIFA dearomatisation of a pseudopeptide 
The pseudopeptide 158 was made from the reaction between the key amine 71 and Z-Gly-OH 
as shown below. It was then subjected to PIFA dearomatisation to give direct access to 
piperazinone-containing skeleta such as 139 above. However, the complexity-generating step 
did not proceed as desired. The mass of the intended product was observed by LCMS in the 
course of the reaction but it decomposed into an unknown mixture upon work up. 
 
Scheme 56. Attempted synthesis of a key scaffold via PIFA deromatisation of a pseudopeptide 
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2.8 Summary of scaffolds prepared 
From the primary scaffold variants 83a-c synthesised via PIFA dearomatisation, 14 diverse 
secondary scaffolds were obtained employing the ring addition, cleavage and expansion 
strategies to the top down approach to LOS as shown in the figure below. 
 
Figure 15. Summary of secondary scaffolds obtained from variants of the key scaffold 
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3.0 Results and discussion 2 
3.1 Decoration of secondary scaffolds 
Our plan for decoration of secondary scaffolds involves the functionalisation of such scaffolds 
along different vectors, with exemplar medicinal chemistry capping groups to furnish final 
compounds for biological screening. A typical decoration plan is shown in Figure 16 below. The 
ketone 101a can be reduced to the alcohol for carbamate synthesis or SNAr reactions. Direct 
reductive amination of 101a with exemplar medicinal chemistry capping groups can also furnish 
final compounds. Alternatively, 101a can be used for reductive amination with methylamine to 
keep the molecular weight of the product small enough (not more than +15 mass unit of the 
molecular weight of the ketone of the primary scaffold) for subsequent amidation, 
sulfonylation and Buchwald-Hartwig coupling among other possible decoration reactions. 
Figure 16. A typical diversity-generating decoration plan for the synthesis of final compounds for 
biological screening 
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The medicinal chemistry capping groups were selected on the basis that the final compounds 
would be in lead-like space after assessment by LLAMA. Therefore, with respect to molecular 
weight considerations, there is less flexibility for the design of final compounds for the PMP- 
and tosyl-substituted secondary scaffolds than for the isopropyl substituted ones. 
The series of final compounds prepared by functionalisation of secondary scaffolds are 
discussed below. 
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3.1.1 Final compounds derived from the isopropyl variant of the ketone of the 
primary scaffold 
The final compounds obtained from the ketone 101a for biological screening are shown below. 
Figure 18. Final compounds obtained from the ketone 101a 
75 
 
The ketone 101a was converted to the alcohol 160a for SNAr and carbamate syntheses. 
Therefore, treatment of 101a with LiAlH4 at room temperature gave 160a in 79% yield but the 
product was isolated as a mixture of diastereomers with a dr of 93:7 (proton NMR of the crude 
reaction mixture was not taken). The stereochemistry of the major diastereomer is the same as 
that of the product of the sodium borohydride reduction of 101a (see Scheme 60). 
 
Scheme 57. Lithium aluminium hydride reduction of the ketone101a to the alcohol 160a 
Compound 160a was then used to carry out an SNAr reaction with 2-fluoropyridine to append 
the heteroaromatic ring to the oxygen atom of the alcohol functionality. From the proton NMR 
of the crude reaction mixture, the diastereomeric ratio of the pyridines formed was difficult to 
deduce but the product was isolated as a 93:7 mixture of diastereomers. Half of the starting 
alcohol was recovered. 
 
Scheme 58. Functionalisation of the alcohol 160a with 2-fluoropyridine 
The recovered alcohol 160a was used to react with 2-fluorophenylisocyanate to obtain the 
corresponding carbamate 162. From the proton NMR of the crude reaction mixture, the 
diastereomeric ratio of the product formed is 82:18 but was isolated as an 88:12 mixture of 
diastereomers as shown below. 
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Scheme 59. Carbamate synthesis by reacting 2-fluorophenylisocyanate with the alcohol 160a 
In an attempt to improve diastereoselectivity, reduction of the ketone 101a, under Luche 
conditions104, was carried out to obtain a product with a diastereomeric ratio of 93:7 (from the 
proton NMR of the crude reaction mixture) but was isolated cleanly in 92% yield as a single 
diastereomer. The product is identical to the major diastereomer of the alcohol obtained via 
reduction with lithium aluminium hydride (see Scheme 56). Attempts to determine the 
stereochemistry of 160a by NOE correlations was unsuccessful. However, it was determined 
from the analysis of the coupling constants of the protons at positions 6a (6a-H: dd, J = 10.0, 6.5 
Hz) and 8 (8-H: tt, J = 10.5, 4.2 Hz). Both protons are axial and have to be on the same face of 
the cyclohexanol ring. This was confirmed by the x-ray crystal structure of the derived 
carbamate 163. 
 
Scheme 60. Sodium borohydride reduction of the ketone functionality of 101a to its 
corresponding alcohol 
Generally, nucleophilic attacks on the carbonyl groups of 101a-c respectively gave products that 
indicate that such attacks were predominantly on the diasteretopic face of the carbonyl group 
that is anti to the urea ring. Theoretical and experimental results by Burgi, Dunitz and co-
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workers109,110 have shown that the angle of attack of a nucleophille towards a carbonyl carbon 
is 105 ± 5°. This is consistent with the stereochemical outcome of the attack of nucleophiles on 
the carbonyl function of the scaffolds 101a-c as shown below, both for the boat conformation 
(as this seems to be favoured in the solid state, exemplified by the crystal structures of 101c 
and 104) and the chair conformation of the scaffolds. Similar stereochemical outcome was 
observed for the imines during reductive amination at the carbonyl function of the scaffold. 
Also, attack from the convex face (for the boat conformation) or the axial face (for the chair 
conformation) of the carbonyl group of 101a-c by a nucleophile seems to be the path of less 
steric resistance as compared to a nucleophilic attack on the concave face (for the boat 
conformation) or equatorial face (for the chair conformation) respectively. 
 
Figure 17. Depiction of nucleophilic attack on the carbonyl group of 101a-c 
The alcohol 160a was again obtained under Luche conditions and used crude to react with 3-
fluorophenylisocyanate to obtain the corresponding carbamate as a 93:7 diastereomeric 
mixture in 84% yield. The stereochemistry of the major diastereomer was determined by the 
presence of an NOE correlation between the protons at positions 6a and 8, and was confirmed 
by x-ray crystallography. 
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Scheme 61. Carbamate synthesis by reacting 3-fluorophenylisocyanate with the alcohol 160a 
As indicated in Scheme 61, the aliphatic six-membered ring of 163 adopts the chair 
conformation in the crystalline state upon reduction of the carbonyl group of 101a, followed by 
carbamate synthesis. This is in sharp contrast to what was observed for the x-ray crystal 
structures of 101c and 104. In all cases where the carbonyl and imino groups in the scaffolds 
were reduced to the alcohol or amine respectively, and the crystal structures of the products 
were obtained, the chair conformation is preferred in the solid state. Presumably, the 
cyclohexanone ring in the scaffolds 101a-c shifts from the boat conformation to the chair 
conformation in the crystalline state upon reduction. As stated earlier, the doubly bonded 
oxygen in cyclohexanone rings is known to considerably lower the energy of the boat 
conformer with respect to that of the chair conformer.91–94 (See Section 2.3). 
The ketone 101a was also utilised in making final compounds through reductive aminations. 
The reductive amination of 101a with furfurylamine gave a single diastereomer of the amine 
164 as product. The stereochemistry of the product was determined by an NOE correlation 
between the 6a-H (dd, J = 10.3, 6.5 Hz) and 8-H (dd, J = 9.5, 3.5 Hz) protons. The coupling 
constants of both protons indicate that they are axial and so have to be on the same face of the 
six-membered ring. 
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Scheme 62. Reductive amination of the ketone 101a with furfurylamine 
Cyclopropylamine was also used for reductive amination with the ketone 101a to make the 
amine 165. The diastereomeric ratio of the crude product is difficult to discern from the proton 
NMR but 165 was isolated as a 79:21 mixture of diastereomers in 73% yield. The 
stereochemistry of the major diastereomer was determined from an NOE correlation between 
6a-H (dd, J = 10.2, 6.6 Hz) and 8-H (tt, J = 11.0, 3.5 Hz) as well as the analysis of their coupling 
constants. Both protons are axial and therefore have to be on the same face of the six-
membered ring. 
 
Scheme 63. Reductive amination of the ketone 101a with cyclopropylamine 
In the same vein, reductive amination of 101a with methylamine was carried out to obtain a 
product with a diastereomeric ratio of 83:17 as analysed from the proton NMR of the crude 
reaction mixture. However, the product 166 was isolated as an 88:12 mixture of diatereomers 
in 90% yield. Compound 166 can be further utilised for final library syntheses by reductive 
amination with ketones and aldehydes or in making amides, sulfonamides and carbamates 
among others. The stereochemistry of the major diastereomer of 166 was determined by the 
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presence of an NOE correlation between its 6a-H and 8-H protons. This was confirmed by the x-
ray crystal structure of the derived sulfonamide 168. 
 
Scheme 64. Reductive amination of the ketone 101a with methylamine 
An attempt to perform a one-pot reductive amination on the crude methylamine 166 with 4-
imidazolecarboxaldehyde using sodium borohydride failed as shown below. Only the mass of 
the amine 166 was detected by LCMS. 
 
Scheme 65. Attempted reductive amination of 4-imidazolecarboxaldehyde with the amine 166 
It was thought that the excess sodium borohydride from the first step might be reducing the 4-
imidazolecarboxaldehyde to the corresponding alcohol thereby bringing the last step of the 
reaction to a halt. The crude amine 166 was therefore recovered and used for the same 
reaction using sodium triacetoxyborohydride to prevent the possible reduction of the aldehyde. 
The product 167 was then obtained in 15% yield as an 80:20 mixture of imidazole tautomers at 
50% conversion after 3 days. 
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Scheme 66. Reductive amination of 4-imidazolecarboxaldehyde with the amine 166 
The amine 166 was also used to make the sulfonamide 168 by reacting it with pyridine-3-
sulfonyl chloride as shown below. A single diastereomer was isolated in 67% yield over three 
steps. The stereochemistry of 168 was determined by the presence of an NOE correlation 
between its 6a-H and 8-H protons and confirmed by X-ray crystallography. 
 
Scheme 67. Sulfonamide synthesis from the amine 166 
Amides were also obtained from the amine 166 by reacting it with isoxazole-5-carbonyl chloride 
as shown below. The major diastereomer was obtained as a 63:37 mixture of rotamers while 
the minor diastereomer was obtained as a 50:50 mixture of rotamers as indicated by analysis of 
their proton NMR spectra. 
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Scheme 68. Amide synthesis from the amine 166 
The amine 166 was also used as a substrate for a Buchwald-Hartwig reaction111,112 with 2-
bromothiazole as shown below but only a trace amount of the product was detected by LCMS. 
 
Scheme 69. Attempted Buchwald-Hartwig coupling of the amine 166 with 2-bromothiazole 
Rhodium catalysed 1,4-addition of 4-fluorophenylboronic acid to the enone 83a was attempted 
as shown below but only a trace amount of a product with the correct mass was detected by 
LCMS.  
 
Scheme 70. Attempted 1,4-addition of an arylboronic acid to the enone 83a 
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Using an organocopper as a soft organometallic nucleophile to effect the 1,4- addition to the 
enone 83a113 instead of an arylboronic acid, the 1,2-addition product was observed from the 
proton NMR of the crude product. This might be as a result of the fact that the desired site of 
attack is hindered. 
 
Scheme 71. Attempted 1,4-addition of an organocopper to the enone 83a 
Therefore 1,2-addition of organometallic reagents to the ketone 101a became desirable. 
Adding 2-thienylmagnesium bromide to 101a gave a complex mixture. However, using 
phenyllithium as the nucleophilic reagent, the desired product 174 was obtained as a single 
diastereomer arising from addition to the bottom face of the ketone as in the hydride 
reductions. The stereochemistry was determined by the presence of an NOE correlation 
between 6a-H and the aromatic ring protons. 
 
Scheme 72. 1,2-addition of phenyllithium to the ketone 101a 
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3.1.2 Final compounds derived from the PMP and tosyl variants of the ketone of the 
primary scaffold 
The final compounds obtained from the PMP-subtituted ketone 101b and tosyl-substituted 
ketone 101c are shown below. As stated earlier, there is less flexibility in the design of final 
compounds for 101b and 101c as compared to 101a due to molecular weight limitations. 
 
Figure 19. Final compounds obtained from the ketones 101b and 101c respectively 
The PMP variant of the ketone of the primary scaffold 101b and its tosyl analogue 101c were 
subjected to sodium borohydride reduction, under Luche conditions, to obtain the 
corresponding alcohols 160b (dr of 85:15 both in the crude and isolated product) and 160c (dr 
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of 78:22 both in the crude and isolated product) respectively.The stereochemistry of the major 
diastereomer 160b was determined via the coupling constants of its 6a-H (dd, J = 9.5, 6.2 Hz) 
and 8-H (qd, J =9.0, 4.3 Hz) confirming both protons are axial but that of 160c was assigned by 
analogy to those of 160a and 160b. The NMR peak of the 8-H proton of 160c overlaps with the 
NMR peak of one of its diastereotopic 3-H protons. Therefore, neither NOESY nor coupling 
constant analysis could be used to determine its stereochemistry. 
 
Scheme 73. Sodium borohydride reduction of the ketone functionality of 101b and 101c to their 
corresponding alcohols 
Reacting the alcohol 160b with isopropyl isocyanate to make the corresponding carbamate, 
only the mass of the starting material was detected by LCMS. This is despite the fact that the 
alcohol 160a was used in making carbamates with 2- and 3-fluorophenyl isocyanates (see 
Schemes 59 and 61). 
 
Scheme 74. Attempted carbamate synthesis by reacting isopropyl isocyanate with the alcohol 
160b 
Reductive amination of 101b and 101c with 3-aminooxetane gave the desired products in 58% 
and 41% yields respectively. From the proton NMR of the crude product for the reaction of 
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101b, the diastereomeric ratio is 81:19 but it was isolated as a single diastereomer. Also, from 
the proton NMR analysis of the crude product for the reaction of 101c, the diastereomeric ratio 
is 80:20 but it was isolated as an 85:15 mixture of diastereomers. The stereochemistry of 175b 
and 175c were assigned by analogy, to those of 164-166 (see Section 3.1.1), and also to those of 
176 and 177 (see Schemes 76 and 77). From the proton NMR, the 6a-H peak of 175b overlaps 
with the 3’-H peak (the numbering of the protons is shown below). Similarly, the 8-H peak of 
175c overlaps with the peak of one of the diastereotopic 7-H protons. Therefore, it is difficult to 
determine the stereochemistry of both 175b and 175c either by the presence of NOE 
correlations or coupling constant analyses. 
 
Scheme 75. Reductive amination of the ketones 101b and101c with 3-aminoxetane 
Similarly, subjecting the ketone 101b to reductive amination with furfurylamine gave the 
desired product whose diastereomeric ratio is difficult to tell from the proton NMR of the crude 
reaction mixture. However, it was isolated as a 93:7 mixture of diastereomers in 90% yield as 
shown below. The stereochemistry of the product was determined from the coupling constants 
of its 6a-H (dd, J = 10.1, 6.2 Hz) and 8-H (qd, J = 8.6, 4.0 Hz) protons and by analogy with 
compound 164. Even though the coupling constant of 8.6 Hz for 2-H is not typical for axial/axial 
coupling, 2-H is most probably an axial proton because such a coupling constant is way out of 
range for an equatorial proton. 
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Scheme 76. Reductive amination of the ketone 101b with furfurylamine 
Using azetidine for reductive amination with 101b, the desired product 177 was obtained as a 
74:26 diastereomeric mixture from the proton NMR of the crude reaction mixture. However, 
the product was isolated as a 95:5 mixture of diastereomers in 44% yield. Analysis of the 
stereochemistry of the major product from the presence of NOE correlations or the coupling 
constants of its 6a-H and 8-H protons was difficult. This is because the 8-H signal (in the proton 
NMR) overlaps with the signal of one of the diastereotopic 7-H protons. However, the x-ray 
crystal structure was obtained and it shows that the azetidine is syn to the urea. 
 
Scheme 77. Reductive amination of the ketone 101b with azetidine 
Also, using cyclopropylamine to carry out reductive amination with the ketone 101c, the 
product was isolated as a 79:21 mixture of diastereomers. The diastereomeric ratio from the 
proton NMR of the crude product is difficult to deduce. The stereochemistry of the major 
diastereomer 177 was assigned by analogy to that of 165. Determining the stereochemistry of 
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177 by the presence of NOE correlations and/or coupling constant analysis between the 6a-H 
and 8-H protons proved difficult. This is because the 8-H peak (in the proton NMR) overlaps 
with the peak for one of the diastereotopic 7-H protons, and also overlaps with the peak of one 
of the diastereotopic 3-H protons. 
 
Scheme 78. Reductive amination of the ketone 101c with cyclopropylamine 
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3.1.3 Final compounds derived from the pyrrolidine-fused secondary scaffolds 
The final compounds obtained from the pyrrolidine-fused secondary scaffolds are shown 
below. 
 
Figure 20. Final compounds obtained from the pyrrolidine-fused secondary scaffolds 
The carbonyl group of the pyrrolidine 109 was subjected to sodium borohydride reduction 
under Luche conditions to obtain a product whose diastereomeric ratio was difficult to deduce 
from the proton NMR of the crude product but was isolated as a 3:2 mixture of diastereomers 
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in 67% yield. The identities of the diastereomers were not able to be determined because of 
extensive signal overlap in the proton NMR of the mixture. 
 
Scheme 79. Sodium borohydride reduction of the ketone functionality of the pyrrolidine 109 to 
its corresponding alcohol 
In an attempt to improve diastereoselectivity, LS-selectride was used for the reduction of 110 
instead of sodium borohydride. It is difficult to discern the diastereomeric ratio of the crude 
product from its proton NMR. The crude product was then subjected to debenzylation via 
hydrogenation, catalysed by 20% w/w Pd(OH)2/C as shown below. This was to access the 
secondary pyrrolidine for proposed decoration reactions. However, only the mass of the alcohol 
180 was detected by LCMS. Compound 180 was then recovered from the column as a single 
diastereomer in 38% yield. The stereochemistry of the pyrrolidine ring was determined by the 
presence of NOE correlations of 6a-H, to 8a-H and 11a-H protons. Determination of the 
stereochemistry of the alcohol functionality from the presence of NOE correlations was not 
successful. However, it was analysed from the coupling constants of 6a-H (dd, J = 10.5, 5.4 Hz) 
and 8-H (dt, 9.3, 5.6 Hz). Both protons (6a-H and 8-H) are axial and have to be on the same face 
of the six-membered ring. 
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Scheme 80. LS-selectride reduction of 110 to its alcohol followed by attempted debenzylation 
In a similar vein, using LS-selectride to reduce the carbonyl group of 107 (26 mg scale), the 
alcohols 182 and 183 were obtained in 29% (7.6 mg) and 7% (1.7 mg) yields respectively. From 
the proton NMR of the crude product, the diastereomeric ratio is difficult to determine. The 
stereochemistry of 182 was determined by the presence of an NOE correlation between its 6-H 
and 8-H protons, meaning the stereochemistry of 183 can be assigned by inference. 
 
Scheme 81. LS-selectride reduction of 107 to the corresponding alcohols 
In a two-step process, the crude product of the LS-selectride reduction of 107 (52 mg scale) was 
then subjected to debenzylation via hydrogenation with a slurry of Pd(OH)2/C as catalyst as 
shown below. However, only one diastereomer 184 was isolated in 27% yield as determined 
from both LCMS and NMR spectral data. Compound 184 was taken to be the debenzylated 
product of 182 based on the yield. 
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Scheme 82. LS-selectride reduction of 107 followed by debenzylation 
The alternate pyrrolidine diastereomer 108 was subjected to LS-selectride reduction to give a 
product whose diastereomeric ratio is 3:1 as analysed from the proton NMR of the crude 
reaction mixture. The product was isolated in the same ratio in 40% yield as shown below. The 
stereochemistry of the major diastereomer was assigned by inference from that of 187 (See 
Scheme 84). 
 
Scheme 83. LS-selectride reduction of 108 to the corresponding alcohol 
In a two-step process, the crude product of the LS-selectride reduction of 108 was subjected to 
debenzylation via hydrogenation with a slurry of Pd(OH)2/C as catalyst as shown below. The 
two debenzylated products 186 and 187 were isolated in 30% and 10% yields respectively. 
Attempts to determine the stereochemistry of both 186 and 187 by NOESYexperiments were 
unsuccessful. However, the stereochemistry of the minor diastereomer 187 was determined 
from the analysis of the coupling constants of its 6a-H (dd, J = 9.0, 7.0 Hz) and 8-H (ddd, J = 
11.5, 7.0, 3.0 Hz). The proton 6a-H is thought to be axial because a coupling constant of 9.0 Hz 
is out of range for an equatorial proton. Therefore, both the 6a-H and 8-H protons of 187 would 
have to be on the same face of the six-membered ring. The 6a-H proton of the major 
93 
 
diastereomer 186 is a triplet with a coupling constant of 4.7 Hz while the 8-H and the both of its 
7-H protons appeared as unassignable multiplets in the proton NMR spectrum. Therefore, it is 
difficult to decipher the stereochemistry of the alcohol functionality of the major diastereomer 
from the analysis of coupling constants but it can be deduced from that of the minor 
diastereomer. In this instance, LS selectride seems to have preferentially attacked the face of 
the carbonyl group that is anti to the fused pyrrolidine ring of 108. 
 
Scheme 84. LS-selectride reduction of 108 to the alcohol followed by debenzylation 
The tetracyclic pyrrolidines are complex and have vectors that can be differentially 
functionalised to access a range of lead-like compounds for biological screening. 
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3.1.4 Final compounds derived from the cyclopropane-fused secondary scaffolds 
The final compounds obtained from the cyclopropane-fused secondary scaffolds are shown 
below. 
 
Figure 21. Final compounds obtained from the cyclopropane-fused secondary scaffolds 
Sodium borohydride reduction of 106a under Luche conditions gave the corresponding alcohol 
as an 86:14 mixture of diastereomers from the analysis of the proton NMR of the crude product 
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but was isolated as a 90:10 mixture of diastereomers. The stereochemistry of the major 
diastereomer 133a was determined from the analysis of the coupling constants of its 6a-H (dd, J 
= 12.0, 5.5 Hz) and 8-H (dt, J = 12.0, 4.5 Hz) protons. Both protons are therefore axial and have 
to be on the same face of the cyclopropane-fused cyclohexanol ring. However, the sodium 
borohydride reduction of 106b under Luche conditions gave a single diastereomer133b in 93% 
yield. The stereochemistry of 133b was determined from the coupling constant of its 6a-H (dd, J 
= 12.5, 5.5 Hz) and 8-H (dt, J = 12.0, 4.5 Hz) protons. Both protons are therefore axial and the 
alcohol functionality is syn to the urea ring. 
 
Scheme 85. Sodium borohydride reduction of the ketone functionality of the cyclopropane-fused 
secondary scaffolds 106a and 106b 
The alcohol 133a (dr 90:10) was then reacted with excess pyridine-3-isocyanate to obtain the 
corresponding carbamate. Even though the mass of the desired product 188 was observed by 
LCMS, it was not isolated cleanly. 
 
Scheme 86: Attempted carbamate synthesis by reacting the alcohol 133a (dr 90:10) with excess 
pyridine-3-isocyanate 
Reductive amination of 106a with methylamine gave the desired product whose diastereomeric 
ratio was difficult to determine from the proton NMR of the crude reaction mixture. The 
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product was then subjected crude to amidation with isonicotinoyl chloride. Even though the 
mass of the desired amide 189 was observed by LCMS, it was not isolated cleanly. However, the 
intermediate 190 was recovered from the column as a single diastereomer in 25% yield. From 
the proton NMR of the crude reaction mixture, it is difficult to deduce the ratio of the 
intermediate 190 to that of the desired product 189. The stereochemistry of 190 was 
determined from the analysis of the coupling constants of its 6-H (dd, J = 12.1, 5.2 Hz) and 8-H 
(dt, J = 12.5, 4.5 Hz). Both protons are therefore axial and have to be cis to each other on the 6-
membered ring. 
 
Scheme 87: Attempted amide synthesis by reacting the crude of 190 with isonicotinoyl chloride 
Similarly, subjecting 106b to reductive amination with methylamine gave the desired product 
whose diastereomeric ratio is difficult to determine from the proton NMR of the crude reaction 
mixture but was isolated as a 94:6 mixture of diastereomers. The stereochemistry of the 
cyclopropane was assigned by the NOESY correlation between the 6a-H and 8a-H protons of the 
major diastereomer 191. An attempt to determine the stereochemistry of the amino 
functionality of 191 by NOE correlations or coupling constant analysis was unsuccessful. The 8-
H proton signal colludes with the signal of one of the 3-H protons and appears as an 
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unassignable multiplet in the proton NMR. However, the stereochemistry of the amino 
functionality was assigned by knowledge of the stereochemistry of its derived sulfonamide (see 
Scheme 89). 
 
Scheme 88. Reductive amination of the cyclopropane-fused scaffold 106b with methylamine 
In a three-step process, the crude product of the reductive amination of 106b with 
methylamine was reacted with methanesulfonyl chloride to obtain the desired sulfonamide.The 
diastereomeric ratio of the crude sulfonamide is difficult to deduce from its proton NMR but it 
was isolated as an 89:11 mixture of diastereomers. The stereochemistry of the major product 
was determined by the analysis of the coupling constant of its 6a-H (dd, J = 12.0, 5.0 Hz) and 8-
H (dt, J = 13.0,4.0 Hz) protons. Both protons are therefore axial and have to be cis to each other 
on the six-membered ring. 
 
Scheme 89. Sulfonamide synthesis by reacting the crude amine 191 with methanesulfonyl 
chloride 
Reductive amination of 106b with 2-oxa-6-aza-spiro[3.3]heptane 192 gave the desired product 
with a diastereomeric ratio of 88:12 as analysed from the proton NMR of the crude reaction 
mixture. The desired product was isolated in the same ratio. The stereochemistry of the major 
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diastereomer 193 was determined from the analysis of the coupling constants of its 6a-H (dd, J 
= 12.0, 5.0 Hz) and 8-H (br. d, J =12.5 Hz) protons. Both protons are axial and are therefore cis 
to each other on the six-membered ring. 
 
Scheme 90. Reductive amination of the cyclopropane-fused scaffold 106b with the amine 192 
Finally, 1,2-addition of 2-thienylmagnesium bromide 194 to 106a gave the desired product with 
a diastereomeric ratio that is difficult to determine from the proton NMR of the crude reaction 
mixture but was isolated as a 92:8 mixture of diastereomers. The stereochemistry of the major 
product 195 was determined by the NOESY correlation of its 8a-H proton to an aromatic 
proton. 
 
Scheme 91. 1,2-addition of 2-thienylmagnesium bromide to 106a 
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3.1.5 Final compounds derived from the tosyl-substituted diamine 122 
The final compounds obtained from the tosyl-substituted diamine are shown below. 
 
Figure 22. Final compounds obtained from the tosyl-substituted diamine 122 
It was envisaged that the sulfonamide group of the tosyl-substituted diamine 122 could be 
preferentially alkylated over the alcohol. This is because toluenesulfonamide has a much lower 
pKa (10.17)114 than isopropanol (17.1).108 Therefore, the base-mediated alkylation of the 
sulfonamide group of 122 with (bromomethyl)cyclopropane was attempted in acetone by 
heating the reaction mixture at 56 °C in a pressure vial. There was no reaction as monitored by 
TLC. The acetone was removed and replaced with DMF. The reaction mixture was then heated 
to 150 °C. The mass of the desired product 196 was detected by LCMS. The proton NMR of the 
crude product, and observation by TLC indicated the starting material was used up. However, 
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the product was not successfully isolated. Also, a possibly competing reaction could be the 
alkylation of the tertiary amino group of the pyrrolidine ring to give the quaternary ammonium 
salt. 
 
Scheme 92. Attempted selective alkylation of the sulfonamide group of the diamine 122 
Therefore, it became desirable to convert the alcohol functionality of 122 to that of a ketone 
for onward functionalisation. Using Dess-Martin periodinane for this purpose, the reaction was 
sluggish and did not reach completion after three days as monitored by LCMS. However, using 
Jones’ reagent instead, the desired ketone was obtained in 38% yield. 
 
Scheme 93. Jones oxidation of the alcohol functionality of 122 
When 197 was subjected to Lewis acid-assisted reductive amination with methylamine, the 
desired product was not detected by LCMS but only toluenesulfonamide was isolated cleanly. 
 
Scheme 94. Attempted titanium isopropoxide-catalysed reductive amination of the ketone 197 
with methylamine 
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The proton NMR spectrum of the crude product indicates a mixture of toluenesulfonamide and 
another compound with 2-methyl groups and two proton signals which appear to belong to 
alkene protons. The proposed sequence of events is shown below. 
 
Toluenesulfonamide can also be displaced via the enamine as shown below. 
 
Scheme 95. Proposed mechanism for the titanium isopropoxide-catalysed reductive amination 
of 197 with methylamine 
However, titanium isopropoxide-assisted reductive amination of 197 with 3-aminooxetane gave 
the desired product as a 64:36 mixture of diastereomers as analysed from the proton NMR of 
the crude reaction mixture but was isolated as a 78:22 mixture of diastereomers in 21% yield. 
Two proton signals corresponding to alkenes are present in the proton NMR spectrum of the 
crude product and this may suggest complications due to enolisation as in the case of the 
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reductive amination with methylamine (see Scheme 95). The stereochemistry of the major 
diastereomer 199 was determined from the analysis of the coupling constants of its 6-H (dd, J = 
9.5, 4.5 Hz) and 8-H (tt, J = 12.5, 4.0 Hz). Both protons are considered to be axial and have to be 
cis to each other on the six-membered ring. 
 
Scheme 96. Reductive amination of the ketone 197 with 3-aminooxetane 
There was therefore a need to carry out reductive aminations with 197 without using titanium 
isopropoxide. The ketone 197 was then used for reductive amination with methylamine using 
sodium triacetoxyborohydride as the reducing agent and acetic acid as catalyst. The mass of the 
desired product was detected by LCMS in this case. From the proton NMR of the crude product, 
a 1:1 ratio of diastereomeric amines was obtained. However, the amines were directly 
subjected crude to urea synthesis by reacting them with cyclopropylisocyanate. The mass of the 
desired urea was however not detected by LCMS and the amines 201 and 202 were isolated in 
33% and 19% yields respectively. The stereochemistry of 202 was determined from the analysis 
of the coupling constants of its 6-H (t, J = 3.0 Hz) and its 8-H (tt, 11.0, 4.0 Hz) protons. 6-H is an 
equatorial proton while 8-H is an axial proton. Therefore, both protons have to be anti to each 
other on the six-membered ring. The 8-H proton of 201 appears as an unassignable multiplet 
(overlaps with other peaks) in the proton NMR spectrum. Therefore, its stereochemistry as 
shown below was deduced from that of 202. 
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Scheme 97. Attempted urea synthesis via the reductive amination of 197 with methylamine 
3.1.6 Final compounds derived from the PMP-substituted diamine 123b 
The final compounds whose syntheses were attempted from the PMP-substituted diamine 
123b are shown below. 
 
Figure 23. Attempted synthesis of final compounds from the diamine 123 
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It has been proven that the amino group of the secondary pyrrolidine of 123b can be selectively 
functionalised (see Section 2.7.4, Scheme 45). Therefore an attempt was made to synthesise 
final compounds by reacting the amino group of the secondary pyrrolidine of 123b with 
different electrophiles. 
However, based on the scale (about 20 mg) the reactions were carried out, it was difficult to 
measure 1 eq. of the electrophile required to react with 123b. Amidation of 123b with acetyl 
chloride gave a mixture of the mono-, di-, and trisubstituted products as monitored by LCMS. 
The reaction was allowed to proceed to completion to the trisubstituted product. The ester of 
the trisubstituted product was then hydrolysed with 2M KOH in order to obtain the diamide 
203 but it was not isolated cleanly. 
 
Scheme 98. Attempted selective amidation of the secondary pyrrolidine of 123b 
Also, an attempt was made to selectively synthesise the urea 204 by reacting the secondary 
pyrrolidine of 123b with cyclopropylisocyanate. The reaction was sluggish and did not reach 
completion after 24 h even upon heating to 50 °C. From the proton NMR of the crude reaction 
mixture, it was difficult to deduce the percent conversion of the starting material. The desired 
product was not isolated cleanly. 
 
Scheme 99. Attempted selective urea synthesis with the diamine 123b 
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Attempted selective Buchwald-Hartwig coupling of 4-bromothiazole to the secondary 
pyrrolidine of 123b was also sluggish. Only the mass of trace amounts of the desired product 
was detected by LCMS and observed by TLC after heating at 100 °C for 24 h. From the proton 
NMR of the crude reaction mixture, it is difficult to deduce the percent conversion of the 
starting material. 
 
 
Scheme 100. Attempted Buchwald-Hartwig coupling with the diamine 123b 
Generally, to achieve success with the selective functionalisation of the pyrrolidine nitrogen of 
123b requires adding just an equivalent of the electrophile. This is evident in the triacylation of 
123b as described above (see Scheme 98). The urea synthesis described in Scheme 99 might be 
successful if it is base-catalysed. Finally, the Buchwald-Hartwig reaction described in Scheme 
100 might become successful if different conditions are scoped. 
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3.1.7 Final compounds derived from the piperazinone-containing secondary 
scaffold 138 
The final compounds obtained from the piperazinone-containing scaffold 138 are shown below. 
 
Figure 24. Final compounds obtained from the piperazinone containing secondary scaffold 138 
Alkylation of the alcohol functionality of 138 with (bromomethyl)cyclopropane 206 under the 
conditions shown below gave a product with the desired mass as detected by LCMS but was not 
isolated cleanly. It was contaminated with 27% (molar percentage) of TBAI as deduced from the 
proton NMR spectrum. It was thought that TBAI undergoes Finkelstein reaction115 with 206 in 
order to make the alkylation faster. Therefore, the reaction was repeated with sodium iodide 
instead of TBAI at 90 °C using dioxane as solvent. However, only trace amounts of the product 
was detected by LCMS, as well as the mass of the starting material. 
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Scheme 101. Alkylation of the alcohol functionality of 138 with (bromomethyl)cyclopropane 
Also, the lactam 138 was subjected to SNAr reacton with 2-fluoropyridine as shown below. The 
reaction did not reach completion after 48 h. From the proton NMR of the crude reaction 
mixture, it was difficult to deduce the percent conversion of the starting material. The product 
was not isolated cleanly. 
 
Scheme 102. Attempted SNAr reaction of 138 with 2-fluoropyridine 
However, reacting 138 with 2-fluorophenylisocyanate and 3-fluorophenylisocyanate, the 
desired carbamates 209 and 210 were obtained in 80% and 85% yields respectively. 
 
Scheme 103. Carbamate synthesis by reacting 138 with 2-fluorophenylisocyanate 
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Scheme 104. Carbamate synthesis by reacting 138 with 3-fluorophenylisocyanate 
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3.1.8 Compound series from the piperazinone-containing secondary scaffold 139 
The final compounds whose syntheses were attempted from the piperazinone-containing 
scaffold 139 are shown below. 
 
Figure 25. Attempted synthesis of final compounds from the piperazinone-containing secondary 
scaffold 139 
Attempted alkylation of the alcohol functionality of 139 with (bromomethyl)cyclopropane 206 
under the conditions shown below was not successful. Only the mass of the starting material 
was detected by LCMS. TBAI was then added to the reaction mixture (as in the case of 138, see 
Scheme 101) which was heated at 90 °C but still, there was no reaction. 
 
Scheme 105. Attempted alkylation of the alcoholfunctionality of 108 
Subjecting 139 to SNAr reaction with 2-fluoropyridine, the desired product 212 was formed as 
observed by both LCMS and proton NMR. However, it was not isolated cleanly. The desired 
product was obtained with an unknown contaminant after column chromatography. 
110 
 
 
Scheme 106. Attempted SNAr reaction of 139 with 2-fluoropyridine 
3.1.9 Final compound obtained from the PMP-deprotected urea 
The final compound obtained from the PMP-deprotected urea 104 is shown below. 
 
Figure 26. Final compound obtained from the PMP-deprotected urea 104 
In a two-step process, the alcohol 160b was converted to the silyl ether 213 prior to a proposed 
PMP-deprotection to afford the secondary urea for selective functionalisation as shown below. 
 
 
Scheme 107. Protection of the alcohol 160b prior to a proposed PMP-deprotection. 
Reacting 213 with CAN, the PMP-deprotected product 214 was obtained in 27% yield as well as 
11% of the alcohol 160b. This approach was not investigated further due to the low yield of 
214. 
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Scheme 108. PMP-deprotection of the urea 213 
Therefore the PMP-deprotected urea 104 was subjected to sodium borohydride reduction, 
under Luche conditions, to give the desired alcohol as an 85:15 mixture of diastereomers as 
deduced from the proton NMR of the crude product and was isolated in the same ratio. The 
stereochemistry of the major diastereomer was assigned by analogy to that of 160a-c. Both 
101c and 104 adopt the boat conformation in the solid state and may react in a similar manner 
when subjected to sodium borohydride reduction to give a major product whose alcohol 
functionality is syn to the urea ring. The 8-H proton appears as an unassignable multiplet 
overlapping with the 3-H proton in the NMR spectrum. Therefore, NOESY experiments as well 
as coupling constant analyses will not be helpful for stereochemical determination. 
 
Scheme 109. Sodium borohydride reduction of the ketone functionality of the PMP-deprotected 
urea 104 
3.1.10 Lead-Likeness and Molecular Analysis 
Lead-Likeness and Molecular Analysis (LLAMA) is a computational tool hosted at the University 
of Leeds.56 It is used for the in silico assessment of the ‘lead-likeness’ of molecular scaffolds and 
derived compounds. The software has an in-built set of typical medicinal chemistry building 
blocks and reactions that can be used to virtually decorate molecular scaffolds along different 
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vectors. This will generate a library of final compounds for computational assessment. Penalty 
scores are assigned to compounds based on how close or far away they are from the lead-like 
space. Compounds with low penalty scores are generally more lead-like than those with higher 
scores. The scores are usually assigned to the individual properties that define the lead-like 
space for a molecule. The overall penalty score would then be the sum of all the individual 
scores assigned against any of the molecular properties enumerated below.56 
Heavy atom count: Compounds with a heavy atom count of 17-24 have a penalty score of 0. 
The ones with 16 and 25 heavy atoms have a penalty score of 1, those with 14-15 and 26-27 
heavy atoms have a penalty score of 2 while those with fewer than 14 or more than 27 heavy 
atoms have a penalty score of 3.56 
Lipophilicity: Compounds with AlogP values between -1 and 3 have a penalty score of zero. The 
ones with AlogP values between -1.0 and -1.5 have a penalty score of 1. Also, compounds with 
AlogP values between 3.0 – 3.5 have a penalty score of 1. The ones with AlogP values between -
1.5 and -2.0 have a penalty score of 2, as well as those with AlogP values between 3.5 – 4.0. 
Finally, compounds with AlogP values less than -2.0 or greater than 4.0 have a penalty score of 
3.56 
Number of aromatic rings: Compounds with one or two aromatic rings have a zero penalty 
score. The ones with no aromatic ring or three aromatic rings have a penalty score of 1, those 
with four to five aromatic rings have a penalty score of 2 while those with more than five 
aromatic rings have a penalty score of 3.56 
Undesirable functional groups: Compounds with undesirable functional groups or substructural 
features as discussed earlier (see Section 1.3.2) have a penalty score of 5.56 
Where a final compound was isolated as a mixture of two diastereomers, only the major 
diastereomer was subjected to LLAMA analysis. In the case of the isomeric lactams 152b/153b 
and 152c/153c (see Section 2.7.5.2), only the major isomers were subjected to LLAMA analysis. 
Also, for the isomeric lactams 156b/157b (see Section 2.7.5.3), only the major isomer was 
subjected to LLAMA analysis. 
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3.1.10.1 Penalty score distribution for final compounds 
The lead-likeness penalty distribution obtained from the LLAMA analysis of the final compounds 
is shown in Figure 27 below. Eighteen compounds have an overall penalty score of 0. Sixteen 
compounds have a score of 1. Two compounds have a score of 2. Thirteen compounds have a 
score of 3 while four compounds have a score of 4. The mean penalty score for all the 
compounds is 0.849.116 Medicinal chemistry capping groups were carefully selected so that final 
compounds obtained from them will have good lead-like properties. An average penalty score 
of 1.57 has been interpreted to mean the compounds are in lead-like space. As stated earlier, 
compounds with low penalty scores are generally more lead-like than the ones with higher 
scores.56 As shown in Figure 27, the compounds with the high penalty score of 4 are 162, 209, 
210 and 215. The high overall penalty score for 162, 209 and 210 is due to their high molecular 
weights (out of the lead-like range - penalty score of 3) and lipophilicities (penalty score of 1). 
The PMP group of 209 and 210 could be viewed as a protecting group and when removed will 
improve the lead-like properties of both compounds. Compound 215 has a high overall penalty 
score because of its low molecular weight (penalty score of 3) and the absence of an aromatic 
ring (penalty score of 1). Even though the properties of 215 increase the scope of its 
developability into the drug-like space, such properties take it out of the lead-like space. 
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Figure 27. Structures of four final compounds with a high penalty score and a plot showing the 
lead-likeness penalty distribution of all the final compounds for biological screening 
3.1.10.2 Mass distribution of final compounds for biological screening 
The LLAMA plot of the mass distribution of the final compounds obtained from the secondary 
scaffolds is shown in Figure 28 below. The molecular weight (MW) range for lead-oriented 
synthesis as given by Ian Churcher and co-workers14 is 250 – 350 Da or with respect to heavy 
atom count, the range is 14 ≤ heavy atoms ≤ 26 (although the LLAMA filter is slightly different 
as discussed in Section 3.1.10). Some of the compounds that are way out of the lead-like space 
have protecting groups which when removed will lead to a decrease in their molecular weights. 
An example is the pyrrolidine 181 (MW = 481.61) that has both tosyl and benzyl groups in the 
molecule. The compound with the molecular weight of 196.25 is the derived alcohol of the 
PMP-deprotected urea 104.116 
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Figure 28. Mass distribution of final compounds for screening 
 
3.1.10.3 Lipophilicity distribution of final compounds for biological screening 
All the final compounds have the right lipophilicity values for lead-oriented synthesis except for 
three compounds that have their AlogP values above 3.0. The compounds are: 162 with an 
AlogP of 3.06, 209 with an AlogP of 3.22 and 210 with an AlogP of 3.33. The lipophilicity of 162 
as calculated by LLAMA is 3.06 (slightly higher than the maximum value of 3.0 required for lead-
oriented synthesis).116 Deprotecting the PMP group of both 209 and 210 could increase their 
polarity and hence, enhance their lead-like properties (See Section 3.1.10.1 and Figure 27). 
 
Figure 29. AlogP distribution of final compounds for biological screening 
3.1.10.4 Overall assessment of the lead-likeness of final compounds by LLAMA 
The final compounds can be subjected to lead-likeness assessment with respect to both 
molecular weight and lipophilicity as shown by the plot below. The compounds (indicated as 
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coloured dots based on their overall penalty score) within the dotted bounds of the rectangle 
can be said to be in the lead-like space. Therefore, with respect to Figure 30, 35 compounds 
(66%) are in lead-like space while 18 compounds (34%) are outside lead-like space mainly due 
to molecular weight considerations. 
 
Figure 30. Overall lead-likeness assessment of final compounds for biological screening 
However, the key statistic was obtained from LLAMA with respect to not just molecular weight 
and lipophilicity but also the number of aromatic ring(s) and bad functional group(s). It 
indicates that 58.5% of the final compounds are within the lead-like space. This is a good 
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outcome as considerably more than half of the final compounds have been analysed to 
perfectly be in lead-like space. 
3.1.10.5 Shape distribution of the final compounds for biological screening 
The shape diversity or distribution of the final compounds can be represented by the principal 
moment of inertia (PMI) plot as shown in Figure 32. LLAMA produces PMI coordinates for every 
molecule by first minimizing the energy of a number of generated three-dimensional 
conformers. The conformer of lowest energy will then be selected and its moments of inertia 
along the x, y and z axes will be calculated. The plot is made up of a histogram of 20 bins. The 
compounds in the bins are shown as coloured dots (as in Figure 30) based on the overall 
penalty score. The higher the bin number, the higher the three-dimensionality of the 
compound(s) that are in it. In other words, as molecules spread from the vertex represented by 
the linear diacetylene to the disc-like benzene and finally adamantane, three-dimensionality 
increases.116 Three-dimensionality is a measure of complexity and therefore making 
compounds with increased three-dimensionality is desirable for lead-oriented synthesis (see 
Section 1.3.2). 
The ZINC database contains commercially available compounds that have been made available 
for virtual screening.117,118 It has been shown by Young and co-workers119 that deliberately 
synthesised 3D fragments have a better shape distribution on the PMI plot than a 
representative set of fragments from the ZINC database. Also, Cohen and coworkers120 have 
also shown that intentionally synthesised 3D metallofragments have a better shape diversity on 
the PMI plot than a representative set of fragments from the ZINC database. The fragments 
from the ZINC database tend to occupy the axis between the linear diacetylene and the disc-like 
benzene portion of the PMI plot. 
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Figure 31. Illustration of the low shape diversity of a representative set of fragments from the 
ZINC database119,120 
From the PMI plot shown in Figure 32, the final compounds we made for biological screening 
have a better spread than compounds from the ZINC database, and hence a better shape 
distribution. 
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Figure 32. Shape distribution of final compounds for biological screening 
3.1.10.6 Fraction of sp3 distribution of final compounds for biological screening 
The fraction of sp3 carbon atoms (Fsp3) of a molecule is a measure of the carbon bond 
saturation of the molecule (see Section 1.2.1). It can also be taken to be a measure of 
complexity because saturation allows synthetic chemists access more complex scaffolds. 
Increased Fsp3 is known to correlate well with success during clinical development. The mean 
Fsp3 for approved drugs, as indicated by a study carried out in 2009, is higher than the mean 
Fsp3 for candidates at the earlier stages of drug discovery because those with lower Fsp3 fail 
more often, as shown in Figure 33 below.12 Also, compounds with high Fsp3 sample chemical 
space more efficiently than those with lower Fsp3 without a significant corresponding increase 
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in molecular weight due to saturation. As indicated in Figure 33 below, dimethylpyridine with 
an Fsp3 of 0.29 has 5 isomers while dimethylpiperidine with a perfect Fsp3 has 34 isomers.12 
 
Figure 33. Exhibition of the importance of Fsp3 in drug discovery12 
The Fsp3 distribution of the final compounds for biological screening as assessed by LLAMA116 is 
shown in Figure 34 below. The mean Fsp3 is 0.68. This is higher than the mean Fsp3 for 
approved drugs as indicated in Figure 33. This also means the final compounds have room for 
developability into drug molecules. 
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Figure 34. Fsp3 distribution of final compounds for biological screening 
3.1.10.7 Novelty assessment of final compounds for biological screening 
The novelty of scaffolds could be assessed with respect to their Murcko or Murcko plus alpha 
frameworks. The Murcko framework of a molecule consists of the core scaffold without 
substitutions while the Murcko plus alpha framework includes not just the core scaffold but 
also the positions of alpha-substitutions on it.121 With respect to the scaffold 129, the Murcko 
and Murcko plus alpha frameworks are depicted below. 
 
Figure 35. The triol 129, its Murcko and Murcko plus alpha frameworks 
Each of the 53 final compounds for biological screening was analysed by LLAMA116 for novelty 
with respect to an identical framework (using both the Murcko and Murcko plus alpha 
frameworks) or as a substructure (using both the Murcko and Murcko plus alpha frameworks). 
All the final compounds, except 129, show no match in terms of the same framework or as a 
substructure when compared to a random 2% of the ZINC database of commercially available 
compounds. The triol 129 has 5 hits as a substructure with respect to the Murcko framework 
only. This indicates that the final compounds are highly novel. 
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3.1.10.8 Conclusion 
In conclusion, the top down approach is a viable tool to demonstrate lead-oriented synthesis. 
Comparatively, the bottom up approach to lead-oriented synthesis makes use of different 
precursors ‘armed’ with different functional groups which could be made to undergo mutually 
exclusive cyclisations to generate complex and diverse scaffolds. This approach might generate 
diverse scaffolds faster than the top down approach to lead-oriented synthesis, because in this 
case, the extent to which diversity could be generated depends on: 
i. The type of precursor chosen (different precursors can be obtained for this 
purpose). 
ii. The types of functional groups the precursors are ‘armed’ with. 
iii. The type of pairing reactions the functional groups are made to undergo 
orthogonally. Generally, these reactions could be less difficult than the kind of 
reactions employed for the top down approach to lead-oriented synthesis as 
discussed below. 
In contrast, the top down approach is a more convergent concept and it is meant to rapidly give 
access to complex and diverse scaffolds from a single key scaffold, while keeping a tight control 
of the molecular properties of the scaffolds generated in the process. Through this approach, a 
suitable key scaffold is deconstructed or modified via ring addition, cleavage and expansion to 
generate diversity. However, the diversity generating reactions in this case are intermolecular 
and may be more difficult as compared to the intramolecular pairing reactions employed by the 
bottom up approach to LOS. The ring cleavage and expansion reactions are generally more 
difficult than the ring addition reactions but can lead to compounds that occupy novel chemical 
space which may be more difficult to synthesise otherwise (especially where the key scaffold 
has considerable stereochemical complexity as in the case of compound 83). The products of 
cleavage reactions open great synthetic possibilities and can be used as starting materials to 
generate compounds that have very little structural semblance to the key scaffold. 
In this project, the ring addition reactions that worked are the Van Leusen pyrrole synthesis 
(Scheme 24), Corey-Chaykovsky cyclopropanation (Scheme 25), pyrrolidine synthesis via a 1,3-
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dipolar cycloaddition reaction as described by Fray and coworkers (Scheme 27) and pyridine 
synthesis (Scheme 31). Corey-Chaykovsy cyclopropanation gave products in which the 
stereochemistry of the cyclopropane ring is syn to the urea. The pyrrolidines gave a mixture of 
diastereomers whose diastereomeric ratios could not be determined for the isopropyl- and 
tosyl-substituted urea-pyrrolidines due to extensive overlap in the proton NMR of the crude 
products. However single diastereomers were isolated with the stereochemistry of the 
pyrrolidine ring syn to the urea. For the PMP-substituted urea-pyrrolidines, the major 
diastereomer has its pyrrolidine ring syn to the urea while the minor diastereomer has its 
pyrrolidine ring anti to the urea. The ring addition reaction that did not work is the attempted 
indole synthesis through the Fischer method or via the method described by Chen and 
coworkers (Scheme 32). 
The ring cleavage reactions that worked are the urea cleavage that employed lithium 
aluminium hydride only or lithium aluminium hydride followed by hydroxylamine 
hydrochloride-aided hydrolysis of aminals (Scheme 33), and the ozonolysis of the double bond 
of the key scaffold (Scheme 37). The attempted cleavage reactions that did not work are the 
base-catalysed solvolysis of the urea ring (Table 3) and the osmium tetroxide mediated 
cleavage of the double bond of the key scaffold. The diol precursor was not formed. (Scheme 
36). 
The ring expansion reactions that worked are the ring swap of the urea ring of the key scaffold 
for isomeric piperazinone rings (Schemes 45 and 47) and Beckmann rearrangements (Schemes 
52-55). The ring expansion reactions that did not work are the attempted azepane synthesis via 
double reductive amination or double SN2 reaction (Schemes 38 and 39) and attempted 
cyclopropane ring opening (Schemes 40, 42 and 44). 
Fifty-two final compounds were synthesised, and prepared in 10 mM DMSO solutions for 
biological screening, by functionalising the diverse scaffolds along different vectors. With the 
exception of a few compounds whose stereochemistry were assigned by analogy, final 
compounds obtained via the reduction of the carbonyl group of the scaffolds or through 
reductive amination (via a pre-formed imine) have their alcohol and amino functionalities syn 
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to the urea except compound 186. Compound 186 has its alcohol functionality anti to the urea 
but syn to the neighbouring pyrrolidine ring. Summarily, the structures of the final compounds 
synthesised for biological screening are shown in Figure 36 below. 
 
Figure 36. Structures of final compounds for biological screening 
The final compounds shall be tested against the autophagy target and hedgehog osteogenesis 
target at the Max Planck Institute, Dortmund. They shall also be tested against DNA i-motif at 
the University of East Anglia and Plasmodium falciparum at the University of Cape Town. 
3.1.10.9 Future work 
To mention a few, some future work could be done as an extension of this project as shown 
below. 
Firstly, the enone scaffold 83 could be brominated and the double bond reduced or 
cyclopropanated so that the respective products 217 and 218 could become substrates for 
Hantzch synthesis and other related reactions, as shown below. 
125 
 
 
Scheme 110. Potential syntheses of substrates for Hantzsch thiazole synthesis and other related 
reactions. 
Refluxing 217 and 218 respectively with thioamides in ethanol could give thiazoles as shown 
below. 
 
Scheme 111. Potential Hantzsch synthesis using the α-bromoketones 217 and 218 as substrates 
Secondly, the diamine 123b could be used for other ring swap reactions apart from the isomeric 
piperazinones shown in Section 2.7.4 (see Schemes 45 and 47). An example, among others, is a 
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potential reaction between 123b and chloromethanesulfonyl chloride 222 to give the cyclic 
sulfonamide 223 as shown below. There is literature precedence which suggests that 
sulfonylation at the pyrrolidine nitrogen could be faster than alkylation.122 
 
Scheme 112. Potential ring swap of the original urea ring of 101b for a cyclic sulfonamide 
Thirdly, a scaffold could be made to incorporate the three strategies of the top-down approach 
to lead-oriented synthesis, namely ring addition/cleavage/expansion, in a single molecule. The 
isomeric lactams 152c/153c (90:10 mixture, see Scheme 53) could be subjected to urea 
cleavage with concomitant reduction of the amide to furnish the triamines 224 and 225 which 
could be differentially functionalised along its vectors. 
 
Scheme 113. Potential synthesis of triamines for selective functionalisation 
Compound 224 can also be viewed as an alternating 1,2-diamine. Therefore, treating 224 with 
chloroacetyl chloride could lead to the formation of the lactam 227 which incorporates the ring 
addition/cleavage/expansion strategies in its structure. 
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Scheme 114. Potential synthesis of a hybrid scaffold that incorporates the ring 
addition/cleavage/expansion strategies to lead-oriented synthesis in its structure 
The reaction in Scheme 113 was actually attempted on a 26 mg scale. 13 mg of the major 
isomer 224 was isolated with 82% purity. The triamine 224 was then treated with chloroacetyl 
chloride as shown in Scheme 114. Both the masses of the intermediate 226 and that of the 
desired product were observed as monitored by LCMS. Less than 1 mg of product was isolated. 
Therefore, only the accurate mass was acquired [(M + H+): calculated 378.1846, found 
378.1857, 2.9 ppm error]. Therefore compounds 224, 225 and 227 could be isolated cleanly and 
in sufficient amounts (for full characterisation) in the future if the reactions generating them 
are scaled up. 
 
 
 
 
 
 
 
 
128 
 
4.0 Experimental 
4.1 General experimental 
All reactions were carried out under an atmosphere of nitrogen. Solvents used were of 
analytical grade and were dried where necessary by means of a Pure Solv MD solvent 
purification system (Innovative Technology Inc.). Starting materials were obtained from 
commercial sources and used without further purification. 
Commercially available silica gel-coated aluminium plates (Merck silica Kiesel gel 60F254) were 
used for thin layer chromatography. Also, silica gel (35 – 70 µm) was used for solvent gradient 
column chromatography. 
An Agilent 1200 series LC coupled to a Bruker HCT Ultra ion trap mass spectrometer was used 
for LCMS analysis. High resolution mass spectrometry (HRMS) was recorded on a Bruker HCT 
Ultra spectrometer. Both nominal and accurate mass spectral data were obtained using the 
Bruker Maxis Impact with electrospray ionisation (ESI) source. 
1H and 13C NMR spectral data were acquired using Bruker Avance DPX 300, AV-3 400, Avance 
500, DRX 500 and JEOL ECA600II spectrometers. 2D NMR experiments such as 1H-1H COSY, 
HMQC, HMBC and NOESY were carried out to aid structural assignments. Coupling constants 
are in Hz. The Bruker Alpha FTIR spectrometer using ‘platinum ATR’ accessory was used to 
record the IR spectral data in wavenumbers. 
Crystallographic studies were carried out to determine the conformation of molecules in their 
crystalline state as well as their stereochemistry. The X-ray crystallography experiments were 
carried out by Dr Christopher Pask. 
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4.2 Experimental for the syntheses of compounds 
 
1-(Benzyloxy)-4-bromobenzene 87 
 
To a mixture of 4-bromophenol 86 (11.8 g, 68.2 mmol, 1.01 eq.) and potassium carbonate (12.9 
g, 93.3 mmol, 1.39 eq.) in HPLC grade acetonitrile (80 mL), benzyl bromide (8.0 mL, 67.3 mmol, 
1.0 eq.) was added and the mixture was stirred at room temperature for 22 h. The reaction 
mixture was filtered through a sintered funnel washing with MeCN (300 mL) and concentrated 
in vacuo. Purification by flash chromatography on silica gel eluting with 0 - 10% EtOAc in hexane 
afforded a white solid 87 (17.1 g, 64.8 mmol, 96% yield); Rf = 0.54 (5% EtOAc in hexane). The 
NMR data is in agreement with the literature.122 1H NMR (500 MHz, CDCl3): δ ppm 7.46 – 7.34 
(7H, m, ArH), 6.90 (2H, d, J = 9.0, ArH), 5.07 (2H, s, ArCH2). 13C NMR (125 MHz, CDCl3): δ 157.9 
(Ar), 136.6 (ArH), 132.3 (Ar), 128.7 (ArH), 128.1 (ArH), 127.5 (ArH), 116.7 (ArH), 113.2 (Ar), 70.3 
(ArCH2). IR νmax(neat)/cm-1: 3060, 3031, 2887, 2852 (C-H), 1574, 1485, 1451 (C=C), 1245 (C-O). 
 
1-(Benzyloxy)-4-iodobenzene 79 
 
To a mixture of 4-iodophenol 78 (9.68 g, 44.0 mmol, 1.0 eq.) and potassium carbonate (7.91 g, 
57.2 mmol, 1.3 eq.) in HPLC grade acetonitrile (20 mL), benzyl bromide (5.75 mL, 48.4 mmol, 
1.1 eq.) was added and the mixture was stirred at room temperature for 20 h. The reaction 
mixture was filtered through a sintered funnel washing with 300 mL DCM and concentrated in 
vacuo. Recrystallisation from hexane afforded a brown solid 79 (12.8 g, 41.3 mmol, 94%); Rf = 
0.54 (5% EtOAc in hexane). The NMR data is in agreement with the literature.123 1H NMR (400 
MHz, CDCl3): δ ppm 7.59 (2H, d, J = 8.8, ArH), 7.46 – 7.37 (5H, m, ArH), 6.79 (2H, d, J = 8.8, ArH), 
5.07 (2H, s, ArCH2). 13C NMR (100 MHz, CDCl3): δ 158.5 (Ar), 138.3 (ArH), 136.7 (Ar), 128.5 (ArH), 
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128.0 (ArH), 127.5 (ArH), 117.4 (ArH) 83.1 (ArI), 70.1 (ArCH2). IR νmax (neat)/cm-1: 3062, 3030, 
2928, 2874 (C-H), 1579, 1481, 1378 (C=C), 1235 (C-O). 
 
3-[(4-Benzyloxy)phenyl]propanal 80 
 
To a mixture of sodium bicarbonate (10.8 g, 129 mmol, 2.0 eq.), tetrabutylammonium chloride 
(17.9 g, 64.6 mmol, 1.0 eq.), palladium acetate (146 mg, 0.646 mmol, 1 mol%) and 1-
(benzyloxy)-4-iodobenzene 79 (20.0 g, 64.6 mmol, 1.0 eq.) in anhydrous DMF (65.5 mL) was 
added allyl alcohol (6.59 mL, 96.8 mmol, 1.5 eq.) and the mixture was heated at 50 °C for 20 h. 
The reaction mixture was filtered through a plug of Celite eluting with EtOAc (400 mL) and 
evaporated in vacuo. The filtrate was extracted with EtOAc (5 × 100 mL) in water (50 mL), 
washed with brine (100 mL), dried over Na2SO4 and evaporated in vacuo. Purification by flash 
chromatography on silica gel eluting with 10 – 20% EtOAc in hexane followed by 
recrystallisation from Et2O afforded a brown solid 80 (12.8 g, 53.1 mmol, 82% yield); Rf = 0.55 
(20% EtOAc in hexane). The NMR data is in agreement with the literature.124 1H NMR (400 MHz, 
CDCl3): δ ppm 9.84 (1H, t, J = 1.3, 1-H), 7.51 – 7.35 (5H, m, ArH), 7.17 (2H, d, J = 8.4, ArH), 6.97 
(2H, d, J = 8.8, ArH), 5.09 (2H, s, ArCH2O), 2.95 (2H, t, J = 7.5, 3-HA,B), 2.77 (2H, td, J = 7.6, 1.2, 2-
HA,B). 13C NMR (100 .MHz, CDCl3): δ 201.7 (1-C), 157.5 (Ar), 136.9 (Ar), 132.7 (Ar), 129.3 (ArH), 
128.5 (ArH), 128.0 (ArH), 127.2 (ArH), 115.0 (ArH), 70.1 (ArCH2O), 45.4 (3-C), 27.1 (2-C). IR νmax 
(neat)/cm-1: 3067, 3033, 2925, 2859, 2733 (C-H), 1716 (C=O), 1608, 1579, 1510 (C=C), 1234 (C-
O). 
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N-Benzyl-3-[4-(benzyloxy)phenyl]propan-1-amine 81 
 
To a solution of the aldehyde 80 (1.00 g, 4.16 mmol, 1.0 eq.) in anhydrous MeOH (8.40 ml), 
BnNH2 (0.60 ml, 5.49 mmol, 1.3 eq.) was added and the mixture was allowed to stir for 1.5 h at 
room temperature. Sodium borohydride (79.4 mg, 2.10 mmol, 0.50 eq.) was then added and 
stirring continued at room temperature for 2.5 h. The reaction mixture was extracted with DCM 
(5 × 20 mL), dried over Na2SO4 and evaporated in vacuo. Flash chromatography on silica gel 
eluting with 5 – 10% MeOH in DCM afforded a thick brown oil 81 (1.14 g, 3.44 mmol, 83%); Rf = 
0.39 (100% EtOAc). 1H NMR (400 MHz, CDCl3): δ ppm 7.37 – 7.25 (5H, m, ArH), 7.25 – 7.14 (5H, 
m, ArH), 7.01 (2H, d, J = 8.4, ArH), 6.81 (2H, d, J = 8.4, ArH), 4.96 (2H, s, OCH2Ar), 3.71 (2H, s, 
NHCH2Ar), 2.59 (2H, t, J = 7.2 Hz, 1-HA,B), 2.53(2H, t, J = 7.2, 3-HA,B), 1.75 (2H, quint, J = 7.2, 2-
HA,B). 13C NMR (100 MHz, CDCl3): δ ppm 157.1 (Ar), 139.9 (Ar), 137.3 (Ar), 134.5 (Ar), 129.3 
(ArH), 128.6 (ArH), 128.5 (ArH), 128.3 (ArH), 127.9 (ArH), 127.5 (ArH), 127.1 (ArH), 114.8 (ArH), 
70.1 (OCH2Ar), 53.9 (NHCH2Ar), 48.7 (1-CH2), 32.7 (3-CH2), 31.7 (2-CH2). IR νmax (neat)/cm-1: 3407 
(N-H), 3061, 3030, 2928, 2859, 2804 (C-H), 1609, 1509, 1452 (C=C), 1236 (C-O). HRMS (ESI): 
C23H26NO [M + H+]: calculated 332.2009, found 332.2006. 
 
4-(3-Aminopropyl)phenol 71 
 
To Pd(OH)2/C (3.03 g, 20% w/w) under an inert atmosphere in a round bottomed flask, 10 mL of 
MeOH was gently added. A solution of the amine 81 (15.1 g, 45.7mmol, 1.0 eq.) in MeOH (40 
mL) was then added followed by 76.6 mL of AcOH. The reaction mixture was diluted (by adding 
260 mL of MeOH) and transferred to the steel vessel of the PAT-instrumented batch reactor. 
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The mixture was degassed and nitrogen gas was bubbled into it. This procedure was repeated 
twice. Similarly, the reaction mixture was degassed and hydrogen gas was bubbled into it. This 
procedure was also repeated twice. From the control unit, the mixture was made to stir at 1000 
rpm. The pressure and temperature were set at 15 bar and 40 °C respectively. After 24 h, the 
reaction mixture was filtered through a plug of celite with MeOH (400 mL) and evaporated in 
vacuo. Flash chromatography on silica gel eluting with 10% MeOH in DCM followed by 10% 
saturated NH3/MeOH in DCM afforded a sticky brown oil 71 (6.90 g, 45.6 mmol, quant.); Rf = 
0.19 (10% saturated NH3/MeOH in DCM). The NMR data aligns with the literature.125 1HNMR 
(500 MHz, MeOD): δ ppm 6.90 (2H, d, J = 8.5, ArH), 6.58 (2H, d, 8.5, ArH), 2.53 (2H, t, J = 7.5, 1-
HA,B), 2.44 (2H, t, J = 7.5, 3-HA,B), 1.63 (2H, quint, J = 7.5, 2-HA,B). 13CNMR (125 MHz, MeOD): δ 
ppm 155.3 (Ar), 132.5 (Ar), 128.8 (ArH), 114.8 (ArH), 40.6 (1-C), 34.3 (2-C), 31.9 (3-C). IR νmax 
(neat)/cm-1: 3348 (N-H), 3009, 2928, 2854, 2674, 2586 (C-H), 1592, 1513, 1452 (C=C), 1244 (C-
O). 
 
3-(4-(Benzyloxy)phenyl)propan-1-amine 98 
 
A mixture of the aldehyde 80 (300 mg, 1.25 mmol, 1.0 eq.) and hydroxylamine hydrochloride 
(104 mg, 1.50 mmol, 1.2 eq.) in 3 mL of anhydrous EtOH was allowed to stir for 1 h at room 
temperature. 12 M HCl (0.42 mL, 5.0 mmol, 4.0 eq.) was then added to the reaction mixture 
followed by zinc dust (205 mg, 3.13 mmol, 2.5 eq.) and the mixture was left to stir for 40 min, 
after which 0.36 mL of 30% aqueous ammonia and 0.77 mL of 6 M NaOH were added. The 
reaction mixture was extracted with DCM (5 × 20 mL), dried over Na2SO4 and concentrated in 
vacuo. Purification by silica gel chromatography eluting with 3 – 7% MeOH in DCM followed by 
3 – 10% of saturated NH3/MeOH in DCM, afforded a white solid 98 (132 mg, 0.55 mmol, 44% 
yield); Rf = 0.39 (6% NH3/MeOH in DCM). 1H NMR (300 MHz, MeOD): δ ppm 7.34 – 7.14 (5H, m, 
ArH), 7.00 (2H, d, J = 8.6, ArH), 6.79 (2H, d, J = 8.7, ArH), 4.93 (2H, s, ArOCH2), 2.55 (2H, t, J = 7.4, 
133 
 
1-HA,B), 2.49 (2H, t, J = 7.6, 3-HA,B), 1.66 (2H, quint, J = 7.5, 2-HA,B). 13C NMR (75 MHz, MeOD): δ 
ppm 158.4 (Ar), 138.8 (Ar), 135.3 (Ar), 130.2 (ArH), 129.4 (ArH), 128.7 (ArH), 128.4 (ArH), 115.9 
(ArH), 71.0 (ArOCH2), 41.7 (1-C), 34.9 (3-C), 33.1 (2-C). IR νmax (neat)/cm-1: 3366 (N-H), 3061, 
3032, 2927, 2857 (C-H), 1235 (C-O). HRMS (ESI): C16H20NO [M + H+]: calculated 242.1539, found 
242.1538. 
 
1-(3-(4-(Benzyloxy)phenyl)propyl)-3-isopropylurea 99 
 
Isopropyl isocyanate (0.63 mL, 6.45 mmol, 1.1 eq.) was added to a solution of the amine 98 
(1.41 g, 5.86 mmol, 1.0 eq.) in anhydrous DCM and the mixture was refluxed for 5 h. The 
reaction mixture was then evaporated in vacuo. Flash chromatography with 50 – 100%  EtOAc 
in hexane afforded the compound 99 as a white solid (1.71 g, 5.25 mmol, 90% yield); Rf = 0.75 
(100% EtOAc). 1H NMR (300 MHz, MeOD): δ ppm 7.36 – 7.14 (5H, m, ArH), 6.99 (2H, d, J = 8.4, 
ArH), 6.79 (2H, d, J = 8.7, ArH), 4.93 (2H, s, ArOCH2), 3.70 (1H, hept, J = 6.5, isopropyl CH), 3.01 
(2H, t, J = 7.0, 1-HA,B), 2.47 (2H, t, J = 7.5, 3-HA,B), 1.64 (2H, quint, J = 7.3, 2-HA,B), 1.02 (6H, d, J = 
6.5, isopropyl CH3). 13C NMR (75 MHz, MeOD): δ ppm 160.5 (urea C=O), 158.4 (Ar), 138.9 (Ar), 
135.4 (Ar), 130.3 (ArH), 129.4 (ArH), 128.7 (ArH), 128.5 (ArH), 115.8 (ArH), 71.0 (ArOCH2), 42.8 
(isopropyl-CH), 40.4 (1-C), 33.3 (3-C), 33.2 (2-C), 23.5 (isopropyl CH3). IR νmax (neat)/cm-1: 3328 
(N-H), 2964, 2935, 2864 (C-H), 1726 (C=O), 1236 (C-O). HRMS (ESI): C20H27N2O2 [M + H+]: 
calculated 327.2067, found 327.2065. 
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1-[3-(4-Hydroxyphenyl)propyl]-3-isopropylurea 82a 
 
Method A 
To a mixture of Pd(OH)2/C (10.1 mg, 10% w/w) and urea 99 (101 mg, 0.31 mmol, 1.0 eq.) under 
an atmosphere of nitrogen, 5 mL of MeOH was added gently. The reaction mixture was 
degassed and hydrogen gas was bubbled through it with the aid of a balloon, and this 
procedure was repeated twice. The mixture was then allowed to stir under a balloon of 
hydrogen for 23 h at room temperature. The reaction mixture was filtered through a plug of 
Celite washing with 100 mL MeOH. The filtrate was evaporated in vacuo. Flash chromatography 
eluting with 80 - 100% EtOAc in hexane afforded the product 82a as a colourless oil (70 mg, 
0.30 mmol, 92%). 
Method B 
Isopropyl isocyanate (1.64 mL, 16.7 mmol, 1.01 eq.) was added to a solution of the amine 71 
(2.50 g, 16.6 mmol, 1.0 eq.) in anhydrous THF and the mixture was refluxed for 1 h. The 
reaction mixture was evaporated in vacuo. Flash chromatography with 50 – 100% EtOAc in 
hexane afforded the product 82a as a colourless oil (3.24 g, 13.6 mmol, 83% yield); Rf = 0.55 
(100% EtOAc). 1H NMR (500 MHz, MeOD): δ ppm 7.02 (2H, d, J = 8.4, ArH), 6.74 (2H, d, J = 8.4, 
ArH), 3.82 (1H, hept, J = 6.5, isopropyl CH), 3.13 (2H, t, J = 7.0, 1-HA,B), 2.53 (2H, t, J = 7.5, 3-
HA,B), 1.76 (2H, quint, J = 7.5, 2-HA,B), 1.14 (6H, d, J =6.6, isopropyl CH3). 13C NMR (125 MHz, 
MeOD): δ ppm 160.7 (urea C=O), 156.5 (Ar), 134.0 (Ar), 130.4 (ArH), 116.3 (ArH), 43.0 (isopropyl 
CH), 40.6 (1-C), 33.6 (3-C), 33.3 (2-C), 23.7 (isopropyl CH3). IR νmax (neat)/cm-1: 3334 (O-H, N-H), 
3014, 2969, 2931, 2872 (C-H), 1558, 1514, 1455 (C=C), 1240 (C-O).HRMS (ESI): C13H21N2O2 [M + 
H+]: calculated 237.1598, found 237.1592. 
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1-(3-(4-Hydroxyphenyl)propyl)-3-(4-methoxyphenyl)urea 82b 
 
4-Methoxyphenyl isocyanate (0.30 mL, 2.30 mmol, 1.01 eq.) was added to a solution of the 
amine 71 (345 mg, 2.28 mmol, 1.0 eq.) in anhydrous THF and the mixture was refluxed for 1 h. 
The reaction mixture was evaporated in vacuo. Flash chromatography with 50 – 100% EtOAc in 
hexane afforded the compound 82b as a brown oil (497 mg, 1.66 mmol, 73% yield); Rf = 0.41 
(70% EtOAc in hexane). 1H NMR (300 MHz, MeOD) δ ppm 7.10 (2H, d, J = 9.0, ArH), 6.90 (2H, d, 
J = 8.4, ArH), 6.72 (2H, d, J = 9.0, ArH), 6.59 (2H, d, J = 8.7, ArH), 3.63 (3H, s, ArOCH3), 3.07 (2H, t, 
J = 6.9, 1-HA,B), 2.45 (2H, t, J = 7.2, 3-HA,B), 1.67 (2H, quint, J = 7.3, 2-HA,B). 13C NMR (75 MHz, 
MeOD): δ ppm 158.8 (Urea C=O), 157.0 (Ar), 156.4 (Ar), 133.8 (Ar), 133.6 (Ar), 130.2 (ArH), 
122.8 (ArH), 116.1 (ArH), 115.0 (ArH), 55.8 (ArOCH3), 40.4 (1-C), 33.3 (3-C), 33.2 (2-C). IR νmax 
(neat)/cm-1: 3308 (O-H, N-H), 3053, 2935, 2837 (C-H), 1647 (C=O), 1554, 1509, 1441 (C=C), 1228 
(C-O). HRMS (ESI): C17H21N2O3 [M + H+]: calculated 301.1547, found 301.1543. 
 
N-((3-(4-Hydroxyphenyl)propyl)carbamoyl)-4-methylbenzenesulfonamide 82c 
 
4-Toluenesulfonyl isocyanate (0.35 mL, 2.28 mmol, 1.01 eq.) was added to a solution of the 
amine 71 (341 mg, 2.26 mmol, 1.0 eq.) in anhydrous THF and the mixture was refluxed for 1 h. 
The reaction mixture was evaporated in vacuo. Flash chromatography with 30 – 90% EtOAc in 
hexane afforded the product 82c as a brown oil (595 mg, 1.72 mmol, 76% yield); Rf = 0.48 (70% 
EtOAc in hexane). 1H NMR (300 MHz, MeOD): δ ppm 7.74 (2H, d, J = 8.4, ArH), 7.26 (2H, d, J = 
8.1, ArH), 6.78 (2H, d, J = 8.7, ArH), 6.56 (2H, d, J = 8.7, ArH), 2.97 (2H, t, J = 6.9, 1-HA,B), 2.29 
(2H, t, J = 6.9, 3-HA,B), 2.29 (3H, s, ArCH3), 1.54 (2H, quint, J = 6.9, 2-HA,B). 13C NMR (75 MHz, 
MeOD): δ ppm 156.4 (Urea C=O), 153.9 (Ar), 145.7 (Ar), 138.6 (Ar), 133.4 (Ar), 130.6 (ArH), 
136 
 
130.1 (ArH), 128.5 (ArH), 116.0 (ArH), 40.3 (1-C), 32.8 (3-C), 32.6 (2-C), 21.4 (ArCH3). IR νmax 
(neat)/cm-1: 3352 (O-H, N-H), 2929, 2860 (C-H), 1668 (C=O), 1539,1514, 1444 (C=C), 1157 (C-O). 
HRMS (ESI): C17H21N2O4S [M + H+]: calculated 349.1217, found 349.1217. 
 
(6aR*, 10aS*)-6-Isopropyl-2,3,6a,7-tetrahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazole-5,8(6H)-
dione 83a 
 
A solution of PIFA (1.21g, 2.81 mmol, 1.1 eq.) dissolved in DCM/HFIP (7ml, 50:50) was added to 
a solution of the urea 82a (603 mg, 2.55 mmol, 1.0 eq.) in 7 mL of the same solvent system at 0 
°C and the mixture was stirred for 2 h after which it was allowed to warm up to room 
temperature for 20 min. The reaction mixture was washed with 20 mL of 10% Na2CO3 solution 
and the aqueous layer was extracted with DCM (4 × 25 mL) and evaporated in vacuo. Flash 
chromatography on silica gel eluting with 1% MeOH in DCM gave a colourless oil 83a (222 mg, 
0.95 mmol, 37%); Rf = 0.36 (100% EtOAc). 1H NMR (300 MHz, MeOD): δ ppm 6.58 (1H, d, J = 
10.2, 9-H), 5.96 (1H, d, J =10.2, 10-H), 4.04 (1H, dd, J = 6.9, 5.3, 6a-H), 3.82 (1H, hept, J = 6.9, 
isopropyl CH), 3.65 (1H, ddd, J = 15.6, 7.8, 3.9, 3-HA), 3.02 (1H, m, 3-HB), 2.81 (1H, dd, J = 16.1, 
5.2, 7-HA), 2.61 (1H, dd, J = 16.1, 6.9, 7-HB), 2.05 - 1.90 (1H, m, 2-HA), 1.90 – 1.82 (1H, m, 1-HA), 
1.82 – 1.72 (2H, m, 1-HB, 2-HB), 1.14 (3H, d, J = 6.9, isopropyl CH3A), 1.11 (3H, d, J = 6.9, isopropyl 
CH3B). 13C NMR (75 MHz, MeOD): δ ppm 198.2 (8-C), 164.2 (5-C), 147.8 (9-C), 128.2 (10-C), 64.7 
(10a-C), 59.1 (6a-C), 46.7 (3-C), 46.0 (isopropyl CH), 41.9 (7-C), 35.8 (1-C), 25.5 (2-C), 21.4 
(isopropyl CH3B), 19.5 (isopropyl CH3A). IR νmax (neat)/cm-1: 2966, 2938, 2876 (C-H), 1681 (C=O), 
1456 (C=C). HRMS (ESI): C13H19N2O2 [M + H+]: calculated 235.1441, found 235.1437. 
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(6aR*,10aS*)-6-(4-Methoxyphenyl)-2,3,6a,7-tetrahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazole-
5,8(6H)-dione 83b 
 
A solution of PIFA (361 mg, 0.84 mmol, 1.01 eq.) dissolved in DCM/HFIP (0.62 mL, 50:50) was 
added to a solution of the urea 82b (250 mg, 0.83 mmol, 1.0 eq.) in 2.7 mL of the same solvent 
system at 0 °C and the mixture was stirred for 2 h after which it was allowed to warm up to 
room temperature in 20 min, and then evaporated in vacuo. Flash chromatography on silica gel 
eluting with 1% MeOH in DCM gave a white solid 83b as product (104 mg, 0.35 mmol, 42%); Rf 
= 0.35 (100% EtOAc). 1H NMR (300 MHz, CDCl3): δ ppm 7.13 (2H, d, J = 9.0, ArH), 6.91 (2H, d, J = 
9.0, ArH), 6.56 (1H, d, J = 10.2, 9-H), 6.13 (1H, d, J = 10.3, 10-H), 4.36 (1H, t, J = 5.1, 6a-H), 3.99 – 
3.88 (1H, m, 3-HA), 3.80 (3H, s, ArOCH3), 3.30 - 3.19 (1H, m, 3-HB), 2.74 (1H, dd, J = 16.6, 5.0, 7-
HA), 2.66 (1H, dd, J = 16.6, 5.2, 7-HB), 2.30 – 2.12 (1H, m, 1-HA), 2.12 – 2.07 (1H, m, 1-HB), 2.06 – 
1.99 (2H, m, 2-HA,B). 13C NMR (75 MHz, CDCl3): δ ppm 195.1 (8-C), 160.6 (5-C), 157.7 (Ar), 146.2 
(9-C), 129.8 (Ar), 127.6 (10-C), 125.8 (ArH), 114.6 (ArH), 62.8 (10a-C), 61.7 (6a-C), 55.5 (ArOCH3), 
45.9 (3-C), 38.1 (7-C) 35.5 (1-C), 25.7 (2-C). IR νmax (neat)/cm-1: 2957, 2900, 2834 (C-H), 1686 
(C=O), 1582, 1510, 1443, 1390 (C=C). HRMS (ESI): C17H19N2O3 [M + H+]: calculated 299.1390, 
found 299.1390. 
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(6aR*,10aS*)-6-(4-Toluenesulfonyl)-2,3,6a,7-tetrahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazole-5,8(6H)-dione 83c 
 
A solution of PIFA (645 mg, 1.50 mmol, 1.01 eq.) dissolved in DCM/HFIP (1.1 mL, 50:50) was 
added to a solution of the urea 82c (518 mg, 1.49 mmol, 1.0 eq.) in 4.9 mL of the same solvent 
system at 0 °C and the mixture was stirred for 2 h after which it was allowed to warm up to 
room temperature in 20 min, and then evaporated in vacuo. Flash chromatography on silica gel 
eluting with 40% EtOAc in hexane gave a white solid 83c (118 mg, 0.34 mmol, 23%) Rf = 0.57 
(100% EtOAc). 1H NMR (300 MHz, CDCl3): δ ppm 7.85 (2H, d, J = 8.3, ArH), 7.26 (2H, d, J = 8.2, 
ArH), 6.40 (1H, d, J = 10.3, 9-H), 6.05 (1H, d, J = 10.3, 10-H), 4.54 (1H, dd, J = 8.8, 5.8, 6a-H), 3.84 
– 3.70 (1H, m, 3-HA), 3.12 (1H, dd, J = 15.9, 5.7, 7-HA), 3.05 (1H, ddd, J = 12.9, 5.7, 1.2, 3-HB), 
2.86 (1H, dd, J = 15.9, 8.8, 7-HB), 2.36 (3H, s, ArCH3), 2.04 – 1.82 (3H, m, 1-HA, 2-HA,B), 1.63 (1H, 
dt, J = 12.8, 9.5, 1-HB). 13C NMR (75 MHz, CDCl3): δ ppm 194.5 (8-C), 156.3 (5-C), 145.2 (Ar), 
142.8 (9-C), 135.5 (Ar), 129.7 (ArH), 129.0 (10-C), 128.3 (ArH), 63.2 (10a-C), 58.3 (6a-C), 44.7 (3-
C), 41.3 (7-C) 35.1 (1-C), 23.5 (2-C), 21.7 (ArCH3). IR νmax (neat)/cm-1: 2958, 2930 (C-H), 1736, 
1685 (C=O), 1597, 1494, 1458, 1369 (C=C). HRMS (ESI): C17H19N2O4S [M + H+]: calculated 
347.1060, found 347.1060. 
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(6aR*,10aS*)-6-Isopropylhexahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazole-5,8(6H)-dione 101a 
 
To a solution of the enone 83a (197 mg, 0.84 mmol, 1.0 eq.) and tris(triphenyl)rhodium(I) 
chloride (15.6 mg, 16.9 µmol, 2.0 mol%) in 5 mL THF, 6 mL of TES was added. The mixture was 
stirred at room temperature for 24 h. 0.05 mL of 1M HCl was then added and the mixture was 
stirred at room temperature for 1 h and evaporated in vacuo. Flash chromatography eluting 
with 50 – 100% EtOAc in hexane afforded the product 101a (167 mg, 0.71 mmol, 85%); Rf = 0.43 
(100% EtOAc). 1H NMR (300 MHz, MeOD) δ ppm 4.03 (1H, dd, J = 5.1, 3.2, 6a-H), 3.71 (1H, hept, 
J = 6.9, isopropyl CH), 3.53 (1H, ddd, J = 12.0, 6.0, 3.3, 3-HA), 2.92 (1H, ddd, J = 12.0, 5.7, 3.6, 3-
HB), 2.83 (1H, dd, J = 15.5, 5.3, 7-HA), 2.50 (1H, dd, J = 15.5, 3.1, 7-HB), 2.31 – 2.22 (2H, m, 1-HA, 
9-HA), 2.03 (1H, ddd, J = 14.5, 10.1, 6.5, 1-HB), 1.95 – 1.78 (4H, m,  9-HB, 10-HA, 2-HA,B), 1.65 – 
1.52 (1H, m, 10-HB), 1.14 (3H, d, J = 6.9, isopropyl CH3A), 1.12 (3H, d, J = 6.9, isopropyl CH3B). 13C 
NMR (75 MHz, MeOD) δ ppm 213.1 (8-C), 164.9 (5-C), 66.6 (10a-C), 60.0 (6a-C), 46.3 (isopropyl 
CH), 45.3 (3-C), 43.6 (7-C), 38.0 (10-C), 36.1 (1-C), 29.5 (9-C), 24.6 (2-C), 21.4 (isopropyl CH3B), 
19.5 (isopropyl CH3A). IR νmax (neat)/cm-1: 2967 (C-H), 1682 (C=O). HRMS (ESI): C13H21N2O2 [M + 
H+]: calculated 237.1598, found 237.1595. 
 
(6aR*,10aS*)-6-(4-Methoxyphenyl)hexahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazole-5,8(6H)-
dione 101b 
 
To a mixture of Pd(OH)2/C (20.8 mg, 20% w/w) and enone 83b (104 mg, 0.35 mmol, 1.0 eq.) 
under an atmosphere of nitrogen, 10 mL of HPLC grade EtOAc was added gently. The reaction 
mixture was degassed and hydrogen gas was bubbled through it with the aid of a balloon, and 
this procedure was repeated twice. The mixture was then allowed to stir under a balloon of 
140 
 
hydrogen for 23 h at room temperature. The reaction mixture was filtered through a plug of 
Celite washing with 100 mL EtOAc. The filtrate was evaporated in vacuo. Flash chromatography 
eluting with 2 - 4% MeOH in DCM afforded the product 101b as a brown solid (72 mg, 0.24 
mmol, 69%); Rf = 0.41 (100% EtOAc). 1H NMR (500 MHz, CDCl3): δ ppm 7.04 (2H, d, J = 9.0, ArH), 
6.81 (2H, d, J = 9.0, ArH), 4.35 (1H, t, J = 4.0, 6a-H), 3.76 (1H, ddd, J = 11.5, 5.5, 3.5, 3-HA), 3.71 
(3H, s, ArOCH3), 3.07 (1H, ddd, J = 11.5, 6.0, 3.5, 3-HB), 2.60 – 2.54 (2H, m, 7-HA,B), 2.54 -2.49 
(1H, m, 1-HA), 2.31 (1H, dt, J = 19.0, 3.9, 1-HB), 2.03 – 1.89 (5H, m, 2-HA,B; 9-HA,B; 10-HA), 1.80 
(1H, ddd, J = 16.0, 9.5, 3.5, 10-HB).  13C NMR (125 MHz, CDCl3): δ ppm 208.2 (8-C), 160.0 (5-C), 
156.3 (Ar), 128.9 (Ar), 124.3 (ArH), 113.6 (ArH), 63.2 (10a-C), 60.0 (6a-C), 54.5 (ArOCH3), 43.5 (3-
C), 39.4 (7-C) 37.4 (10-C), 34.2 (1-C), 28.7 (9-C), 23.4 (2-C). IR νmax (neat)/cm-1:  2998, 2953, 2891 
(C-H), 1710 (C=O), 1617, 1586, 1516, 1406 (C=C). HRMS (ESI): C17H21N2O3 [M + H+]: calculated 
301.1547, found 301.1544. 
 
(6aR*,10aS*)-6-(4-Toluenesulfonyl)hexahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazole-5,8(6H)-
dione 38 
 
Method C 
To a mixture of Pd(OH)2/C (20.0 mg, 20% w/w) and enone 83c (98.0 mg, 0.28 mmol, 1.0 eq.) 
under an atmosphere of nitrogen, 10 mL of HPLC grade MeOH was added gently. The reaction 
mixture was degassed and hydrogen gas was bubbled through it with the aid of a balloon, and 
this procedure was repeated twice. The mixture was then allowed to stir under a balloon of 
hydrogen for 3 days at room temperature. The reaction mixture was filtered through a plug of 
Celite washing with 100 mL MeOH. The filtrate was evaporated in vacuo. To a solution of the 
crude in 2 mL of THF, 0.68 mL of 1 M HCl was added and stirred at room temperature for 6 h. 4 
mL of a saturated solution of aqueous NaHCO3 was then added. The reaction mixture was 
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extracted with EtOAc (5 × 20 mL), dried over MgSO4, and evaporated in vacuo. Flash 
chromatography eluting with 30 - 90% EtOAc in hexane afforded the product 101c as a white 
solid (70.0 mg, 0.20 mmol, 71%). 
Method D 
To a mixture of Pd(OH)2/C (27.0 mg, 20% w/w) and enone 83c (133 mg, 0.38 mmol, 1.0 eq.) 
under an atmosphere of nitrogen, 10 mL of HPLC grade EtOAc was added gently. The reaction 
mixture was degassed and hydrogen gas was bubbled through it with the aid of a balloon, and 
this procedure was repeated twice. The mixture was then allowed to stir under a balloon of 
hydrogen for 27 h at room temperature. The reaction mixture was filtered through a plug of 
Celite washing with 100 mL EtOAc. The filtrate was evaporated in vacuo. Flash chromatography 
eluting with 50 - 90% EtOAc in hexane afforded the product 101c as a white solid (111 mg, 0.32 
mmol, 83%); Rf = 0.61 (100% EtOAc). 1H NMR (400 MHz, CDCl3): δ ppm 7.83 (2H, d, J = 8.4, ArH), 
7.32 (2H, d, J = 8.8, ArH), 4.56 (1H, dd, J = 5.2, 3.8, 6a-H), 3.66 (1H, ddd, J = 12.0, 5.6, 3.2, 3-HA), 
3.13 (1H, dd, J = 16.3, 3.7, 7-HA), 2.94 (1H, ddd, J = 12.1, 9.2, 4.9, 3-HB), 2.84 (1H, dd, J = 16.3, 
5.3, 7-HB), 2.35 (3H, s, ArCH3), 2.34 - 2.18 (2H, m, 1-HA,B), 2.03 – 1.79 (5H, m, 2-HA,B; 9-HA,B; 10-
HA), 1.59-1.50 (1H, m, 10-HB). 13C NMR (100 MHz, CDCl3): δ ppm 208.1 (8-C), 156.6 (5-C), 145.0 
(Ar), 135.4 (Ar), 129.6 (ArH), 128.4 (ArH), 65.1 (10a-C), 59.4 (6a-C), 43.6 (3-C), 42.9 (7-C), 37.1 
(10-C), 34.8 (1-C), 28.4 (9-C), 23.5 (2-C), 21.7 (ArCH3). IR νmax (neat)/cm-1: 2959 (C-H), 1718 
(C=O), 1596, 1494, 1455, 1352 (C=C). HRMS (ESI): C17H21N2O4S [M + H+]: calculated 349.1217, 
found 349.1217. 
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(6aR*,10aS*)-Hexahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazole-5,8(6H)-dione 104 
 
To a mixure of the ketone 101b (13 mg, 0.04 mmol, 1.0 eq.) and CAN (94 mg, 0.17, 4.0 eq.) in 
0.43 mL of HPLC grade MeCN, 0.24 mL of H2O was added and the mixture was left to stir for 5 
min. The reaction mixture was extracted with EtOAc (5 × 20 mL), dried over MgSO4, and 
evaporated in vacuo. Flash chromatography with 2 – 4% MeOH in DCM afforded the product 
104 as a pale yellow solid (8 mg, 0.04 mmol, 95% yield). 1H NMR (400 MHz, CDCl3): δ ppm 4.79 
(1H, s, 6-H), 3.99 (1H, m, 6a-H), 3.65 (1H, ddd, J = 12.0, 5.6, 4.0, 3-HA), 2.98 (1H, ddd, J = 12.0, 
5.2, 2.0, 3-HB), 2.64 (1H, dd, J = 16.3, 4.5, 7-HA), 2.52 (1H, ddd, J = 18.8, 10.4, 1.6, 1-HA), 2.45 
(1H, dd, J = 16.4, 3.6, 7-HB), 2.29 (1H, dt, J = 19.0, 3.9, 1-HB), 1.99 – 1.83 (5H, m, 2-HA,B; 10-HA, 9-
HA,B), 1.81 – 1.71 (1H, m, 10-HB). 13C NMR (100 MHz, CDCl3): δ ppm 208.6 (8-C), 162.8 (5-C), 65.9 
(10a-C), 55.1 (6a-C), 43.1 (3-C), 42.5 (7-C), 37.2 (10-C), 34.1 (1-C), 30.1 (9-C), 24.9 (2-C). IR νmax 
(neat)/cm-1: 3312 (N-H), 2969, 2938 (C-H), 1734, 1703 (C=O). HRMS (ESI): C10H14N2NaO2 [M + 
Na+]: calculated 217.0947, found 217.0946. 
 
(6aR*,11bS*)-6-Isopropyl-2,3,6a,7-tetrahydro-1H-pyrrolo[1’,2’:3,4]imidazole[4,5-e]isoindole-
5,8(6H, 10H)-dione 105 
 
To a mixture of potassium tert-butoxide (382 mg, 3.40 mmol, 5.0 eq.) and TosMIC (132.8 mg, 
0.68 mmol, 1.0 eq.), a solution of the enone 83a (160 mg, 0.68 mmol, 1.0 eq.) in 3.5 mL 
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anhydrous THF was added and the mixture was stirred for 17 h at room temperature. The 
reaction mixture was extracted with DCM (5 × 12 mL), dried over Na2SO4 and evaporated in 
vacuo. Flash chromatography on silica gel eluting with 50 – 100% EtOAc in hexane afforded a 
brown oil 105 (32.0 mg, 0.12 mmol, 17%). Rf = 0.50 (100% EtOAc). 1H NMR (300 MHz, MeOD): δ 
ppm 7.25 (1H, d, J = 1.8, ArH), 6.80 (1H, d, J = 1.8, ArH), 4.15 (1H, dd, J = 9.5, 5.7, 6a-H), 3.92 
(1H, hept, J = 6.9, isopropyl CH), 3.79 (1H, ddd, J = 12.0, 7.2, 3.4, 3-HA), 3.02 (1H, ddd, J = 12.4, 
8.8, 7.0, 3-HB), 2.87 (1H, dd, J = 16.1, 5.7, 7-HA), 2.61 (1H, dd, J = 16.2, 9.6, 7-HB), 2.12 – 1.78 
(4H, m, 1-HA,B; 2-HA,B), 1.18 (6H, d, J = 6.9, isopropyl CH3A,B). 13C NMR (75 MHz, MeOD): δ ppm 
194.0 (8-C), 165.0 (5-C), 127.8 (Ar), 120.4 (ArH), 120.4 (Ar), 117.6 (ArH), 64.9 (11b-C), 59.2 (6a-
C), 46.2 (isopropyl CH), 45.6 (3-C), 45.2 (7-C), 37.4 (1-C), 24.5 (2-C), 22.0 (isopropyl-CH3A), 19.8 
(isopropyl-CH3B). IR νmax (neat)/cm-1: 3271 (N-H), 2968, 2931 (C-H), 1691, 1665 (C=O), 1521, 
1474, 1456 (C=C). X-ray crystal structure: See Scheme 24. 
 
(6aR*,8aR*,9aS*,9bS*)-6-Isopropylhexahydro-1H-cyclopropa[5,6]benzo[1,2-d]pyrrolo[1,2-
c]imidazole-5,8(6H, 8aH)-dione 106a 
 
To a mixture of trimethylsulfoxonium chloride (75.9 mg, 0.59 mmol, 1.1 eq.) and 60% sodium 
hydride in mineral oil (23.6 mg, 0.59 mmol, 1.1 eq.) at 0 °C, 2 mL of anhydrous THF was added 
and the mixture was left to stir for 15 min. The ice bath was removed and the chalky mixture 
was left to stir at room temperature for 30 min. 2 mL of anhydrous THF was then used to 
transfer the enone 83a  (126 mg, 0.54 mmol, 1.0 eq.) to the chalky mixture and was further left 
to stir for 2.5 h. The reaction mixture was extracted with DCM (5 × 15 mL) in 5 mL water, dried 
over Na2SO4 and concentrated in vacuo. Flash chromatography on silica gel eluting with 1% 
MeOH in DCM afforded the compound as a white solid 106a (95 mg, 0.38 mmol, 71%). Rf = 0.36 
144 
 
(100% EtOAc). 1H NMR (300 MHz, MeOD): δ ppm 3.87 (1H, dd, J = 11.4, 6.3, 6a-H), 3.81 (1H, 
hept, J = 6.9, isopropyl CH), 3.68 (1H, ddd, 12.3, 8.8, 5.5, 3-HA), 3.02 (1H, ddd,12.2, 8.8, 5.6, 3-
HB), 2.52 – 2.34 (2H, m, 7-HA,B), 2.00 – 1.81 (4H, m, 9a-H, 1-HA, 2-HA,B), 1.70 – 1.61 (1H, m, 8a-H), 
1.53 – 1.37 (2H, m, 1-HB, 9-HA), 1.27 (1H, td, J = 9.0, 5.4, 9-HB), 1.11 (3H, d, 6.9, isopropyl CH3A), 
1.10 (3H, d, 6.6, isopropyl CH3B). 13C NMR (75 MHz, MeOD): δ ppm 208.9 (8-C), 164.7 (5-C), 66.1 
(9b-C), 60.6 (6a-C), 46.1 (isopropyl CH), 45.0 (3-C), 41.4 (7-C), 37.3 (1-C), 28.41 (8a-C), 28.37 (9a-
C), 23.5 (2-C), 22.1 (isopropyl CH3B), 19.7 (isopropyl CH3A), 16.5 (9-C). IR νmax (neat)/cm-1: 2972, 
2938, 2892 (C-H), 1682 (C=O). HRMS (ESI): C14H21N2O2 [M + H+]: calculated 249.1598, found 
249.1598. 
 
(6aR*,8aR*,9aS*,9bS*)-6-(4-Methoxyphenyl)hexahydro-1H-cyclopropa[5,6]benzo[1,2-
d]pyrrolo[1,2-c]imidazole-5,8(6H, 8aH)-dione 106b 
 
To a mixture of trimethylsulphoxonium chloride (240 mg, 1.87 mmol, 1.1 eq.) and 60% sodium 
hydride in mineral oil (74.9 mg, 1.87 mmol, 1.1 eq.) at 0 °C, 12.7 mL of anhydrous THF was 
added and the mixture was left to stir for 15 min. The ice bath was removed and the chalky 
mixture was left to stir at room temperature for 30 min. 3 mL of anhydrous DCM was then used 
to transfer the enone 83b (508 mg, 0.54 mmol, 1.70 eq.) to the chalky mixture and was further 
left to stir overnight. The reaction mixture was extracted with DCM (5 × 20 mL) in 5 mL water, 
dried over sodium sulphate and concentrated in vacuo. Flash chromatography on silica gel 
eluting with 1% MeOH in DCM afforded the product 106b (343 mg, 1.10 mmol, 64%). Rf = 0.56 
(100% EtOAc). 1H NMR (500 MHz, CDCl3): δ ppm 7.18 (2H, d, 9.5, ArH), 6.80 (2H, d, 9.0, ArH), 
4.24 (1H, dd, J = 11.6, 5.9, 6a-H), 3.90 (1H, ddd, 12.0, 6.5, 3.5, 3-HA), 3.71 (3H, s, ArOCH3), 3.16 
(1H, ddd,12.3, 9.3, 4.9, 3-HB), 2.42 (1H, ddd, 14.1, 5.9, 1.3, 7-HA), 2.28 (1H, dd, 14.0, 11.8, 7-HB), 
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2.05 – 1.95 (3H, 1-HA,B; 2-HA), 1.96 – 1.91 (1H, m, 9a-H), 1.76 – 1.67 (1H, m, 2-HB), 1.62 – 1.56 
(1H, m, 8a-H), 1.45 (1H, q, J = 5.5, 9-HA), 1.30 (1H, td, J = 8.9, 6.0, 9-HB). 13C NMR (125 MHz, 
CDCl3): δ ppm 205.1 (8-C), 159.7 (5-C), 155.8 (Ar), 129.2 (Ar), 122.4 (ArH), 113.5 (ArH), 62.6 (9b-
C), 61.0 (6a-C), 54.5 (ArOCH3), 43.2 (3-C), 36.7 (7-C), 36.0 (1-C), 26.9 (8a-C), 26.6 (9a-C), 22.0 (2-
C), 14.8 (9-C). IR νmax (neat)/cm-1: 2960, 2837 (C-H), 1692 (C=O), 1611, 1512, 1460 (C=C), 1246 
(C-O). HRMS (ESI): C18H21N2O3 [M + H+]: calculated 313.1547, found 313.1545. 
 
(6aR*,8aS*,11aR*,11bS*)-10-Benzyl-6-(4-methoxyphenyl)octahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindole-5,8(6H,8aH)-dione 107 
(6aR*,8aR*,11aS*,11bS*)-10-Benzyl-6-(4-methoxyphenyl)octahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindole-5,8(6H,8aH)-dione 108 
 
To a mixture of lithium fluoride (22.1 mg, 0.85 mmol, 1.2 eq.) and the enone 83b (211 mg, 0.71 
mmol, 1.0 eq.) in dry MeCN (5.00 mL), N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine 
(0.20 mL, 0.78 mmol, 1.1 eq.) was added and the mixture was left to stir overnight. The reaction 
mixture was evaporated in vacuo and taken up in 1 mL H2O. 100 mL EtOAc was then added and 
the mixture was dried over sodium sulfate, and concentrated in vacuo. Flash chromatography 
on silica gel eluting with 2% MeOH in DCM afforded the two diastereomeric pyrrolidines 107 
[major product, 131 mg, 0.30 mmol, 43%, Rf = 0.38 (4% MeOH in DCM)] and 108 [minor 
product, 72 mg, 0.17 mmol, 25%, Rf = 0.35 (4% MeOH in DCM)]. 1H NMR (Major diastereomer, 
500 MHz, CDCl3): δ ppm 7.26 - 7.16 (5H, m, ArH), 7.14 (2H, d, J = 9.0, ArH), 6.82 (2H, d, J = 9.0, 
ArH), 4.50 (1H, br.d, J = 6.0, 6a-H), 3.81 (1H, ddd, J = 12.3, 9.2, 5.3, 3-HA), 3.72 (3H, s, ArOCH3), 
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3.68 (1H, d, J = 13.0, ArCH2A), 3.48 (1H, d, J = 13.0, ArCH2B), 3.11 (1H, dd, J = 14.5, 6.5, 7-HA), 
3.00 (1H, ddd, J = 12.2, 8.7, 5.2, 3-HB), 2.90 (1H, dd, J = 10.0, 1.5, 9-HA), 2.84 – 2.81 (1H, m, 11-
HA), 2.81 – 2.77 (2H, m, 8a-H, 11a-H), 2.75 (1H, dd, 9.5, 6.0, 9-HB), 2.65 (1H, t, 9.0, 11-HB), 2.45 
(1H, br.d, 14.5, 7-HB), 1.97 – 1.62 (4H, m, 1-HA,B; 2-HA,B). 13C NMR (Major diastereomer, 125 
MHz, CDCl3): δ ppm 211.1 (8-C), 160.9 (5-C), 157.3 (Ar), 138.6 (Ar), 130.0 (Ar), 128.6 (ArH), 
128.6 (ArH), 127.4 (ArH), 125.4 (ArH), 114.7 (ArH), 66.2 (11b-C), 60.6 (6a-C), 59.8 (ArCH2), 59.1 
(9-C), 55.7 (ArOCH3), 54.1 (11-C), 49.0 (11a-C), 44.4 (3-C), 43.4 (8a-C), 41.3 (7-C), 35.1 (1-C), 23.6 
(2-C). IR νmax (neat)/cm-1: 2961, 2834, 2800 (C-H), 1697 (C=O), 1610, 1584, 1511 (C=C), 1245 (C-
O). HRMS (ESI): C26H30N3O3 [M + H+]: calculated 432.2282, found 432.2289. 1H NMR (Minor 
diastereomer, 500 MHz, CDCl3): δ ppm 7.29 - 7.21 (5H, m, ArH), 6.96 (2H, d, J = 9.0, ArH), 6.81 
(2H, d, J = 9.0, ArH), 4.29 (1H, dd, J = 3.9, 2.2, 6a-H), 3.79 (1H, ddd, J = 11.5, 6.0, 2.0, 3-HA), 3.71 
(3H, s, ArOCH3), 3.68 (1H, d, J = 13.0, ArCH2A), 3.62 (1H, d, J = 13.0, ArCH2B), 3.18 (1H, dd, J = 9.8, 
7.2, 9-HA), 3.10 (1H, ddd, J = 12.9, 9.9, 7.1, 8a-H), 3.03 (1H, dt, J = 11.7, 7.0, 3-HB), 2.93 (1H, dd, J 
= 8.0, 5.5, 11-HA), 2.64 – 2.49 (3H, m, 9-HB, 7-HA,B), 2.49 – 2.43 (1H, m, 11a-H), 2.38 (1H, dd, 
10.3, 7.9, 11-HB), 2.10 – 1.84 (4H, m, 1-HA,B; 2-HA,B). 13C NMR (Minor diastereomer, 125 MHz, 
CDCl3): δ ppm 206.0 (8-C), 161.0 (5-C), 156.6 (Ar), 137.8 (Ar), 128.5 (Ar), 127.6 (ArH), 127.4 
(ArH), 126.1 (ArH), 124.7 (ArH), 113.6 (ArH), 64.2 (11b-C), 63.1 (6a-C), 59.7 (ArCH2), 54.5 
(ArOCH3), 52.4 (11-C), 49.0 (9-C), 48.1 (8a-C), 48.1 (11a-C), 46.4 (3-C), 37.8 (7-C), 37.7 (1-C), 24.8 
(2-C). IR νmax (neat)/cm-1: 2960, 2928, 2836 (C-H), 1697 (C=O), 1610, 1583, 1511 (C=C), 1246 (C-
O). HRMS (ESI): C26H30N3O3 [M + H+]: calculated 432.2282, found 432.2292. 
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(6aR*,8aS*,11aR*,11bS*)-10-Benzyl-6-isopropyloctahydro-1H-pyrrolo[1’,2’:3,4]imidazo[4,5-
e]isoindole-5,8(6H,8aH)-dione 109 
 
To a mixture of lithium fluoride (23.4 mg, 0.90 mmol, 1.2 eq.) and the enone 83a (175 mg, 0.75 
mmol, 1.0 eq.) in dry MeCN (1.60 mL), N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine 
(0.22 mL, 0.83 mmol, 1.1 eq.) was added and the mixture was left to stir overnight. The reaction 
mixture was extracted with DCM (5 × 10 mL) in 10 mL of water, dried over sodium sulphate and 
evaporated in vacuo. Flash chromatography on silica gel eluting with 50 – 100% EtOAc in 
hexane afforded the product 109 (106 mg, 0.29 mmol, 39%). Rf = 0.58 (10% MeOH in DCM).1H 
NMR (500 MHz, CDCl3): δ ppm 7.27 - 7.11 (5H, m, ArH), 3.87 (1H, hept, 7.0, isopropyl CH), 3.83 
(1H, dd, J = 6.0, 2.5, 6a-H), 3.74 – 3.68 (1H, m, 3-HA), 3.64 (1H, d, J = 12.5, ArCH2A), 3.59 (1H, d, J 
= 13.0, ArCH2B), 3.15 (1H, dd, J = 10.0, 7.2, 9-HA), 2.98 – 2.92 (1H, m, 8a-H), 2.91 – 2.85 (2H, m, 
3-HB, 11-HA), 2.63 (2H, dd, J = 5.5, 2.5, 7-HA,B), 2.54 (1H, t, J = 10.2, 9-HB), 2.41 (1H, ddd, J = 13.0, 
8.0, 3.0, 11a-H), 2.30 (1H, dd, J = 10.3, 8.0, 11-HB), 1.98 – 1.89 (1H, m, 1-HA), 1.78 – 1.69 (3H, m, 
1-HB; 2-HA,B), 1.14 (3H, d, J = 7.0, isopropyl CH3A), 1.09 (3H, d, J = 7.0, isopropyl CH3B). 13C NMR 
(125 MHz, CDCl3): δ ppm 206.7 (8-C), 162.5 (5-C), 137.7 (Ar), 127.6 (ArH), 127.4 (ArH), 126.1 
(ArH), 64.0 (11b-C), 60.8 (6a-C), 59.7 (ArCH2), 52.5 (11-C), 49.1 (9-C), 48.2 (8a-C), 48.0 (11a-C), 
46.6 (3-C), 43.6 (isopropyl CH), 39.9 (7-C), 37.5 (1-C), 24.6 (2-C), 20.2 (isopropyl CH3B), 18.1 
(isopropyl CH3A). IR νmax (neat)/cm-1: 2967, 2929, 2799 (C-H), 1685 (C=O), 1453, 1413, 1379 
(C=C). HRMS (ESI): C22H30N3O2 [M + H+]: calculated 368.2333, found 368.2330. 
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(6aR*,8aS*,11aR*,11bS*)-10-Benzyl-6-tosyloctahydro-1H-pyrrolo[1’,2’:3,4]imidazo[4,5-
e]isoindole-5,8(6H,8aH)-dione 110 
 
To a mixture of lithium fluoride (5.71 mg, 0.22 mmol, 1.2 eq.) and the enone 83c (64.7 mg, 0.19 
mmol, 1.0 eq.) in dry MeCN (5.00 mL), N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine 
(0.05 mL, 0.78 mmol, 1.1 eq.) was added and the mixture was left to stir overnight. The reaction 
mixture was evaporated in vacuo and taken up in 1 mL H2O. 100 mL EtOAc was then added and 
the mixture was dried over sodium sulfate, and concentrated in vacuo. Flash chromatography 
on silica gel eluting with 0.5 - 2% MeOH in DCM afforded the pyrrolidine 110 (22 mg, 0.05 
mmol, 25%). Rf = 0.36 (3% MeOH in DCM). 1H NMR (500 MHz, CDCl3): δ ppm 7.78 (2H, d, J = 8.4, 
ArH), 7.25 - 7.14 (7H, m, ArH), 4.43 (1H, dd, J = 4.2, 2.2, 6a-H), 3.64 (1H, ddd, J = 11.5, 8.0, 5.6, 
3-HA), 3.59 (1H, d, J = 13.0, ArCH2A), 3.54 (1H, d, J = 13.0, ArCH2B), 3.50 (1H, dd, J = 19.0, 2.0, 7-
HA), 3.14 (1H, dd, J = 10.1, 6.8, 9-HA), 2.96 (1H, ddd, J = 11.5, 6.0, 4.0, 3-HB), 2.86 (1H, dd, J = 8.0, 
5.6, 11-HA), 2.77 – 2.73 (1H, m, 8a-H), 2.73 – 2.69 (1H, m, 7-HB), 2.45 (1H, t, 10.2, 9-HB), 2.43 – 
2.37 (1H, m, 11a-H), 2.35 (3H, s, ArCH3), 2.13 (1H, dd, J = 10.3, 8.1, 11-HB), 2.05 – 1.71 (4H, m, 1-
HA,B; 2-HA,B). 13C NMR (125 MHz, CDCl3): δ ppm 205.3 (8-C), 156.5 (5-C), 144.2 (Ar), 137.5 (Ar), 
134.1 (Ar), 128.6 (ArH), 127.5 (ArH), 127.4 (ArH), 127.4 (ArH) 126.2 (ArH), 65.2 (11b-C), 62.5 (6a-
C), 59.5 (ArCH2), 52.8 (11-C), 48.7 (9-C), 48.1 (8a-C), 47.9 (11a-C), 46.1 (3-C), 40.2 (7-C), 37.3 (1-
C), 24.1 (2-C), 20.7 (ArCH3). IR νmax (neat)/cm-1: 3029, 2922, 2801 (C-H), 1720 (C=O), 1596, 1513, 
1458 (C=C). HRMS (ESI): C26H30N3O4S [M + H+]: calculated 480.1952, found 480.1964. 
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(4bR*, 10aS*, 10bS*, 11aR*)-5-(4-Methoxyphenyl)-4b,9,10,10b,11,11a-hexahydro-8H-
cyclopropa[h]pyrrolo[1',2':1,5]imidazo [4,5-f]quinolin-6(5H)-one 115 
 
Anhydrous THF (1 mL) was added to a dry mixture of trimethylsulphoxonium chloride (11.6 mg, 
0.09 mmol, 1.1 eq.) and 60% NaH in mineral oil (3.6 mg, 0.09 mmol, 1.1 eq.) and the mixture 
was stirred at 0 °C for 15 min after which it was allowed to warm up to room temperature for 
30 min. 4 mL of anhydrous THF was then used to transfer the enone 83b (24 mg, 0.08 mmol, 
1.0 eq.) to the reaction mixture and it was stirred for 19 h at room temperature. The reaction 
mixture was then extracted with DCM (5 × 20 mL), dried over MgSO4 and evaporated in vacuo. 
A mixture of the crude, NaAuCl4.2H2O (3.8 mg, 12 mol%) and propargylamine (10.2 µL, 0.16 
mmol, 2.0) in HPLC grade EtOH was refluxed for 16 h. The reaction mixture was extracted with 
DCM (5 × 20 mL), dried over Na2SO4, and evaporated in vacuo. Flash chromatography eluting 
with 1 – 6 % MeOH in DCM afforded the product as a colourless oil (7 mg, 0.02 mmol, 25% yield 
over two steps). 1H NMR (600 MHz, CDCl3) δ ppm 8.47 (1H, d, J = 4.8, ArH), 7.29 (1H, t, J = 6.6, 
ArH), 7.22 – 7.20 (1H, m, ArH), 6.85 -6.80 (4H, m, ArH), 4.73 (1H, s, 4b-H), 3.77 – 3.72 (4H, m, 8-
HA, ArOCH3), 3.46 – 3.39 (2H, m, 8-HB, 11a-H), 2.34 – 2.23 (1H, m, 10-HA), 2.22 - 2.09 (2H, m, 9-
HA,B), 2.06 (1H, q, J  = 7.2, 10-HB), 1.83 (1H, dt, J = 12.7, 7.9, 10b-H), 1.71 (1H, td, J = 8.4, 5.4, 11-
HA), 1.65 (1H, dd, J = 7.8, 5.4, 11-HB). 13C NMR (150 MHz, CDCl3) δ ppm 159.7 (6-C), 158.4 (Ar), 
155.8 (Ar), 145.6 (ArH), 139.2 (ArH), 129.0 (Ar), 128.5 (ArH), 127.4 (Ar), 120.9 (ArH), 114.1 (ArH), 
67.0 (4b-C), 60.6 (10a-C), 54.5 (ArOCH3), 43.8 (8-C), 37.7 (10-C), 26.7 (9-C), 26.1 (11a-C), 18.7 
(10b-C), 16.4 (11-C). IR νmax (neat)/cm-1: 2959, 2931 (C-H), 1700 (C=O), 1513, 1457, 1381 (C=C), 
1248 (C-O). HRMS (ESI): C21H22N3O2 [M + H+]: calculated 348.1707, found 348.1706. 
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N-(5S*,6R*,8R*)-8-Hydroxy-1-methyl-1-azaspiro[4.5]decan-6-yl)-4-methylbenzenesulfonamide 
122 
 
To a solution of the ketone 101c (54 mg, 0.16 mmol, 1.0 eq.) in 4 mL of anhydrous THF, 1 M 
LiAlH4 in THF (1.55 mL, 1.55 mmol, 10.0 eq.) was added and the mixture was refluxed for 6.5 h. 
The reaction mixture was quenched with 0.1 mL 10% KOH and and 0.1 mL H2O, diluted with 50 
mL EtOAc, dried over Na2SO4, and evaporated in vacuo. Flash chromatography eluting with 5% 
MeOH in DCM followed by 5% of a saturated solution of NH3/MeOH in DCM afforded the 
product 122 as a pale yellow solid (28 mg, 0.08 mmol, 54% yield); Rf = 0.42 (6% of saturated 
NH3/MeOH in DCM). 1H NMR (300 MHz, CDCl3): δ ppm 7.69 (2H, d, J = 8.1, ArH), 7.22 (2H, d, J = 
8.2, ArH), 3.78 (1H, tt, J = 6.0, 3.6, 8-H), 2.91 (1H, dd, J = 6.6, 4.4, 6-H), 2.63 - 2.53 (1H, m, 2-HA), 
2.46 – 2.37 (1H, m, 2-HB), 2.35 (3H, s, ArCH3), 2.31 (3H, s, 1-CH3), 1.99 (1H, ddd, J = 14.1, 9.3, 
4.2, 9-HA), 1.83 (1H, dt, J = 13.4, 6.6, 7-HA), 1.73 – 1.62 (2H, m, 7-HB, 10-HA), 1.60 – 1.47 (3H, m, 
9-HB, 4-HA, 3-HA), 1.47 – 1.30 (2H, m, 3-HB, 4-HB), 1.16 (1H, ddd, 13.8, 7.2, 4.5, 10-HB). 13C NMR 
(75 MHz, CDCl3): δ ppm 143.1 (Ar), 137.5 (Ar), 129.5 (ArH), 127.2 (ArH), 67.0 (8-C), 63.5 (5-C), 
56.0 (6-C), 55.4 (2-C), 38.4 (1-C), 36.6 (4-C), 35.6 (7-C), 31.2 (9-C), 25.6 (10-C), 22.6 (3-C), 21.5 
(ArCH3). IR νmax (neat)/cm-1: 3245 (O-H, N-H), 2929, 2871, 2787 (C-H), 1599, 1447, 1382 (C=C). 
HRMS (ESI): C17H27N2O3S [M + H+]: calculated 339.1737, found 339.1735. 
 
(5S*,6R*,8R*)-6-(Isopropylamino)-1-methyl-1-azaspiro[4.5]decan-8-ol 123a 
 
To a solution of the ketone 101a (59 mg, 0.25 mmol, 1.0 eq.) in 6.5 mL of anhydrous THF, 4 M 
LiAlH4 in ether (0.63 mL, 2.52 mmol, 10.0 eq.) was added and refluxed for 12 h. The reaction 
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mixture was quenched with 0.1 mL 10% KOH and and 0.1 mL H2O, diluted with 50 mL EtOAc, 
dried over Na2SO4, filtered and evaporated in vacuo. To a mixture of the crude and 
hydroxylamine hydrochloride (88 mg, 1.26 mmol, 5.0 eq.) was added 7 mL of 0.01% HCl and 
heated at 60 °C for 1 h. 29.3 mL of 0.5 M HCl was then added to the reaction mixture and 
washed with CHCl3 (2 × 25 mL). The aqueous layer was carefully basified with copious amounts 
of solid Na2CO3, extracted with CHCl3 (7 × 25 mL), dried over Na2SO4 and evaporated in vacuo. 
Flash chromatography eluting with 3% of a saturated solution of NH3/MeOH in DCM afforded a 
brown solid 123a (34 mg, 0.16 mmol, 64% yield); Rf = 0.33 (6% NH3/MeOH in DCM). 1H NMR 
(400 MHz, CDCl3): δ ppm 3.87 (1H, quint, J = 2.4, 8-H), 2.91 (1H, ddd, J = 11.8, 7.6, 4.2, 2-HA), 
2.83 (1H, hept, J  = 6.4, isopropyl CH), 2.61 (1H, dt, J = 11.6, 4.0, 2-HB), 2.51 (1H, t, J = 3.2, 6-H), 
2.04 (1H, td, J = 13.4, 4.2, 10-HA), 2.00 - 1.93 (1H, m, 7-HA), 1.83 – 1.45 (7H, m, 9-HA,B; 10-HB; 3-
HA,B; 4-HA,B), 1.31 (1H, dt, J = 14.4, 2.8, 7-HB), 1.03 (3H, d, J = 6.4,isopropyl CH3A), 0.95 (3H, d, J = 
6.4, isopropyl CH3B). 13C NMR (100 MHz, CDCl3): δ ppm 66.9 (8-C), 64.9 (5-C), 56.0 (6-C), 45.5 (2-
C), 45.4 (isopropyl CH), 35.2 (4-C), 31.8 (9-C), 29.9 (7-C), 28.1 (10-C), 27.2 (3-C), 24.5 (isopropyl 
CH3A), 21.1 (isopropyl CH3B). IR νmax (neat)/cm-1: 3256 (O-H, N-H), 2958, 2928, 2865 (C-H), 1135 
(C-O). HRMS (ESI): C12H25N2O [M + H+]: calculated 213.1961, found 213.1960. 
 
(5S*,6R*,8R*)-6-(4-Methoxyphenyl)amino-1-azaspiro[4.5]decan-8-ol 123b 
 
To a solution of the ketone 101b (798 mg, 2.66 mmol, 1.0 eq.) in 33 mL of anhydrous THF, 2 M 
LiAlH4 in THF (7.98 mL, 16.0 mmol, 6.0 eq.) was added and refluxed for 11.5 h. The reaction 
mixture was quenched with 2 mL 10% KOH and and 2 mL H2O, diluted with 300 mL EtOAc, dried 
over Na2SO4, filtered and evaporated in vacuo. To a mixture of the crude and hydroxylamine 
hydrochloride (924 mg, 13.3 mmol, 5.0 eq.), 74 mL of 0.01% HCl was added and heated at 60 °C 
overnight. The reaction mixture was washed with CHCl3 (2 × 50 mL). The aqueous layer was 
carefully basified with copious amounts of solid Na2CO3, extracted with CHCl3 (7 × 50 mL), dried 
over Na2SO4 and evaporated in vacuo. Flash chromatography eluting with 8 – 10% MeOH in 
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DCM followed by 6 - 10% of a saturated solution of NH3/MeOH in DCM afforded a pale yellow 
oil 123b (620 mg, 2.24 mmol, 84% yield); Rf = 0.37 (6% NH3/MeOH in DCM). 1H NMR (400 MHz, 
CDCl3): δ ppm 6.70 (2H, d, 8.8, ArH), 6.58 (2H, d, 8.8, ArH), 3.75 – 3.68 (1H, m, 8-H), 3.67 (3H, s, 
ArOCH3), 3.00 (1H, dd, 8.3, 3.5, 6-H), 2.93 (1H, dt, J = 10.4, 6.7, 2-HA), 2.81 (1H, dt, J = 10.4, 6.5, 
2-HB), 1.95 – 1.79 (3H, m, 7-HA, 9-HA,B), 1.76 – 1.35 (6H, m, 3-HA,B; 4-HA,B; 7-HB; 10-HA), 1.27 (1H, 
ddd, J = 13.6, 9.6, 4.0, 10-HB). 13C NMR (100 MHz, CDCl3): δ ppm 151.5 (Ar), 141.0 (Ar), 115.1 
(ArH), 113.9 (ArH), 67.0 (8-C), 62.4 (5-C), 55.8 (6-C), 54.8 (ArOCH3), 45.2 (2-C), 34.5 (9-C), 34.5 
(4-C), 31.2 (10-C), 30.6 (7-C), 25.1 (3-C). IR νmax (neat)/cm-1: 3346 (O-H, N-H), 2931, 2862, 2832 
(C-H), 1509, 1464, 1441 (C=C), 1232 (C-O). HRMS (ESI): C16H25N2O2 [M + H+]: calculated 
277.1911, found 277.1909. 
 
(6aR*,8S*,10S*)-8-Hydroxy-6-isopropyl-2,3,6,6a,7,8-hexahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 124 
 
 
A mixture of enone 83a (186 mg, 0.79 mmol, 1.0 eq.) and CeCl3.7H2O (354 mg, 0.95 mmol, 1.2 
eq.) in 4 mL of HPLC grade methanol was allowed to stir for 30 min at -78 °C after which NaBH4  
(35.9 mg, 0.95 mmol, 1.2 eq.) was added and the mixture was further stirred at the same 
temperature for 40 min. The reaction mixture was then allowed to warm up to room 
temperature for 1 h. It was extracted with EtOAc (5 × 20mL), dried over MgSO4 and evaporated 
in vacuo. Silica gel chromatography eluting with 70 – 90% EtOAc in hexane afforded the 
compound as a white solid (173 mg, 0.73 mmol, 92% yield); Rf = 0.42 (100% EtOAc). 1H NMR 
(300 MHz, MeOD): δ ppm 5.87 (1H, dt, J = 10.2, 1.3, 10-H), 5.67 (1H, dd, J = 10.2, 2.2, 9-H), 4.21 
(1H, ddd, J = 10.8, 4.5, 2.4, 8-H), 3.96 (1H, hept, J = 6.9, isopropyl CH), 3.79 (1H, dd, J = 12.0, 5.1, 
6a-H), 3.71 (1H, ddd, J = 12.3, 5.7, 3.0, 3-HA), 3.04 (1H, ddd, J = 12.2, 9.2, 5.7, 3-HB), 2.44 (1H, 
dtd, J = 11.2, 4.8, 1.4, 7-HA), 2.04 – 1.79 (2H, m, 2-HA,B), 1.69 (1H, ddd, J = 12.3, 7.8, 2.6, 1-HA), 
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1.61 – 1.40 (2H, m, 1-HB, 7-HB), 1.28 (3H, d, J = 6.9, isopropyl CH3A), 1.26 (3H, d, J = 6.6, isopropyl 
CH3B). 13C NMR (75 MHz, MeOD): δ ppm 164.5 (5-C), 134.7 (10-C), 127.0 (9-C), 65.8 (10a-C), 65.5 
(8-C), 56.0 (6-C), 46.1 (isopropyl CH), 45.3 (3-C), 39.8 (7-C), 36.3 (1-C), 23.6 (2-C), 22.4 (isopropyl 
CH3A), 19.6 (isopropyl CH3B). IR νmax (neat)/cm-1: 3369 (O-H), 2971, 2937 (C-H), 1666 (C=O), 1416 
(C=C), 1223 (C-O). HRMS (ESI): C13H21N2O2 [M + H+]: calculated 237.1598, found 237.1598. 
 
(6aR*,8S*,10aS*)-8-((tert-Butyldimethylsilyl)oxy)-6-isopropyl-2,3,6,6a,7,8-hexahydro-1H,5H-
benzo[d]pyrrolo[1,2-c]imidazol-5-one 125 
 
A mixture of enone 83a (57.0 mg, 0.24 mmol, 1.0 eq.) and CeCl3.7H2O (108 mg, 0.29 mmol, 1.2 
eq.) in 2 mL of HPLC grade methanol was allowed to stir for 30 min at -78 °C after which NaBH4  
(11.0 mg, 0.29 mmol, 1.2 eq.) was added and the mixture was further stirred at the same 
temperature for 40 min. The reaction mixture was then allowed to warm up to room 
temperature for 1 h. It was extracted with DCM (5 × 20mL), dried over MgSO4 and evaporated 
in vacuo. To a solution of the crude in 2 mL of anhydrous DCM; 2,6-lutidine (0.06 mL, 0.48 
mmol, 2.0 eq.) and TBSOTf (0.08 mL, 0.36 mmol, 1.5 eq.) were added. The mixture was allowed 
to stir at room temperature for 15 h. It was extracted with DCM (5 × 20 mL), dried over MgSO4 
and evaporated in vacuo. Flash chromatography with 70 – 90% EtOAc in hexane afforded the 
product as a white solid (82 mg, 0.23 mmol, 96% yield over two steps); Rf = 0.82 (100% EtOAc). 
1H NMR (300 MHz, MeOD): δ ppm 5.67 (1H, dt, J = 10.2, 1.2, 10-H), 5.51 (1H, dd, J = 10.2, 2.1, 9-
H), 4.27 – 4.17 (1H, m, 8-H), 3.83 (1H, hept, J = 6.9, isopropyl CH), 3.68 (1H, dd, J = 12.1, 4.9, 6a-
H), 3.58 (1H, ddd, J = 12.2, 9.0, 5.8, 3-HA), 2.91 (1H, ddd, J = 12.2, 9.2, 5.7, 3-HB), 2.21 (1H, dtd, J 
= 11.3, 4.8, 1.4, 7-HA), 1.91 – 1.66 (2H, m, 2-HA,B), 1.55 (1H, ddd, J = 10.6, 7.9, 2.6, 1-HA), 1.47 – 
1.29 (2H, m, 1-HB, 7-HB), 1.14 (3H, d, J = 6.9, isopropyl CH3A), 1.12 (3H, d, J = 6.6, isopropyl CH3B), 
154 
 
0.79 (9H, s, tert-butyl CH3), 0.00 (3H, s, SiCH3A), -0.01 (3H, s, SiCH3B). 13C NMR (300MHz, MeOD): 
δ ppm 164.6 (5-C), 135.3 (10-C), 126.7 (9-C), 67.0 (8-C), 65.7 (10a-C), 55.8 (6a-C), 46.1 (isopropyl 
CH), 45.3 (3-C), 40.6 (7-C), 36.2 (1-C), 26.2 (tert-butyl CH3), 23.6 (2-C), 22.3 (isopropyl CH3A), 19.7 
(isopropyl CH3B), 18.9 (tert-butyl C), 4.6 (SiCH3A), 4.5 (SiCH3B). IR νmax (neat)/cm-1: 2956, 2930 (C-
H), 1678 (C=O), 1508 (C=C), 1062 (C-O). HRMS (ESI): C19H34N2NaO2Si [M + Na+]: calculated 
373.2282, found 373.2281. 
 
(1R*, 7aR*)-1-(2,3-Dihydoxypropyl)-7a-(hydroxymethyl)-2-isopropylhexahydro-3H-pyrrolo[1,2-
c]imidazole-3-one 129 
 
Through a solution of the alkene 125 (40 mg, 0.11 mmol, 1.0 eq.) in 1 mL DCM, ozonized oxygen 
gas was passed at -78 °C until the solution turned blue in colour. Oxygen gas was then passed 
through the solution to get rid of the residual ozone (indicated by the disappearance of the blue 
colour). 8 mL of methanol was added followed by a careful addition of NaBH4 (excess) at -78 °C, 
and left to stand for 30 min at the same temperature. The reaction mixture was then allowed to 
warm up to room temperature overnight and evaporated in vacuo. It was extracted with EtOAc 
(5×20 mL) in 5 mL water, dried over Na2SO4 and evaporated in vacuo. To a solution of the crude 
in 4 mL THF, 0.10 mL of 1 M TBAF (in THF) was added and the mixture was allowed to stir 
overnight. The reaction mixture was evaporated in vacuo and taken up in 2 mL H2O. It was then 
diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. Flash chromatography 
with 4 – 10% MeOH in DCM afforded the product 129 with 4% TBAF contamination (12.0 mg, 
0.04 mmol, 39%); Rf = 0.23 (10% MeOH in DCM). 1H NMR (500 MHz, MeOD): δ ppm 3.84 (1H, 
qd, J = 6.6, 3.0, 2’-H), 3.80 – 3.68 (3H, m, 1-H, 5-HA, isopropyl CH), 3.63 – 3.54 (3H, m, 3’-HA, 7a-
CH2A,B), 3.42 (1H, dd, J = 11.0, 7.0, 3’-HB), 2.97 – 2.92 (4H, m, 5-HB, 2’-CHOH, 3’- CH2OH, 7a- 
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CH2OH), 2.06 (1H, ddd, J = 14.5, 10.0, 2.5, 1’-HA), 1.99 – 1.92 (1H, m, 7-HA), 1.84 – 1.70 (3H, m, 
1’-HB, 6-HA,B), 1.47 (1H, dt, J = 12.7, 8.8, 7-HB), 1.24 (3H, d, J = 6.9, isopropyl CH3A), 1.19 (3H, d, J 
= 6.8, isopropyl CH3B). 13C NMR (125 MHz, MeOD): δ ppm 161.6 (3-C), 68.8 (7a-C), 68.3 (2’-C), 
65.9 (3’-C), 60.8 (7a-CH2OH), 58.2 (1-C), 45.1 (5-C), 44.5 (isopropyl CH), 32.7 (7-C), 31.7 (1’-C), 
23.1 (6-C), 19.9 (isopropyl CH3B), 18.6 (isopropyl CH3A). IR νmax (neat)/cm-1: 3385 (O-H), 2962, 
2927, 2876 (C-H), 1670 (C=O), 1053 (C-O). HRMS (ESI): C13H25N2O4 [M + H+]: calculated 
273.1809, found 273.1801. 
 
Methyl 2-((5S*, 6R*, 8R*)-8-Hydroxy-6-((4-methoxyphenyl)amino)-1-azaspiro[4.5]decan-1-
yl)acetate 137 
 
A mixture of the diamine 123b (33 mg, 0.12 mmol, 1.0 eq), methyl bromoacetate (13.6 µL, 0.14 
mmol, 1.2 eq.) and KHCO3 (16 mg, 0.16 mmol, 1.3 eq.) in 2 mL of anhydrous THF was refluxed 
for 6 h, and evaporated in vacuo. Flash chromatography eluting with 1 – 2% MeOH in DCM 
afforded the product 137 as a brown oil (25 mg, 0.07 mmol, 60% yield); Rf = 0.54 (6% MeOH in 
DCM). 1H NMR (400 MHz, CDCl3) δ ppm 6.77 (2H, d, J = 9.2, ArH), 6.72 (2H, d, J = 8.8, ArH), 3.92 
(1H, quint, J = 3.2, 8-H), 3.86 (1H, d, J = 16.8, pyrrolidine NCH2A), 3.68 (3H, s, COOCH3), 3.61 (3H, 
s, ArOCH3), 3.21 (1H, d, J = 16.9, pyrrolidine NCH2B), 3.11 (1H, ddd, J = 10.6, 7.7, 5.4, 2-HA), 2.99 
(1H, t, J = 3.3, 6-H), 2.64 (1H, dt, J = 10.5, 7.4, 2-HB), 2.19 -2.07 (2H, m, 7-HA,B), 1.92 – 1.80 (2H, 
m, 9-HA,B), 1.79 – 1.70 (2H, m, 3-HA,B), 1.64 – 1.50 (4H, m, NH, 10-HA, 4-HA,B), 1.26 (1H, dt, 12.8, 
3.7, 10-HB). 13C NMR (100 MHz, CDCl3) δ ppm 173.4 (ester C=O), 153.5 (Ar), 142.3 (Ar), 118.3 
(ArH), 114.6 (ArH), 66.8 (8-C), 66.3 (5-C), 58.4 (6-C), 55.8 (COOCH3), 53.9 (2-C), 52.8 (pyrrolidine 
NCH2), 51.8 (ArOCH3) 34.9 (4-C), 32.3 (7-C), 31.5 (9-C), 24.1 (10-C), 22.9 (3-C). IR νmax (neat)/cm-
1: 3368 (O-H, N-H), 2933 (C-H), 1734 (C=O), 1509, 1439, 1365 (C=C), 1232 (C-O). HRMS (ESI): 
C19H29N2O4 [M + H+]: calculated 349.2122, found 349.2120. 
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(7aR*,9R*,11aS*)-9-Hydroxy-7-(4-methoxyphenyl)octahydro-1H-pyrrolo[1,2-d]quinoxalin-
6(5H)-one 138 
 
 
A solution of the diamine 137 (18 mg, 0.05 mmol, 1.0 eq.) and NaOMe (7.1 mg, 0.13 mmol, 1.1 
eq.) in 2 mL of anhydrous MeOH was refluxed for 6 h. The reaction mixture was evaporated in 
vacuo. Flash chromatography eluting with 2 – 10% MeOH in DCM afforded the product 138 as a 
brown oil (14 mg, 0.04 mmol, 88%); Rf = 0.26 (6% MeOH in DCM) When the reaction was 
telescoped from the diamine 123b without further purification of the intermediate 137, the 
piperazinone 138 was isolated in 90% yield. 1H NMR (400 MHz, CDCl3): δ ppm 7.11 (2H, d, J = 
9.2, ArH), 6.85 (2H, d, J = 8.8, ArH), 3.81 (1H, d, J = 17.6, 5-HA), 3.73 (3H, s, ArOCH3), 3.66 – 3.55 
(2H, m, 9-H, 7a-H), 3.31 (1H, d, J = 17.6, 5-HB), 3.05 (1H, ddd, J = 10.4, 6.4, 3.6, 3-HA), 2.86 (1H, 
dt, 10.5, 6.8, 3-HB), 2.05 (1H, dt, J = 13.4, 4.6, 8-HA), 2.02 – 1.96 (1H, m, 10-HA), 1.95 -1.89 (1H, 
m, 8-HB), 1.85 – 1.82 (1H, m, 10-HB), 1.82 – 1.77 (2H, m, 2-HA,B), 1.77 – 1.60 (4H, m, 1-HA; 11-
HA,B; 9-CHOH), 1.19 – 1.11 (1H, m, 1-HB). 13C NMR (100 MHz, CDCl3): δ ppm 169.7 (6-C), 158.3 
(Ar), 133.9 (Ar), 127.9 (ArH), 114.5 (ArH), 67.6 (9-C), 62.2 (11a-C), 61.9 (7a-C), 55.6 (3-C), 55.5 
(ArOCH3), 54.5 (5-C), 36.9 (8-C), 36.5 (10-C), 30.7 (11-C), 30.2 (1-C), 23.3 (2-C). IR νmax (neat)/cm-
1: 3378 (O-H), 2940, 2870 (C-H), 1642 (C=O), 1509, 1431, 1365 (C=C), 1242 (C-O). HRMS (ESI): 
C18H25N2O3 [M + H+]: calculated 317.1860, found 317.1855. 
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(7aR*, 9R*, 11aS*)-9-Hydroxy-7-(4-methoxyphenyl)octahydro-1H-pyrrolo[1,2-d]quinoxalin-
5(6H)-one 
 
To a solution of the diamine 123b (100 mg, 0.36 mmol, 1.0 eq.) in 14 mL THF was added 
chloroacetyl chloride (0.03 mL, 0.40 mmol, 1.1 eq.) and DIPEA (0.15 mL, 0.87 mmol, 2.4 eq.) at -
78 °C. The reaction mixture was left to warm up to room temperature overnight. 2 M KOH (2 
mL) was then added and also left to stir at room temperature overnight. The reaction mixture 
was extracted with EtOAc (5 × 20 mL), dried over Na2SO4 and evaporated in vacuo. Flash 
chromatography eluting with 1 – 4% MeOH in DCM afforded the product 139 as a colourless oil 
(70 mg, 0.22 mmol, 61% yield); Rf = 0.38 (5% MeOH in DCM). 1H NMR (400 MHz, CDCl3): δ ppm 
7.01 (2H, d, J = 8.8, ArH), 6.83 (2H, d, J = 8.8, ArH), 4.34 (1H, s, 9-CHOH), 3.96 (1H, d, J = 17.6, 6-
HA), 3.79 – 3.66 (5H, m, 9-H, 3-HA, ArOCH3), 3.58 – 3.47 (1H, m, 3-HB), 3.32 (1H, d, J = 17.6, 6-
HB), 3.24 (1H, t, J = 3.2, 7a-H), 2.27 – 2.06 (3H, m, 1-HA, 8-HA, 11-HA), 2.02 – 1.92 (2H, m, 2-HA,B), 
1.89 – 1.80 (1H, m, 10-HA), 1.59 – 1.46 (3H, m, 1-HB, 10-HB, 11-HB), 1.41 (1H, dt, J = 15.0, 3.0, 8-
HB). 13C NMR (100 MHz, CDCl3): δ ppm 164.0 (5-C), 156.1 (Ar), 142.0 (Ar), 124.2 (ArH), 114.1 
(ArH), 64.6 (9-C), 62.7 (11a-C), 60.0 (7a-C), 58.4 (6-C), 54.4 (ArOCH3), 43.2 (3-C), 33.6 (11-C), 
29.9 (10-C), 29.5 (8-C), 24.3 (1-C), 19.8 (2-C). IR νmax (neat)/cm-1: 3434 (O-H), 2935, (C-H), 1642 
(C=O), 1509, 1463, 1427 (C=C), 1242 (C-O). HRMS (ESI): C18H25N2O3 [M + H+]: calculated 
317.1860, found 317.1857. 
 
 
 
 
158 
 
(5aR*,11aS*)-6-Isopropyloctahydro-9H-pyrrolo[1',2':1,5]imidazo[4,5-c]azepine-3,7-dione 152a 
 
A solution of the ketone 101a (51 mg, 0.22 mmol, 1.0 eq.), hydroxylamine hydrochloride (31 
mg, 0.44 mmol, 2.0 eq.) and potassium carbonate (91.2 mg, 0.66 mmol, 3.0 eq.) in 3 mL 
EtOH/H2O (2:1 respectively) was refluxed for 2 h. The reaction mixture was extracted with DCM 
(5 × 20 mL), dried over MgSO4 and evaporated in vacuo. To a solution of the crude, TsCl (63.0 
mg, 0.33 mmol, 1.5 eq.) and DMAP (2.69 mg, 0.02 mmol, 10 mol%) in 14 mL of anhydrous DCM; 
Et3N (52 µL, 0.37 mmol, 1.7 eq.) was added and the mixture was allowed to stir at room 
temperature for 1.5 h. The reaction mixture was evaporated in vacuo. 1 mL of 98% sulphuric 
acid was then added to a solution of the crude in anhydrous MeOH and refluxed for 2 h. The 
reaction mixture was neutralized with copious amounts of solid Na2CO3 in 5 mL H2O, extracted 
with DCM (5×40 mL), dried over MgSO4 and evaporated in vacuo. Flash chromatography with 3 
– 4% MeOH in DCM afforded the product 152a as a pale yellow oil (28 mg, 0.11 mmol, 52%). Rf 
= 0.20 (5% MeOH in DCM). 1H NMR (500 MHz, CDCl3): δ ppm 6.37 (1H, s, 4-H), 3.94 (1H, hept, J 
= 7.0, isopropyl CH), 3.79 (1H, ddd, J = 12.5, 4.5, 3.0, 9-HA), 3.53 (1H, t, J = 5.5, 5a-H), 3.37 (2H, t, 
J = 6.0, 5-HA,B), 2.84 (1H, ddd, J = 12.0, 5.5, 3.0, 9-HB), 2.65 (1H, ddd, J = 17.3, 9.4, 4.4, 2-HA), 
2.39 (1H, ddd, J = 17.3, 7.5, 4.1, 2-HB), 1.90 – 1.69 (5H, m, 1-HA,B; 10-HA,B; 11-HA), 1.42 – 1.31 
(1H, m, 11-HB), 1.18 (3H, d, J = 6.9, isopropyl CH3A), 1.16 (3H, d, J = 6.9, isopropyl CH3B). 13C NMR 
(125 MHz, CDCl3): δ ppm 174.7 (3-C), 162.4 (7-C), 67.5 (11a-C), 58.8 (5a-C), 43.8 (isopropyl CH), 
43.2 (9-C), 41.7 (5-C), 34.1 (11-C), 30.1 (2-C), 25.6 (1-C), 21.8 (10-C), 21.1 (isopropyl CH3A), 18.6 
(isopropyl CH3B). IR νmax (neat)/cm-1: 3398 (N-H), 2976, 2945 (C-H), 1671, 1656 (C=O). HRMS 
(ESI): C13H22N3O2 [M + H+]: calculated 252.1707, found 252.1707. 
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(5aR*,11aS*)-6-(4-Methoxyphenyl)octahydro-9H-pyrrolo[1',2':1,5]imidazo[4,5-c]azepine-3,7-
dione 152b 
(5aR*,11aS*)-6-(4-Methoxyphenyl)hexahydro-9H-pyrrolo[1',2':1,5]imidazo[4,5-d]azepine-
4,7(1H,5H)-dione 153b 
 
A solution of the ketone 101b (127 mg, 0.42 mmol, 1.0 eq.), hydroxylamine hydrochloride (58.6 
mg, 0.84 mmol, 2.0 eq.) and potassium carbonate (175 mg, 1.27 mmol, 3.0 eq.) in 8 mL 
EtOH/H2O (2:1 respectively) was refluxed for 2 h. The reaction mixture was evaporated in vacuo 
and taken up in 2 mL H2O. It was then diluted with 100 mL EtOAc, dried over Na2SO4 and 
evaporated in vacuo. To a solution of the crude, TsCl (121 mg, 0.63 mmol, 1.5 eq.), and DMAP 
(5.16 mg, 0.04 mmol, 10 mol%) in 14 mL of anhydrous DCM; Et3N (0.10 mL, 0.72 mmol, 1.7 eq.) 
was added and the mixture was allowed to stir at room temperature for 1.5 h. The reaction 
mixture was evaporated in vacuo. 2 mL of 98% sulphuric acid was then added to a solution of 
the crude in 7 mL of anhydrous MeOH and refluxed for 2 h. The reaction mixture was 
neutralized with copious amounts of solid Na2CO3 in 10 mL H2O, extracted with EtOAc (5 × 50 
mL), dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 – 6% MeOH in 
DCM afforded the product as an isomeric mixture in the ratio of 93:7 (83 mg, 0.26 mmol, 62%). 
Rf = 0.36 (6% MeOH in DCM). 1H NMR (Major isomer, 400 MHz, CDCl3): δ ppm 7.20 (2H, d, J = 
9.2, ArH), 6.83 (2H, d, J = 8.8, ArH), 6.26 (1H, s, 4-H), 4.08 (1H, t, J = 5.1, 5a-H), 3.84 (1H, ddd, J = 
14.0, 9.6, 4.9, 9-HA), 3.72 (3H, s, ArOCH3), 3.30 (2H, t, J = 4.9, 5-HA,B), 2.98 (1H, ddd, J = 14.4, 9.2, 
5.6, 9-HB), 2.69 (1H, ddd, J = 17.6, 8.8, 5.6, 2-HA), 2.45 (1H, dt, J = 17.6, 5.6, 2-HB), 1.98 – 1.77 
(5H, m, 1-HA,B; 10-HA,B; 11-HA), 1.71 – 1.61 (1H, m, 11-HB). Signals for minor isomer visible at: 
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4.15 (0.07H, dd, J = 10.6, 2.9, 5a-H), 2.80 (0.08H, dd, J = 14.8, 10.6, 5-H). 13C NMR (Major 
isomer, 100 MHz, CDCl3): δ ppm 175.3 (3-C), 161.5 (7-C), 157.1 (Ar), 130.3 (Ar), 124.4 (ArH), 
114.6 (ArH), 67.4 (11a-C), 63.0 (5a-C), 55.6 (ArOCH3), 44.4 (9-C), 40.4 (5-C), 36.0 (11-C), 31.3 (2-
C), 26.9 (1-C), 23.1 (10-C). Signals for minor isomer visible at: ppm 124.8, 59.3, 50.8, 38.2, 35.4, 
32.2, 23.5. IR νmax (neat)/cm-1: 3291 (N-H), 3052, 2954, 2837 (C-H), 1693, 1659 (C=O), 1513, 
1465, 1403 (C=C), 1246 (C-O). HRMS (ESI): C17H22N3O3 [M + H+]: calculated 316.1656, found 
316.1657. 
 
(5aR*,11aS*)-6-(4-Toluenesulfonyl)octahydro-9H-pyrrolo[1',2':1,5]imidazo[4,5-c]azepine-3,7-
dione 152c 
(5aR*,11aS*)-6-(4-Toluenesulfonyl)hexahydro-9H-pyrrolo[1',2':1,5]imidazo[4,5-d]azepine-
4,7(1H,5H)-dione 153c 
 
A solution of the ketone 101c (110 mg, 0.32 mmol, 1.0 eq.), hydroxylamine hydrochloride (45.0 
mg, 0.64 mmol, 2.0 eq.) and potassium carbonate (134 mg, 0.96 mmol, 3.0 eq.) in 6 mL 
EtOH/H2O (2:1 respectively) was refluxed for 2 h. The reaction mixture was evaporated in vacuo 
and taken up in 2 mL H2O. It was then diluted with 100 mL EtOAc, dried over Na2SO4 and 
evaporated in vacuo. To a solution of the crude, TsCl (93.0 mg, 0.48 mmol, 1.5 eq.), and DMAP 
(3.95 mg, 0.03 mmol, 10 mol%) in 12 mL of anhydrous DCM; Et3N (0.08 mL, 0.55 mmol, 1.7 eq.) 
was added and the mixture was allowed to stir at room temperature for 1.5 h. The reaction 
mixture was evaporated in vacuo. 1.5 mL of 98% sulphuric acid was then added to a solution of 
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the crude in 5 mL of anhydrous MeOH and refluxed for 2 h. The reaction mixture was 
neutralized with copious amounts of solid Na2CO3 in 10 mL H2O, extracted with EtOAc (5 × 50 
mL), dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 – 4% MeOH in 
DCM afforded the product as an isomeric mixture in the ratio of 90:10 (46 mg, 0.13 mmol, 
40%). Rf = 0.41 (5% MeOH in DCM). 1H NMR (Major isomer, 400 MHz, CDCl3): δ ppm 7.85 (2H, 
d, J = 8.3, ArH), 7.27 (2H, d, J = 8.1, ArH), 6.04 (1H, t, J = 7.2, 4-H), 4.16 (1H, dd, J = 6.8, 2.1, 5a-
H), 3.75 (1H, ddd, 15.5, 6.2, 2.2, 9-HA), 3.72 – 3.59 (2H, m, 5-HA,B), 2.92 – 2.82 (1H, m, 9-HB), 2.56 
(1H, apdt, J = 18.0, 7.2, 2-HA), 2.46 (1H, dt, J = 17.6, 5.5, 2-HB), 2.37 (3H, s, ArCH3), 1.86 – 1.69 
(5H, m, 1-HA,B; 10-HA,B; 11-HA), 1.25 – 1.09 (1H, m, 11-HB). Signals for minor isomer visible at: 
7.91 (0.23H, d, J = 8.3, ArH), 6.33 (0.11H, s, 3-H), 4.43 (0.11H, dd, J = 7.6, 5.6, 5a-H). 13C NMR 
(Major isomer, 100 MHz, CDCl3): δ ppm 173.3 (3-C), 156.6 (7-C), 144.2 (Ar), 134.4 (Ar), 128.8 
(ArH), 127.0 (ArH), 67.1 (11a-C), 61.0 (5a-C), 43.0 (9-C), 41.4 (5-C), 34.7 (11-C), 29.8 (2-C), 24.9 
(1-C), 21.5 (10-C), 20.7 (ArCH3). Signals for minor isomer visible at: 170.0, 128.6, 127.5, 57.4, 
49.8, 37.6, 36.9, 34.7, 33.9, 21.9. IR νmax (neat)/cm-1: 3228 (N-H), 3062, 2960 (C-H), 1726, 1657 
(C=O), 1596, 1464, 1400 (C=C) HRMS (ESI): C17H22N3O4S [M + H+]: calculated 364.1326, found 
364.1323. 
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(2aR*,5aR*,6aS*,6bS*)-2-Isopropyloctahydro-1H,7H-cyclopropa[c]pyrrolo[1',2':3,4]imidazo[4,5-
e]azepine-1,5(5aH)-dione 156a 
(2aR*,5aR*,6aS*,6bS*)-2-Isopropyloctahydro-1H,7H-cyclopropa[b]pyrrolo[1',2':3,4]imidazo[4,5-
d]azepine-1,4(2H)-dione 157a 
 
A solution of the cyclopropane scaffold 106a (50.0 mg, 0.20 mmol, 1.0 eq.), hydroxylamine 
hydrochloride (28.0 mg, 0.40 mmol, 2.0 eq.) and potassium carbonate (83.5 mg, 0.60 mmol, 3.0 
eq.) in 3 mL EtOH/H2O (2:1 respectively) was refluxed for 2 h. The reaction mixture was 
evaporated in vacuo and taken up in 2 mL H2O. It was then diluted with 100 mL EtOAc, dried 
over Na2SO4 and evaporated in vacuo. To a solution of the crude, TsCl (57.6 mg, 0.30 mmol, 1.5 
eq.) and DMAP (2.46 mg, 0.02 mmol, 10 mol%) in 14 mL of anhydrous DCM; Et3N (47.0 µL, 0.34 
mmol, 1.7 eq.) was added and the mixture was allowed to stir at room temperature for 1.5 h. 
The reaction mixture was evaporated in vacuo. 0.90 mL of 98% sulphuric acid was then added 
to a solution of the crude in 3 mL of anhydrous MeOH and refluxed for 2 h. The reaction 
mixture was neutralized with copious amounts of solid Na2CO3 in 5 mL H2O, extracted with 
EtOAc (5×20 mL), dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 – 
6% MeOH in DCM afforded the isomeric lactams 156a [major isomer, 12 mg, 0.05 mmol, 23%, 
Rf = 0.31 (6% MeOH in DCM)] and 157a [minor isomer, 11 mg, 0.04 mmol, 21%, Rf = 0.37 (6% 
MeOH in DCM)]. 1H NMR (Major isomer, 500 MHz, CDCl3): δ ppm 5.71 (1H, s, 4-H), 4.02 (1H, 
hept, J = 7.0, isopropyl CH), 3.93 (1H, dd, J = 15.2, 6.7, 3-HA), 3.60 (1H, dt, J = 11.7, 7.8, 9-HA), 
3.54 (1H, br. s, 2a-H), 3.11 (1H, ddd, J = 15.4, 6.2, 2.5, 3-HB), 2.97 – 2.87 (1H, m, 9-HB), 1.87 – 
1.79 (3H, m, 7-HA, 8-HA,B), 1.71 – 1.65 (1H, m, 5a-H), 1.52 – 1.43 (1H, m, 7-HB), 1.18 (3H, d,  J = 
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6.9, isopropyl CH3A), 1.14 (3H, d, J = 6.9, isopropyl CH3B), 1.02 – 0.96 (1H, m, 6-HA). 0.90 (1H, td, J 
= 8.5, 5.6, 6a-H), 0.73 (1H, q, J = 5.5, 6-HB). 13C NMR (Major isomer, 125 MHz, CDCl3): δ ppm 
170.5 (5-C), 163.0 (1-C), 66.5 (6b-C), 57.3 (2a-C), 46.4 (9-C), 43.5 (isopropyl CH), 42.7 (3-C), 37.5 
(7-C), 22.2 (8-C), 21.3 (isopropyl CH3A), 18.5 (isopropyl CH3B), 15.7 (6a-C), 15.0 (5a-C), 7.1 (6-C). 
IR νmax (neat)/cm-1: 3320 (N-H), 2968, 2904, 2878 (C-H), 1681 (C=O). HRMS (ESI): C14H22N3O2 [M 
+ H+]: calculated 264.1707, found 264.1701. 1H NMR (Minor isomer, 500 MHz, CDCl3): δ ppm 
5.52 (1H, s, 5-H), 3.83 (1H, t, J = 3.5, 2a-H), 3.78 (1H, hept, J = 7.0, isopropyl CH), 3.68 – 3.61 
(1H, m, 9-HA), 3.12 (1H, dd, J = 13.5, 3.0, 3-HA), 2.97 – 2.89 (1H, m, 9-HB), 2.65 (1H, td, J = 7.2, 
4.2, 5a-H), 2.47 (1H, ddd, J = 13.5, 3.9, 1.7, 3-HB), 1.93 – 1.77 (3H, m, 7-HA, 8-HA,B), 1.48 (1H, td, J 
= 11.5, 9.2, 7-HB), 1.25 (3H, d,  J = 6.9, isopropyl CH3A), 1.23 (3H, d, J = 6.9, isopropyl CH3B), 1.00 
(1H, ddd, J = 9.0, 7.3, 5.0, 6-HA). 0.87 – 0.79 (1H, m, 6a-H), 0.73 (1H, dt, J = 6.5, 4.5, 6-HB). 13C 
NMR (Minor isomer, 125 MHz, CDCl3): δ ppm 171.2 (4-C), 162.1 (1-C), 66.3 (6b-C), 56.6 (2a-C), 
45.3 (9-C), 44.5 (isopropyl CH), 39.0 (7-C), 36.8 (3-C), 25.4 (5a-C), 22.6 (8-C), 20.4 (isopropyl 
CH3A), 19.1 (6a-C), 18.4 (isopropyl CH3B), 12.1 (6-C). IR νmax (neat)/cm-1: 3266 (N-H), 2968, 2930 
(C-H), 1684 (C=O). HRMS (ESI): C14H22N3O2 [M + H+]: calculated 264.1707, found 264.1704. 
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(2aR*,5aR*,6aS*,6bS*)-2-(4-Methoxyphenyl)octahydro-1H,7H-
cyclopropa[c]pyrrolo[1',2':3,4]imidazo[4,5-e]azepine-1,5(5aH)-dione 156b 
(2aR*,5aR*,6aS*,6bS*)-2-Isopropyloctahydro-1H,7H-cyclopropa[b]pyrrolo[1',2':3,4]imidazo[4,5-
d]azepine-1,4(2H)-dione 157b 
 
A solution of the cyclopropane scaffold 106b (101 mg, 0.32 mmol, 1.0 eq.), hydroxylamine 
hydrochloride (45.2 mg, 0.65 mmol, 2.0 eq.) and potassium carbonate (134 mg, 0.97 mmol, 3.0 
eq.) in 6 mL EtOH/H2O (2:1 respectively) was refluxed for 2 h. The reaction mixture was 
evaporated in vacuo and taken up in 2 mL H2O. It was then diluted with 100 mL EtOAc, dried 
over Na2SO4 and evaporated in vacuo. To a solution of the crude, TsCl (93.4 mg, 0.49 mmol, 1.5 
eq.), and DMAP (3.95 mg, 0.03 mmol, 10 mol%) in 14 mL of anhydrous DCM; Et3N (0.08 mL, 
0.55 mmol, 1.7 eq.) was added and allowed to stir at room temperature for 1.5 h. The reaction 
mixture was evaporated in vacuo. 1.5 mL of 98% sulphuric acid was then added to a solution of 
the crude in 5 mL of anhydrous MeOH and refluxed for 2 h. The reaction mixture was 
neutralized with copious amounts of solid Na2CO3 in 10 mL H2O, extracted with EtOAc (5 × 50 
mL), dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 – 6% MeOH in 
DCM afforded the product as an isomeric mixture in the ratio of 78:22 (83 mg, 0.26 mmol, 
62%). Rf = 0.36 (6% MeOH in DCM). 1H NMR (Major isomer, 500 MHz, CDCl3): δ ppm 7.22 (2H, 
d, J = 9.0, ArH), 6.83 (2H, d, J = 9.0, ArH), 5.62 (1H, s, 4-H), 4.34 (1H, t, J = 3.4, 2a-H), 3.82 – 3.73 
(1H, m, 9-HA), 3.72 (3H, s, ArOCH3), 3.08 (1H, dt, 12.5, 3.5, 9-HB), 3.03 (1H, dd, J = 13.5, 3.0, 3-
HA), 2.68 (1H, td, J = 7.0, 4.0, 5a-H), 2.47 (1H, ddd, J = 13.8, 3.4, 1.7, 3-HB), 2.05 (1H, ddd, J = 
11.5, 5.0, 1.5, 7-HA), 1.97 – 1.92 (2H, m, 8-HA,B), 1.81 (1H, dt, J = 11.0, 9.0, 7-HB), 1.07 (1H, ddd, 
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9.5, 4.5, 2.0, 6-HA), 0.97 – 0.91 (1H, m, 6a-H), 0.84 – 0.79 (1H, m, 6-HB). Signal for minor isomer 
visible at: 5.50 (0.28H, t, J = 5.5, 5-H). 13C NMR (Major isomer, 125 MHz, CDCl3): δ ppm 170.9 (5-
C), 160.7 (1-C), 156.4 (Ar), 129.3 (Ar), 125.4 (ArH), 113.4 (ArH), 65.6 (6b-C), 59.7 (2a-C), 54.4 
(ArOCH3), 45.6 (9-C), 39.2 (7-C), 35.1 (3-C), 25.2 (5a-C), 22.8 (8-C), 19.4 (6a-C), 12.1 (6-C). Signals 
for minor isomer visible at: 155.9, 122.9, 113.7, 65.4, 61.0, 54.5, 46.4, 39.9, 38.3, 22.4, 16.2, 
15.3, 7.1. IR νmax (neat)/cm-1: 3300 (N-H), 2933 (C-H), 1691 (C=O), 1585, 1513, 1458 (C=C), 1246 
(C-O). HRMS (ESI): C18H22N3O3 [M + H+]: calculated 328.1656, found 328.1653. 
 
(6aR*,8R*,10aS*)-8-Hydroxy-6-isopropyloctahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazol-5-one 
160a 
 
Method E 
To a solution of the ketone 101a (81.0 mg, 0.34 mmol, 1.0 eq.) in anhydrous THF (4 mL), 0.13 
mL of LiAlH4 (4 M in THF) was added at room temperature and the mixture was allowed to stir 
for 30 min. The reaction mixture was quenched with 0.1 mL 10% KOH and 0.1 mL H2O, diluted 
with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 – 
4% MeOH in DCM afforded the product as a diastereomeric mixture in the ratio of 93:7 (65.0 
mg, 0.27 mmol, 79% yield). Rf = 0.34 (5% MeOH in DCM). 1H NMR (Major diastereomer, 500 
MHz, CDCl3): δ ppm 3.99 (1H, hept, J = 7.0, isopropyl CH), 3.78 (1H, ddd, J = 12.4, 9.2, 5.2, 3-HA), 
3.57 (1H, tt, J = 10.5, 4.0, 8-H), 3.44 (1H, dd, J = 10.1, 6.5, 6a-H), 2.85 (1H, ddd, J =12.0, 6.0, 3.0, 
3-HB), 2.33 (1H, dddd, J = 12.7, 6.5, 4.3, 2.2, 7-HA), 2.13 (1H, s, 8-CHOH), 1.85 (1H, dt, J = 14.5, 
4.0, 10-HA), 1.80 – 1.63 (3H, m, 2-HA,B; 9-HA), 1.50 – 1.34 (4H, m, 1-HA,B; 7-HB; 9-HB), 1.31 – 1.23 
(1H, m, 10-HB), 1.14 (3H, d, J = 7.0, isopropyl CH3A), 1.11 (3H, d, J = 6.5, isopropyl CH3B). Signals 
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for minor isomer visible at: 3.72 (0.08H, ddd, J = 12.0, 6.0, 3.0, 3-HA), 3.63 (0.07H, dd, J = 8.0, 
6.0, 7-HA). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 162.6 (5-C), 66.2 (8-C), 64.5 
(10a-C), 53.6 (6a-C), 43.2 (isopropyl CH), 43.0 (3-C), 40.8 (7-C), 33.6 (1-C), 29.6 (10-C), 28.1 (9-C), 
21.9 (2-C), 21.4 (isopropyl CH3A), 18.8 (isopropyl CH3B). Signals for minor isomer visible at: 64.7, 
63.3, 52.3, 36.4, 34.3, 27.2, 24.6, 22.1, 21.2, 18.6. IR νmax (neat)/cm-1: 3399 (O-H), 2937 (C-H), 
1666 (C=O), 1056 (C-O). HRMS (ESI): C13H23N2O2 [M + H+]: calculated 239.1754, found 239.1750. 
 
Method F 
A mixture of the ketone 101a (24.0 mg, 0.10 mmol, 1.0 eq.) and CeCl3.7H2O (45.5 mg, 0.12 
mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH and it was allowed to stir at –78 °C for 30 min. 
NaBH4 (4.62 mg, 0.12 mmol, 1.2 eq.) was then added and the mixture was left to warm up to 
room temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was 
then taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in 
vacuo. Flash chromatography with 1 – 4% MeOH in DCM afforded the product 160a as a single 
diastereomer (22.0 mg, 0.09 mmol, 92% yield) that is identical to the major diastereomer 
obtained from Method E. 
 
(6aR*,8R*,10aS*)-6-Isopropyl-8-(pyridine-2-yloxy)octahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 161 
 
To a mixture of the alcohol 160a (28.0 mg, 0.12 mmol, 1.0 eq., obtained from Method E) and 
NaH (7.20 mg, 0.18 mmol, 1.5 eq.) in 4 mL THF, 2-fluoropyridine (0.02 mL, 0.18 mmol, 1.5 eq.) 
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was added and the mixture was heated at 65 °C for 24 h. The reaction mixture was evaporated 
in vacuo and taken up in 1 mL H2O. It was then diluted with 50 mL DCM, dried over MgSO4, and 
evaporated in vacuo. Flash chromatography with 1 – 5% MeOH in DCM afforded the product as 
a diastereomeric mixture in the ratio of 93:7 (12 mg, 0.04 mmol, 32% yield). Rf = 0.41 (5% 
MeOH in DCM). 1H NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 8.05 (1H, ddd, J = 5.1, 
1.9, 0.6, ArH), 7.49 (1H, ddd, J = 8.4, 7.1, 2.0, ArH), 6.78 (1H, ddd, 7.0, 5.1, 0.9, ArH), 6.62 (1H, 
dt, J = 8.5, 0.8, ArH), 5.00 (1H, ddt, J = 11.4, 9.6, 4.2, 8-H), 3.99 (1H, hept, J = 7.0, isopropyl CH), 
3.81 (1H, ddd, J = 12.5, 7.0, 3.0, 3-HA), 3.55 (1H, dd, J = 10.2, 6.4, 6a-H), 2.89 (1H, ddd, J =12.3, 
9.3, 5.8, 3-HB), 2.48 (1H, dddd, J = 12.6, 6.4, 4.5, 1.8, 7-HA), 1.93 – 1.85 (2H, m, 9-HA, 10-HA), 1.82 
– 1.58 (4H, m, 2-HA,B; 7-HB; 10-HB), 1.51 – 1.38 (3H, m, 1-HA,B; 9-HB), 1.13 (3H, d, J = 7.0, 
isopropyl CH3A), 1.12 (3H, d, J = 6.5, isopropyl CH3B). Signals for minor isomer visible at: 3.70 
(0.07H, dd, J = 12.0, 4.5, 6a-H), 2.99 (0.08H, ddd, J = 12.3, 8.8, 6.1, 3-H). 13C NMR (Major 
diastereomer, 125 MHz, CDCl3): δ ppm 162.5 (5-C), 162.0 (Ar), 145.7 (ArH), 137.7 (ArH), 115.6 
(ArH) 110.8 (ArH), 68.7 (8-C), 64.6 (10a-C), 53.5 (6a-C), 43.2 (isopropyl CH), 43.0 (3-C), 36.8 (7-
C), 33.8 (1-C), 27.9 (9-C), 26.0 (10-C), 21.9 (2-C), 21.4 (isopropyl CH3A), 18.7 (isopropyl CH3B). 
Signals for minor isomer visible at: 129.2, 126.4, 116.0, 110.4, 66.9, 63.9, 63.4, 53.1, 43.4, 21.4, 
18.5. IR νmax (neat)/cm-1: 2964 (C-H), 1692 (C=O), 1594, 1569, 1470 (C=C), 1286 (C-O). HRMS 
(ESI): C18H26N3O2 [M + H+]: calculated 316.2020, found 316.2020. 
 
(6aR*,8R*,10aS*)-6-Isopropyl-5-oxooctahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazol-8-yl (2-
fluorophenyl)carbamate 162 
 
To a solution of the alcohol 160a (14.0 mg, 0.06 mmol, 1.0 eq., obtained from Method E) in 5 
mL DCM, 2-fluorophenylisocyanate (0.01 mL, 0.07 mmol, 1.5 eq.) and TEA (0.03 mL, 0.18 mmol, 
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3.0 eq.) were added and the mixture was stirred at room temperature overnight. The reaction 
mixture was evaporated in vacuo. Flash chromatography with 10 – 90% EtOAc in hexane 
afforded the product as a diastereomeric mixture in the ratio of 88:12 (17 mg, 0.05 mmol, 77% 
yield). Rf = 0.47 (80% EtOAc in hexane). 1H NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 
8.00 (1H, br.s, ArH), 7.06 (1H, t, J = 7.8, ArH), 7.03 – 6.98 (1H, m, ArH), 6.96 – 6.91 (1H, m, ArH), 
6.76 (1H, s, ArNH), 4.70 (1H, tt, J = 11.0, 4.0, 8-H), 4.00 (1H, hept, J = 7.0, isopropyl CH), 3.81 
(1H, ddd, J = 12.4, 9.2, 5.2, 3-HA), 3.51 (1H, dd, J = 10.0, 6.5, 6a-H), 2.88 (1H, ddd, J =12.3, 9.4, 
5.8, 3-HB), 2.42 (1H, dddd, J = 10.5, 6.0, 4.5, 2.0, 7-HA), 1.90 (1H, dt, J = 15.0, 4.5, 10-HA), 1.86 – 
1.71 (3H, m, 2-HA,B; 9-HA), 1.66 – 1.61 (1H, m, 9-HB), 1.56 – 1.32 (4H, m, 1-HA,B; 7-HB, 10-HB), 1.15 
(3H, d, J = 7.0, isopropyl CH3A), 1.12 (3H, d, J = 7.0, isopropyl CH3B). Signals for minor isomer 
visible at: 5.07 (0.14H, quint, J = 5.0, 8-H), 3.70 (0.14H, dd, J = 8.5, 6.0, 6a-H), 2.19 (0.13H, dt, J = 
10.7, 5.2, 10-H). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 162.4 (5-C), 151.6 
(carbamate C=O), 151.1 (d, J = 241, ArF), 125.3 (d, J =10.0, Ar), 123.6 (d, J = 3.63, ArH), 122.5 (d, 
J = 7.25, ArH), 119.1 (ArH), 113.9 (d, J = 19.0, ArH), 69.8 (8-C), 64.4 (10a-C), 53.2 (6a-C), 43.3 
(isopropyl CH), 43.0 (3-C), 36.9 (7-C), 33.6 (1-C), 27.7 (10-C), 26.0 (9-C), 21.9 (2-C), 21.4 
(isopropyl CH3A), 18.7 (isopropyl CH3B). Signals for minor isomer visible at: 68.4, 52.0, 34.3, 33.7, 
25.0, 24.0, 22.1, 21.2, 18.6. IR νmax (neat)/cm-1: 3246 (N-H); 2967 (C-H); 1724, 1682 (C=O); 1620, 
1597, 1538 (C=C); 1258 (C-O). HRMS (ESI): C20H27FN3O3 [M + H+]: calculated 376.2031, found 
376.2027. 
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(6aR*,8R*,10aS*)-6-Isopropyl-5-oxooctahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazol-8-yl (3-
fluorophenyl)carbamate 163 
 
A mixture of the ketone 101a (27.0 mg, 0.11 mmol, 1.0 eq.) and CeCl3.7H2O (51.0 mg, 0.14 
mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH was allowed to stir at – 78 °C for 30 min. NaBH4 
(5.18 mg, 0.14 mmol, 1.2 eq.) was then added and the mixture was left to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. To 
a solution of the crude product in 5 mL DCM, 3-fluorophenylisocyanate (13 µL, 0.11 mmol, 1.0 
eq.) and TEA (0.05 mL, 0.34 mmol, 3.0 eq.) were added and the mixture was stirred at room 
temperature overnight. The reaction mixture was evaporated in vacuo. Flash chromatography 
with 1 – 4% MeOH in DCM afforded the carbamate as a diastereomeric mixture in the ratio of 
93:7 (36 mg, 0.10 mmol, 84% yield). 1H NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 7.30 
(1H, d, J = 10.6, ArH), 7.17 (1H, td, J = 8.2, 6.6, ArH), 7.00 (1H, d, J = 8.0, ArH), 6.68 (1H, td, J = 
8.3, 2.3, ArH), 4.69 (1H, tt, J = 10.8, 4.0, 8-H), 3.99 (1H, hept, J = 6.9, isopropyl CH), 3.79 (1H, 
ddd, J = 12.4, 9.3, 5.2, 3-HA), 3.52 (1H, dd, J = 9.9, 6.5, 6a-H), 2.85 (1H, ddd, J =12.5, 7.0, 4.0, 3-
HB), 2.44 – 2.35 (1H, m, 7-HA), 1.88 (1H, dt, J = 15.0, 4.0, 10-HA), 1.85 – 1.80 (1H, m, 9-HA), 1.77 
(1H, ddd, J = 12.5, 6.0, 3.0, 1-HA), 1.75 – 1.66 (1H, m, 2-HA), 1.62 – 1.39 (4H, m, 1-HB, 2-HB, 7-HB, 
9-HB), 1.36 (1H, ddd, J = 14.6, 10.8, 4.7, 10-HB), 1.14 (3H, d, J = 6.9, isopropyl CH3A), 1.12 (3H, d, J 
= 6.9, isopropyl CH3B). Signals for minor isomer visible at: 5.06 (0.07H, quint, J = 4.5, 8-H), 3.70 
(0.07H, dd, J = 8.2, 5.7, 6a-H). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 162.6 (5-
C), 162.2 (d, J = 243, ArF), 151.8 (carbamate C=O), 138.7 (d, J =13.2, Ar), 129.1 (d, J = 9.50, ArH), 
112.8 (ArH), 108.9 (d, J = 21.3, ArH), 104.9 (d, J = 26.8, ArH), 69.3 (8-C), 64.4 (10a-C), 53.2 (6a-C), 
43.3 (isopropyl CH), 43.0 (3-C), 36.9 (7-C), 33.6 (1-C), 27.6 (10-C), 26.0 (9-C), 21.9 (2-C), 21.4 
(isopropyl CH3A), 18.7 (isopropyl CH3B). Signals for minor isomer visible at: 52.1, 34.4, 25.1, 24.1, 
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22.2, 21.2. IR νmax (neat)/cm-1: 3254 (N-H); 3076, 2968 (C-H); 1723, 1671 (C=O); 1606, 1546, 
1495 (C=C); 1221 (C-O). HRMS (ESI): C20H27FN3O3 [M + H+]: calculated 376.2031, found 
376.2028. 
 
(6aR*,8R*,10aS*)-8-[(Furan-2-ylmethyl)amino]-6-isopropyloctahydro-1H,5H-
benzo[d]pyrrolo[1,2-c]imidazol-5-one 164 
 
To a solution of the ketone 101a (39.0 mg, 0.17 mmol, 1.0 eq.) in 4 mL THF, furfurylamine (17.0 
µL, 0.20 mmol, 1.2 eq.) and titanium isopropoxide (0.10 mL, 0.33 mmol, 2.0 eq.) were added 
and the mixture was left to stir at room temperature overnight. NaBH4 (9.4 mg, 0.25 mmol, 1.5 
eq.) was added to the reaction mixture at -78 °C and it was stirred at the same temperature for 
30 min. It was then allowed to warm up to room temperature for another 30 min. The reaction 
mixture was evaporated in vacuo and dissolved in 1 mL DMSO. Reverse phase chromatography 
by the use of a biotage machine (MeCN/1% HCOOH in H2O) afforded the product 164 as a single 
diastereomer (28 mg, 0.09 mmol, 53% yield). Rf = 0.36 (6% MeOH in DCM). 1H NMR (500 MHz, 
CDCl3): δ ppm 7.30 (1H, dd, J = 1.8, 0.7, ArH), 6.26 (1H, dd, J = 3.1, 1.9, ArH), 6.16 (1H, d, J = 3.0, 
ArH), 3.98 (1H, hept, J = 7.0, isopropyl CH), 3.88 – 3.69 (3H, m, 3-HA, ArCH2A,B), 3.39 (1H, dd, J = 
10.3, 6.5, 6a-H), 2.85 (1H, ddd, J = 12.3, 9.4, 5.8, 3-HB), 2.49 (1H, tt J = 9.5, 3.5, 8-H), 2.28 – 2.21 
(1H, m, 7-HA), 1.88 – 1.83 (1H, m, 9-HA), 1.75 – 1.67 (3H, m, 2-HA,B; 10-HA,), 1.42 – 1.36 (2H, m, 
1-HA,B), 1.31 – 1.18 (4H, m, 7-HB, 9-HB, 10-HB, ArCH2NH), 1.13 (3H, d, J = 7.0, isopropyl CH3A), 
1.10 (3H, d, J = 7.0, isopropyl CH3B). 13C NMR (125 MHz, CDCl3): δ ppm 162.5 (5-C), 152.1 (Ar), 
141.0 (ArH), 109.3 (ArH), 106.4 (ArH), 64.8 (10a-C), 53.6 (6a-C), 51.4 (8-C), 43.2 (isopropyl CH), 
43.0 (3-C), 42.0 (ArCH2), 38.4 (7-C), 33.7 (1-C), 28.7 (9-C), 26.5 (10-C), 21.9 (2-C), 21.5 (isopropyl 
171 
 
CH3A), 18.7 (isopropyl CH3B). IR νmax (neat)/cm-1: 3304 (N-H); 2933 (C-H); 1687 (C=O); 1512, 1460 
(C=C); 1246 (C-O). HRMS (ESI): C18H28N3O2 [M + H+]: calculated 318.2176, found 318.2177. 
 
(6aR*,8R*,10aS*)-8-(Cyclopropylamino)-6-isopropyloctahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 165 
 
To a solution of the ketone 101a (18.0 mg, 0.08 mmol, 1.0 eq.) in 4 mL THF, cyclopropylamine 
(0.03 mL, 0.38 mmol, 5.0 eq.) and titanium isopropoxide (0.05 mL, 0.15 mmol, 2.0 eq.) were 
added and the mixture was left to stir at room temperature overnight. NaBH4 (4.30 mg, 0.11 
mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was stirred at the same 
temperature for 30 min. It was then allowed to warm up to room temperature for another 30 
min. The reaction mixture was evaporated in vacuo. It was then taken up in 1 mL H2O, diluted 
with 50 mL DCM, dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 – 
3.5% MeOH in DCM afforded the product as a diastereomeric mixture in the ratio of 79:21 (16.0 
mg, 0.06 mmol, 76% yield). Rf = 0.47 (8% MeOH in DCM). 1H NMR (Major diastereomer, 500 
MHz, CDCl3): δ ppm 3.99 (1H, hept, J = 7.0, isopropyl CH), 3.78 (1H, ddd, J = 12.4, 9.1, 5.2, 3-HA), 
3.43 (1H, dd, J = 10.2, 6.6, 6a-H), 2.85 (1H, ddd, J = 12.4, 9.3, 5.9, 3-HB), 2.58 (1H, tt, J =11.0, 3.5, 
8-H), 2.35 – 2.30 (1H, m, 7-HA), 2.12 (1H, ddd, J = 10.2, 6.8, 3.7, cyclopropyl CH), 1.89 – 1.84 (1H, 
m, 10-HA), 1.81 – 1.70 (3H, m, 2-HA,B; 9-HA), 1.43 – 1.38 (2H, m, 1-HA,B), 1.26 – 1.17 (3H, m, 7-HB, 
9-HB, 10-HB), 1.14 (3H, d, J = 7.0, isopropyl CH3A), 1.12 (3H, d, J = 7.0, isopropyl CH3B), 0.44 – 0.27 
(4H, m, cyclopropyl CH2A,B; cyclopropyl CH2C,D). Signals for minor isomer visible at: 3.70 (0.33H, 
ddd, J = 11.9, 8.8, 5.9, 3-HA), 3.60 (0.27H, t, 5.2, 6a-H), 2.65 (0.27H, ddd, J = 14.0, 7.5, 4.0, 8-H). 
13C NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 162.6 (5-C), 64.9 (10a-C), 53.7 (6a-C), 
52.8 (8-C), 43.2 (isopropyl CH), 43.0 (3-C), 39.0 (7-C), 33.8 (1-C), 28.9 (10-C), 27.1 (9-C), 26.7 
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(cyclopropyl CH), 21.9 (2-C), 21.5 (isopropyl CH3A), 18.7 (isopropyl CH3B), 5.5 (cyclopropyl 
CH2A,B), 5.2 (cyclopropyl CH2C,D). Signals for minor isomer visible at: 64.7, 57.8, 54.1, 48.9, 43.3, 
43.0, 36.7, 35.0, 27.9, 25.4, 22.2, 21.2, 18.5, 4.6. IR νmax (neat)/cm-1: 3288 (O-H), 2969, 2934 (C-
H), 1687 (C=O). HRMS (ESI): C16H28N3O [M + H+]: calculated 278.2227, found 278.2224. 
 
(6aR*,8R*,10aS*)-6-Isopropyl-8-(methylamino)octahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 166 
 
To a solution of the ketone 101a (22.0 mg, 0.09 mmol, 1.0 eq.) in 6 mL THF, 33 wt% 
methylamine in EtOH (0.10 mL, 0.93 mmol, 10.0 eq.) and titanium isopropoxide (0.06 mL, 0.19 
mmol, 2.0 eq.) were added and the mixture was left to stir at room temperature overnight. 
NaBH4 (5.30 mg, 0.14 mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was 
stirred at the same temperature for 30 min. It was then allowed to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over MgSO4 and evaporated in vacuo. 
Flash chromatography with 5% MeOH in DCM, followed by 99:9:1 of DCM/MeOH/aq. NH3 
respectively, afforded the product as a diastereomeric mixture in the ratio of 88:12 (21.0 mg, 
0.08 mmol, 90% yield). 1H NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 3.98 (1H, hept, J 
= 7.0, isopropyl CH), 3.77 (1H, ddd, J = 12.4, 9.2, 5.3, 3-HA), 3.41 (1H, dd, J = 10.4, 6.5, 6a-H), 
2.84 (1H, ddd, J = 12.4, 9.3, 5.9, 3-HB), 2.37 – 2.31 (4H, m, 8-H, NHCH3), 2.26 (1H, dddd, J =12.5, 
6.1, 3.7, 2.2, 9-HA), 1.88 – 1.82 (1H, m, 7-HA), 1.77 – 1.65 (4H, m, 2-HA,B; 10-HA; NH), 1.44 – 1.34 
(2H, m, 1-HA,B), 1.29 – 1.15 (3H, m, 7-HB, 9-HB, 10-HB), 1.14 (3H, d, J = 7.0, isopropyl CH3A), 1.11 
(3H, d, J = 7.0, isopropyl CH3B). Signals for minor isomer visible at: 3.69 (0.14H, ddd, J = 12.1, 8.8, 
6.0, 3-HA), 3.61 (0.13H, t, 5.5, 6a-H). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 
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162.6 (5-C), 64.9 (10a-C), 54.0 (6a-C), 53.7 (8-C), 43.2 (isopropyl CH), 43.0 (3-C), 38.4 (7-C), 33.8 
(1-C), 32.3 (NHCH3), 28.8 (10-C), 26.4 (9-C), 21.9 (2-C), 21.5 (isopropyl CH3A), 18.7 (isopropyl 
CH3B). Signals for minor isomer visible at: 162.4, 64.8, 53.8, 43.3, 34.8, 32.8, 25.3, 24.4, 22.2, 
21.2, 18.5. IR νmax (neat)/cm-1: 3306 (N-H), 2966, 2936, 2791 (C-H), 1686 (C=O). HRMS (ESI): 
C14H26N3O [M + H+]: calculated 252.2070, found 252.2079. 
 
(6aR*,8R*,10aS*)-8-(((1-H-Imidazol-4-yl)methyl)amino)-6-isopropyloctahydro-1H,5H-
benzo[d]pyrrolo[1,2-c]imidazol-5-one 167 
 
To a solution of the ketone 101a (28.0 mg, 0.12 mmol, 1.0 eq.) in 5 mL THF, 2 M methylamine in 
MeOH (0.60 mL, 1.20 mmol, 10.0 eq.) and titanium isopropoxide (0.07 mL, 0.24 mmol, 2.0 eq.) 
were added and the mixture was left to stir at room temperature overnight. NaBH4 (6.80 mg, 
0.18 mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was stirred at the same 
temperature for 30 min. It was then allowed to warm up to room temperature for another 30 
min. The reaction mixture was evaporated in vacuo. It was then taken up in 1 mL H2O, diluted 
with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. To a mixture of the crude, 4-
imidazolecarboxaldehyde (17.3 mg, 0.18 mmol, 1.5 eq.) and sodium triacetoxyborohydride 
(38.1 mg, 0.18 mmol, 1.5 eq.) in 5 mL DCM; 14.0 µL of acetic acid was added. The reaction 
mixture was allowed to stir at room temperature for 3 days after which 2 mL of saturated 
aqueous Na2CO3 was added. It was diluted with 100 mL DCM, dried over Na2SO4 and 
evaporated in vacuo. Flash chromatography with 5% MeOH in DCM followed by 2 - 4% of 
saturated NH3/MeOH in DCM afforded the product as a single diastereomer but an 80:20 
mixture of tautomers (8.00 mg, 0.03 mmol, 15% yield). Rf = 0.57 (8% of saturated NH3/MeOH in 
DCM). 1H NMR (400 MHz, CDCl3): δ ppm 7.53 (0.75H, s, ArH), 7.51 (0.20H, s, ArH), 6.85 (0.72H, 
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s, ArH), 6.83 (0.20H, s, ArH), 3.99 (0.78H, hept, J = 6.8, isopropyl CH), 3.90 (0.20H, hept, J = 6.8, 
isopropyl CH), 3.77 (0.78H, ddd, J = 12.4, 7.2, 3.2, 3-HA), 3.69 (0.15H, ddd, J = 12.4, 6.0, 3.6, 3-
HA), 3.65 (0.28H, m, 6a-H), 3.55 (1.44H, s, ArCH2A,B), 3.52 (0.41H, s, ArCH2A,B), 3.41 (0.86H, dd, J = 
10.0, 6.4, 6a-H), 2.86 (1.21H, ddd, J = 12.4, 6.4, 3.2, 3-HB), 2.48 (0.77H, t, J =11.2, 8-H), 2.20 – 
2.04 (3.87H, s, NCH3, 7-HA), 1.88 (0.96H, dt, J = 14.4, 4,1, 10-HA), 1.82 – 1.30 (8.09H, m, 1-HA,B; 2-
HA,B; 7-HB; 9-HA,B; ArNH), 1.29 – 1.18 (1.23H, m, 10-HB), 1.15 (3.21H, d, J = 6.8, isopropyl CH3A), 
1.12 (2.73H, d, J = 6.8, isopropyl CH3B). 13C NMR (Major tautomer, 100 MHz, CDCl3): δ ppm 
163.6 (5-C), 153.6 (Ar), 152.7 (Ar), 134.9 (ArH), 66.0 (10a-C), 57.7 (8-C), 55.5 (6a-C), 49.9 (ArCH2, 
missing – found by HSQC), 44.2 (isopropyl CH), 44.0 (3-C), 36.9 (NCH3), 35.0 (7-C), 34.7 (9-C), 
30.5 (10-C), 23.0 (1-C), 22.6 (isopropyl CH3A), 22.4 (2-C), 19.8 (isopropyl CH3B). Signals for minor 
tautomer visible at: 56.6, 44.4, 36.6, 27.2, 23.3, 22.1, 21.6, 19.5. IR νmax (neat)/cm-1: 3049, 2967, 
2937, 2794 (C-H), 1679 (C=O), 1459, 1412 (C=C). HRMS (ESI): C18H30N5O [M + H+]: calculated 
332.2445, found 332.2437. 
 
(6aR*,8R*,10aS*)-6-Isopropyl-5-oxooctahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazol-8-yl)-N-
methylpyridine-3-sulfonamide 168 
 
To a solution of the ketone 101a (27.0 mg, 0.11 mmol, 1.0 eq.) in 5 mL THF, 2 M methylamine in 
MeOH (0.55 mL, 1.10 mmol, 10.0 eq.) and titanium isopropoxide (0.07 mL, 0.22 mmol, 2.0 eq.) 
were added and the mixture was left to stir at room temperature overnight. NaBH4 (6.40 mg, 
0.17 mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was stirred at the same 
temperature for 30 min. It was then allowed to warm up to room temperature for another 30 
min. The reaction mixture was evaporated in vacuo. It was then taken up in 1 mL H2O, diluted 
with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. To a solution of the crude and 
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DMAP (1.00 mg, 2.75 µmol, 2.5 mol%) in 6 mL DCM, pyridine-3-sulfonyl chloride (14.0 µL, 0.12 
mmol, 1.1 eq.) and TEA (23.0 µL, 0.17 mmol, 1.5 eq.) were added. The reaction mixture was 
allowed to stir at room temperature for 12 h after which 1 mL of saturated aqueous Na2CO3 
was added. It was then diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. 
Flash chromatography with 1 - 3% MeOH in DCM afforded the product 168 as a single 
diastereomer (30.0 mg, 0.08 mmol, 67% yield). Rf = 0.30 (5% MeOH in DCM). 1H NMR (500 
MHz, CDCl3): δ ppm 9.03 (1H, dd, J = 2.3, 0.6, ArH), 8.80 (1H, dd, J = 4.8, 1.6, ArH), 8.09 (1H, ddd, 
J = 8.0, 2.3, 1.7, ArH), 7.47 (1H, ddd, J = 8.0, 4.8, 0.7, ArH), 4.03 (1H, hept, J = 6.9, isopropyl CH), 
3.89 (1H, tt, J = 12.0, 3.5, 8-H), 3.83 (1H, ddd, J = 12.5, 9.4, 5.0, 3-HA), 3.55 (1H, dd, J = 9.9, 6.7, 
6a-H), 2.84 (1H, ddd, J = 12.4, 9.5, 5.9, 3-HB), 2.74 (3H, s, NCH3), 2.00 (1H, dddd, J =12.5, 6.3, 3.5, 
2.4, 7-HA), 1.89 (1H, dt, J = 14.7, 3.8, 10-HA), 1.85 – 1.72 (2H, m, 2-HA,B), 1.60 – 1.49 (2H, m, 7-HB, 
9-HA), 1.48 – 1.43 (2H, m, 1-HA,B), 1.37 (1H, ddd, J = 14.7, 12.6, 3.9, 10-HB), 1.28 - 1.22 (1H, m, 9-
HB), 1.13 (3H, d, J = 6.9, isopropyl CH3A), 1.10 (3H, d, J = 6.8, isopropyl CH3B). 13C NMR (125 MHz, 
CDCl3): δ ppm 163.4 (5-C), 153.2 (ArH), 147.8 (ArH), 136.5 (Ar), 134.5 (ArH), 123.8 (ArH), 65.2 
(10a-C), 54.4 (6a-C), 53.2 (8-C), 44.2 (isopropyl CH), 44.0 (3-C), 37.0 (7-C), 34.4 (1-C), 30.1 (10-C), 
28.6 (NCH3), 24.8 (9-C), 22.8 (2-C), 22.4 (isopropyl CH3B), 19.8 (isopropyl CH3A). IR νmax 
(neat)/cm-1: 3054, 2966 (C-H), 1686 (C=O), 1572, 1463, 1438 (C=C). HRMS (ESI): C19H29N4O3S [M 
+ H+]: calculated 393.1955, found 393.1952. 
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(6aR*,8R*,10aS*)-6-Isopropyl-5-oxooctahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazol-8-yl)-N-
methylisoxazole-5-carboxamide 169 
(6aR,8S,10aS)-6-Isopropyl-5-oxooctahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazol-8-yl)-N-
methylisoxazole-5-carboxamide 170 
 
To a solution of the ketone 101a (30.0 mg, 0.13 mmol, 1.0 eq.) in 5 mL THF, 33 wt% 
methylamine in EtOH (0.16 mL, 1.30 mmol, 10.0 eq.) and titanium isopropoxide (0.08 mL, 0.26 
mmol, 2.0 eq.) were added and the mixture was left to stir at room temperature overnight. 
NaBH4 (7.40 mg, 0.20 mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was 
further stirred at the same temperature for 30 min. It was then allowed to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. 
To a solution of the crude and DMAP (1.00 mg, 8.19 µmol, 6.3 mol%) in 6 mL DCM, isoxazole-5-
carbonyl chloride (14.0 µL, 0.14 mmol, 1.1 eq.) and TEA (27.0 µL, 0.20 mmol, 1.5 eq.) were 
added. The reaction mixture was allowed to stir at room temperature overnight after which 2 
mL of saturated aqueous Na2CO3 was added. It was diluted with 100 mL DCM, dried over 
Na2SO4 and evaporated in vacuo. Flash chromatography with 1 - 2% MeOH in DCM afforded the 
products 169 [Major diastereomer, 22.0 mg, 0.06 mmol, 50% yield, 63:37 mixture of rotamers, 
Rf = 0.37 (5% MeOH in DCM)] and 170 [Minor diastereomer, 4.00 mg, 0.01 mmol, 9% yield, 
50:50 mixture of rotamers, Rf = 0.41 (5% MeOH in DCM)]. 1H NMR (Major diastereomer, 400 
MHz, CDCl3): δ ppm 8.28 (0.3H, d, J = 1.7, ArH), 8.25 (0.6H, d, J = 1.6, ArH), 6.74 (0.3H, d, J = 1.6, 
ArH), 6.71 (0.6H, d, J = 1.7, ArH), 4.48 (0.6H, tt, 12.4, 3.2, 8-H), 4.02 (1.0H, m, isopropyl CH), 3.82 
(1.4H, m, 3-HA), 3.60 (0.6H, dd, J = 9.7, 6.8, 6a-H), 3.51 (0.3H, dd, J = 9.7, 6.7, 6a-H), 2.98 (1.9H, 
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s, NCH3), 2.91 (1.0H, s, NCH3), 2.85 (1.1H, ddd, J = 15.0, 7.5, 4.0, 3-HB), 2.22 (0.4H, m, 7-HA), 2.15 
(0.6H, m, 7-HA), 1.95 (1.0H, tt, J = 14.5, 3.6, 2-HA), 1.87 – 1.28 (8.0H, m, 1-HA,B; 2-HB; 7-HB; 9-HA,B; 
10-HA,B), 1.15 (2.9H, d, J = 6.8, isopropyl CH3A), 1.12 (3.0H, d, J = 6.9, isopropyl CH3A). 13C NMR 
(Major diastereomer, 100 MHz, CDCl3): δ ppm 164.1 (amide C=O), 163.6 (5-C), 158.3/158.1 (Ar), 
150.3/150.1 (ArH), 107.7/107.4 (ArH), 65.4/65.2 (10a-C), 54.4/54.0 (6a-C), 50.2 (8-C), 44.3 
(isopropyl CH), 44.0 (3-C), 37.6/35.8 (7-C), 34.5/34.4 (1-C), 30.6/28.2 (NCH3), 30.1 (10-C), 26.1 
(9-C), 24.6/22.9 (2-C), 22.6/22.5 (isopropyl CH3A), 19.9 (isopropyl CH3B). IR νmax (neat)/cm-1: 
3104, 2965, 2935 (C-H), 1692, 1643 (C=O), 1576, 1512 (C=C), 1283 (C-O). HRMS (ESI): 
C18H27N4O3 [M + H+]: calculated 347.2078, found 347.2072. 1H NMR (Minor diastereomer, 500 
MHz, CDCl3): δ ppm 8.23 (1.0H, s, ArH), 6.71 (0.5H, s, ArH), 6.54 (0.5H, s, ArH), 4.46 (0.5H, s, 8-
H), 4.23 (0.5H, s, 8-H), 3.94 (0.5H, hept, J = 6.6, isopropyl CH), 3.80 (0.5H, hept, J = 6.7, isopropyl 
CH), 3.74 (0.5H, s, 6a-H), 3.66 (1.4H, s, 6a-H, 3-HA), 3.07 (1.5H, s, NCH3), 2.93 (1.4H, s, NCH3), 
2.88 (0.9H, m, 3-HB), 2.20 – 1.91 (2.2H, m, 2-HA, 7-HA), 1.85 – 1.55 (7.1H, m, 1-HA; 2-HB; 7-HB; 9-
HA,B; 10-HA,B), 1.46 – 1.30 (1.2H, m, 1-HB), 1.21 (1.5H, d, J = 7.0, isopropyl CH3A), 1.18 (1.5H, d, J = 
7.0, isopropyl CH3B), 1.07 (1.5H, d, J = 7.0, isopropyl CH3B), 1.01 (1.5H, d, J = 7.0, isopropyl CH3A). 
13C NMR (Minor diastereomer, 125 MHz, CDCl3): δ ppm 164.5 (amide C=O), 163.0/162.9 (5-C), 
158.9/158.0 (Ar), 150.1/149.9 (ArH), 107.5/105.6 (ArH), 64.8/64.6 (10a-C), 57.5/57.1 (6a-C), 
48.8/48.3 (8-C), 44.5 (isopropyl CH), 44.1 (3-C), 37.4/37.2 (1-C), 33.4/28.3 (NCH3), 30.3/28.5 (7-
C), 27.7/27.5 (10-C), 23.6/23.5 (9-C), 22.9 (2-C), 21.9/21.4 (isopropyl CH3A), 19.3 (isopropyl 
CH3B). IR νmax (neat)/cm-1: 3100, 2927 (C-H), 1686, 1642 (C=O), 1576, 1460 (C=C), 1245 (C-O). 
HRMS (ESI): C18H27N4O3 [M + H+]: calculated 347.2078, found 347.2072. 
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(6aR*,8R*,10aS*)-8-Hydoxy-6-isopropyl-8-phenyloctahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 174 
 
To a solution of the ketone 101a (19.0 mg, 0.08 mmol, 1.0 eq.) in 4 mL THF at -78 °C, 1.9 M PhLi 
in diethyl ether (0.17 mL, 0.32 mmol, 4.0 eq.) was added and stirred at the same temperature 
for 4.5 h after which it was left to warm up to room temperature overnight. 0.10 mL of 
saturated aqueous ammonia and 0.9 mL of saturated aqueous ammonium chloride were added 
and allowed to stir for 20 min. The reaction mixture was diluted with 100 mL EtOAc, dried over 
Na2SO4 and evaporated in vacuo. Flash chromatography with 1 - 3% MeOH in DCM afforded the 
product 174 as a single diastereomer (15.0 mg, 0.05 mmol, 59% yield). Rf = 0.36 (5% MeOH in 
DCM). 1H NMR (500 MHz, CDCl3): δ ppm 7.43 (2H, dt, J = 8.0, 2.0, ArH), 7.33 (2H, tt, J = 7.5, 2.0, 
ArH), 7.24 (1H, tt, J = 7.5, 2.0, ArH), 3.96 (1H, hept, J = 6.9, isopropyl CH), 3.75 (1H, ddd, J = 12.2, 
9.1, 5.7, 3-HA), 3.55 (1H, dd, J = 8.9, 5.6, 6a-H), 2.92 (1H, ddd, J = 12.2, 9.2, 5.6, 3-HB), 2.55 (1H, 
ddd, J = 14.0, 5.5, 1.3, 7-HA), 2.26 (1H, s, 8-COH), 2.11 – 2.03 (1H, m, 9-HA), 1.99 – 1.91 (2H, m, 
7-HB, 9-HB), 1.81 (1H, ddd, J = 14.5, 6.5, 3.5, 10-HA), 1.79 – 1.67 (2H, m, 2-HA,B), 1.46 (1H, ddd, J = 
12.0, 8.0, 3.0, 1-HA), 1.35 (1H, dt, J = 12.0, 10.0, 1-HB), 1.28 (1H, ddd, J = 14.7, 9.2, 3.8, 10-HB), 
1.22 (3H, d, J = 6.8, isopropyl CH3A), 1.18 (3H, d, J = 6.9, isopropyl CH3B). 13C NMR (125 MHz, 
CDCl3): δ ppm 163.4 (5-C), 145.7 (Ar), 128.8 (ArH), 127.6 (ArH), 125.2 (ArH), 72.2 (8-C), 65.4 
(10a-C), 55.6 (6a-C), 44.7 (isopropyl CH), 44.0 (3-C), 42.7 (7-C), 35.2 (1-C), 35.1 (9-C), 28.6 (10-C), 
23.2 (2-C), 22.0 (isopropyl CH3A), 19.9 (isopropyl CH3B). IR νmax (neat)/cm-1: 3388 (O-H), 2964 (C-
H), 1673 (C=O), 1447 (C=C), 1052 (C-O). HRMS (ESI): C19H27N2O2 [M + H+]: calculated 315.2067, 
found 315.2061. 
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(6aR*,8R*,10aS*)-8-Hydroxy-6-(4-methoxyphenyl)octahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 160b 
 
A mixture of the ketone 101b (30.0 mg, 0.10 mmol, 1.0 eq.) and CeCl3.7H2O (44.7 mg, 0.12 
mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH was allowed to stir at –78 °C for 30 min. NaBH4 
(4.54 mg, 0.12 mmol, 1.2 eq.) was then added and the mixture was left to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. 
Flash chromatography with 1 – 3% MeOH in DCM afforded the product 160b as an 85:15 
mixture of diastereomers (29.0 mg, 0.10 mmol, 96% yield). Rf = 0.37 (4% MeOH in DCM). 1H 
NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 7.27 (2H, d, J = 9.0, ArH), 6.80 (2H, d, J = 
9.5, ArH), 3.96 (1H, dd, J = 9.5, 6.2, 6a-H), 3.85 (1H, ddd, J = 12.3, 9.0, 5.5, 3-HA), 3.72 (3H, s, 
ArOCH3), 3.65 (1H, qd, J = 9.0, 4.3, 8-H), 2.99 (1H, ddd, J =12.0, 6.0, 3.0, 3-HB), 2.24 (1H, dddd, J 
= 12.7, 6.2, 4.5, 1.9, 7-HA), 1.91 (1H, dt, J = 14.5, 4.0, 10-HA), 1.89 – 1.73 (6H, m, 1-HA,B; 2-HA,B; 8-
CHOH; 9-HA), 1.49 (1H, tdd, J = 12.9, 9.4, 3.6, 9-HB), 1.41 – 1.36 (1H, m, 7-HB), 1.36 – 1.31 (1H, 
m, 10-HB). Signals for minor isomer visible at: 4.15 (0.17H, dd, J = 6.5, 5.5, 6a-H), 4.03 (0.18H, 
quint, J = 5.5, 8-H). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 162.0 (5-C), 156.4 
(Ar), 131.4 (Ar), 123.4 (ArH), 114.4 (ArH), 69.9 (8-C), 64.4 (10a-C), 58.4 (6a-C), 55.5 (ArOCH3), 
44.3 (3-C), 38.0 (7-C), 35.4 (1-C), 30.5 (9-C), 29.0 (10-C), 23.2 (2-C). Signals for minor isomer 
visible at: 64.6, 64.0, 57.7, 36.3, 33.9, 28.4, 26.6, 23.7. IR νmax (neat)/cm-1: 3398 (O-H), 2934 (C-
H), 1674 (C=O), 1582, 1510, 1462 (C=C), 1244 (C-O). HRMS (ESI): C17H23N2O3 [M + H+]: calculated 
303.1703, found 303.1698. 
 
180 
 
(6aR*,8R*,10aS*)-8-Hydroxy-6-(4-toluenesulfonyl)octahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 160c 
 
A mixture of the ketone 101c (18.0 mg, 0.05 mmol, 1.0 eq.) and CeCl3.7H2O (23.2 mg, 0.06 
mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH was allowed to stir at –78 °C for 30 min. NaBH4 
(2.40 mg, 0.06 mmol, 1.2 eq.) was then added and the mixture was left to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. 
Flash chromatography with 1 – 2% MeOH in DCM afforded the product 160c as a 78:22 mixture 
of diastereomers (15.0 mg, 0.04 mmol, 83% yield). Rf = 0.44 (4% MeOH in DCM). 1H NMR (Major 
diastereomer, 500 MHz, CDCl3): δ ppm 7.87 (2H, d, J = 8.5, ArH), 7.24 (2H, d, J = 8.5, ArH), 4.17 
(1H, dd, J = 10.0, 6.4, 6a-H), 3.74 – 3.61 (2H, m, 8-H, 3-HA), 2.89 (1H, ddd, J =12.1, 9.4, 5.7, 3-HB), 
2.67 (1H, dddd, J = 12.8, 6.4, 4.5, 1.9, 7-HA), 2.35 (3H, s, ArCH3), 1.86 – 1.70 (4H, m, 2-HA,B; 9-HA, 
10-HA), 1.60 – 1.24 (6H, m, 1-HA,B; 7-HB; 8-CHOH; 9-HB; 10-HB). Signals for minor isomer visible 
at: 4.29 (0.29H, dd, J = 8.0, 5.5, 6a-H), 4.09 (0.29H, quint, J = 5.0, 8-H). 13C NMR (Major 
diastereomer, 125 MHz, CDCl3): δ ppm 158.4 (5-C), 144.8 (Ar), 136.2 (Ar), 129.6 (ArH), 128.2 
(ArH), 66.4 (8-C), 65.1 (10a-C), 57.7 (6a-C), 44.0 (3-C), 39.4 (7-C), 34.4 (1-C), 30.0 (9-C), 28.2 (10-
C), 22.9 (2-C), 21.7 (ArCH3). Signals for minor isomer visible at: 158.1, 144.7, 136.1, 129.5, 128.1, 
65.4, 63.9, 57.3, 43.8, 36.7, 35.2, 27.6, 25.3, 23.0. IR νmax (neat)/cm-1: 3388 (O-H), 2922, 2852 
(C-H), 1727 (C=O), 1658, 1597 (C=C), 1161 (C-O). HRMS (ESI): C17H23N2O4S [M + H+]: calculated 
351.1373, found 351.1369. 
 
 
181 
 
(6aR*,8R*,10aS*)-6-(4-Methoxyphenyl)-8-(oxetan-3-ylamino)octahydro-1H,5H-
benzo[d]pyrrolo[1,2-c]imidazol-5-one 175b 
 
To a solution of the ketone 101b (19.0 mg, 0.06 mmol, 1.0 eq.) in 6 mL THF, 3-aminooxetane 
(5.30 µL, 0.08 mmol, 1.2 eq.) and titanium isopropoxide (0.04 mL, 0.13 mmol, 2.0 eq.) were 
added and the mixture was left to stir at room temperature overnight. NaBH4 (2.88 mg, 0.08 
mmol, 1.2 eq.) was added to the reaction mixture at -78 °C and it was stirred at the same 
temperature for 1 h. It was then allowed to warm up to room temperature for 4 h. The reaction 
mixture was evaporated in vacuo. It was then taken up in 1 mL H2O, diluted with 50 mL EtOAc, 
dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 2 - 4% MeOH in DCM 
afforded the product 175b as a single diastereomer (13.0 mg, 0.04 mmol, 58% yield). Rf = 0.37. 
1H NMR (400 MHz, CDCl3): δ ppm 7.27 (2H, d, J = 8.8, ArH), 6.81 (2H, d, J = 9.2, ArH), 4.71 (1H, t, 
J = 6.4, 2’-HA), 4.66 (1H, t, J = 6.8, 2’’-HA), 4.29 (1H, t, J = 6.4, 2’-HB), 4.23 (1H, t, J = 6.4, 2’’-HB), 
3.98 – 3.89 (2H, m, 6a-H, 3’-H), 3.85 (1H, ddd, J = 12.4, 9.0, 5.7, 3-HA), 3.73 (3H, s, ArOCH3), 2.98 
(1H, ddd, J = 12.3, 9.1, 5.9, 3-HB), 2.47 (1H, tt, J = 14.6, 4.0, 8-H), 2.09 (1H, dddd, J =10.1, 5.9, 
4.0, 1.9, 7-HA), 1.95 – 1.73 (3H, m, 2-HA,B; 10-HA), 1.70 – 1.54 (3H, m, 1-HA,B; 9-HA), 1.37 – 1.21 
(2H, m, 9-HB, 10-HB), 1.21 – 1.13 (1H, m, 7-HB). 13C NMR (100 MHz, CDCl3): δ ppm 162.0 (5-C), 
156.4 (Ar), 131.4 (Ar), 123.3 (ArH), 114.4 (ArH), 80.8 (2’-C), 80.3 (2’’-C), 64.7 (10a-C), 58.2 (6a-C), 
55.5 (ArOCH3), 51.8 (8-C), 51.4 (3’-C), 44.3 (3-C), 36.6 (7-C), 35.4 (1-C), 29.8 (10-C), 28.8 (9-C), 
23.2 (2-C). IR νmax (neat)/cm-1: 3296 (N-H), 2933, 2864 (C-H), 1691 (C=O), 1511, 1462, 1395 
(C=C), 1246 (C-O). HRMS (ESI): C20H28N3O3 [M + H+]: calculated 358.2125, found 358.2128. 
 
 
182 
 
(6aR*,8R*,10aS*)-8-(Oxetan-3-ylamino)-6-(4-toluenesulfonyl)octahydro-1H,5H-
benzo[d]pyrrolo[1,2-c]imidazol-5-one 175c 
 
To a solution of the ketone 101c (55.0 mg, 0.16 mmol, 1.0 eq.) in 6 mL THF, 3-aminooxetane 
(22.0 µL, 0.32 mmol, 2.0 eq.) and titanium isopropoxide (0.10 mL, 0.32 mmol, 2.0 eq.) were 
added and the mixture was left to stir at room temperature overnight. NaBH4 (9.10 mg, 0.24 
mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was stirred at the same 
temperature for 2 h. It was then allowed to warm up to room temperature for 1 h. The reaction 
mixture was evaporated in vacuo. It was then taken up in 2 mL H2O, diluted with 100 mL EtOAc, 
dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 - 2% MeOH in DCM 
afforded the product as an 85:15 mixture of diastereomers (26.0 mg, 0.06 mmol, 41% yield). Rf 
= 0.38. 1H NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 7.86 (2H, d, J = 8.5, ArH), 7.25 
(2H, d, J = 8.0, ArH), 4.77 (1H, t, J = 7.0, 2’-HA), 4.74 (1H, t, J = 6.5, 2’’-HA), 4.32 (1H, t, J = 6.5, 2’-
HB), 4.30 (1H, t, J = 6.5, 2’’-HB), 4.15 (1H, dd, J = 10.3, 6.2, 6a-H), 3.97 (1H, quint, J = 6.7, 3’-H), 
3.70 (1H, ddd, J = 12.4, 9.1, 5.6, 3-HA), 2.86 (1H, ddd, J = 12.0, 6.5, 3.0, 3-HB), 2.54 – 2.45 (2H, m, 
7-HA, 8-H), 2.36 (3H, s, ArCH3), 1.81 (1H, dt, J =15.0, 4.0, 10-HA), 1.78 – 1.70 (2H, m, 2-HA,B), 1.59 
– 1.08 (7H, m, 1-HA,B; 7-HB; 8-CHNH; 9-HA,B; 10-HB). Signals for minor isomer visible at: 4.21 
(0.17H, t, J = 6.0, 6a-H), 3.88 (0.18H, quint, J = 6.5, 3’-H), 3.61 (0.20H, dt, J = 12.0, 7.6, 3-H). 13C 
NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 158.5 (5-C), 144.8 (Ar), 136.3 (Ar), 129.6 
(ArH), 128.1 (ArH), 80.6 (2’-C), 80.5 (2’’-C), 65.4 (10a-C), 57.6 (6a-C), 51.6 (8-C), 51.5 (3’-C), 44.0 
(3-C), 38.3 (7-C), 34.4 (1-C), 29.0 (10-C), 28.2 (9-C), 22.8 (2-C), 21.7 (ArCH3). Signals for minor 
isomer visible at: 157.6, 144.7, 136.2, 128.0, 80.3, 80.0, 65.5, 58.5, 51.4, 47.0, 43.7, 35.5, 33.8, 
26.0, 23.2. IR νmax (neat)/cm-1: 3303 (N-H), 2946, 2867 (C-H), 1727 (C=O), 1596, 1494, 1461 
(C=C), 1168 (C-O). HRMS (ESI): C20H28N3O4S [M + H+]: calculated 405.1795, found 405.1802. 
183 
 
(6aR*,8R*,10aS*)-8-[(Furan-2-ylmethyl)amino]-6-(4-methoxyphenyl)octahydro-1H,5H-
benzo[d]pyrrolo[1,2-c]imidazol-5-one 176 
 
To a solution of the ketone 101b (40.0 mg, 0.13 mmol, 1.0 eq.) in 6 mL THF, 3-aminooxetane 
(14.1 µL, 0.16 mmol, 1.2 eq.) and titanium isopropoxide (0.08 mL, 0.27 mmol, 2.0 eq.) were 
added and the mixture was left to stir at room temperature overnight. NaBH4 (6.05 mg, 0.16 
mmol, 1.2 eq.) was added to the reaction mixture at -78 °C and it was stirred at the same 
temperature for 1 h. It was then allowed to warm up to room temperature overnight. The 
reaction mixture was evaporated in vacuo. It was then taken up in 2 mL H2O, diluted with 100 
mL DCM, dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 - 3% MeOH 
in DCM afforded the product 176 as a single diastereomer (45.7 mg, 0.90 mmol, 90% yield). Rf = 
0.42 (5% MeOH in DCM). 1H NMR (500 MHz, CDCl3): δ ppm 7.27 (2H, d, J = 9.0, ArH), 7.25 (1H, 
dd, J = 2.0, 0.5, ArH), 6.80 (2H, d, J = 9.0, ArH), 6.21 (1H, dd, J = 3.0, 2.0, ArH), 6.04 (1H, dd, J = 
3.0, 0.5, ArH), 3.93 (1H, dd, J = 10.1, 6.2, 6a-H), 3.84 (1H, ddd, J = 12.3, 9.0, 5.5, 3-HA), 3.72 (3H, 
s, ArOCH3), 3.67 (2H, d, J = 1.5, ArCH2A,B), 2.98 (1H, ddd, J = 12.3, 9.2, 5.8, 3-HB), 2.51 (1H, qd, J = 
8.6, 4.0, 8-H), 2.17 (1H, dddd, J = 12.5, 8.0, 6.0, 2.0, 7-HA), 1.93 – 1.55 (6H, m, 1-HA,B; 2-HA,B; 9-
HA; 10-HA), 1.37 – 1.25 (3H, m, 8-CHNH, 9-HB; 10-HB), 1.24 – 1.18 (1H, m, 7-HB). 13C NMR (125 
MHz, CDCl3): δ ppm 162.0 (5-C), 156.3 (Ar) 153.8 (Ar), 141.8 (ArH), 131.6 (Ar), 123.4 (ArH), 114.3 
(ArH), 110.1 (ArH), 106.7 (ArH), 64.9 (10a-C), 58.4 (6a-C), 55.5 (ArOCH3), 51.9 (8-C), 44.3 (3-C), 
43.3 (ArCH2) 36.0 (7-C), 35.4 (1-C), 29.7 (10-C), 28.0 (9-C), 23.2 (2-C). IR νmax (neat)/cm-1: 3315 
(N-H), 2925, 2854 (C-H), 1692 (C=O), 1511, 1462, 1394 (C=C), 1245 (C-O). HRMS (ESI): 
C22H28N3O3 [M + H+]: calculated 382.2125, found 382.2125. 
 
 
184 
 
(6aR*,8R*,10aS*)-8-(Azetidin-1-yl)-6-(4-methoxyphenyl)octahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 177 
 
To a solution of the ketone 101b (20.0 mg, 0.07 mmol, 1.0 eq.) in 6 mL THF, azetidine (14.1 µL, 
0.21 mmol, 3.0 eq.) and titanium isopropoxide (0.04 mL, 0.14 mmol, 2.0 eq.) were added and 
the mixture was left to stir at room temperature overnight. Sodium triacetoxyborohydride (29.7 
mg, 0.14 mmol, 2.0 eq.) was added to the reaction mixture at -78 °C and it was allowed to 
warm up to room temperature overnight. 1 mL of saturated aqueous Na2CO3 was added. It was 
then diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. Flash 
chromatography with 3 - 10% MeOH in DCM afforded the product 177 as a 95:5 mixture of 
diastereomers (10.0 mg, 0.03 mmol, 44% yield). Rf = 0.14 (10% MeOH in DCM). 1H NMR ( Major 
diastereomer, 500 MHz, CDCl3): δ ppm 7.27 (2H, d, J = 9.0, ArH), 6.81 (2H, d, J = 9.0, ArH), 3.88 
(1H, dd, J = 10.7, 6.2, 6a-H), 3.83 (1H, ddd, J = 12.0, 7.0, 3.5, 3-HA), 3.72 (3H, s, ArOCH3), 3.09 
(4H, sext, J = 7.0, 2’-HA,B; 2’’-HA,B), 2.97 (1H, ddd, J = 12.3, 9.3, 5.7, 3-HB), 2.06 – 1.98 (2H, m, 7-
HA, 8-H), 1.94 (2H, t, J = 7.0, 3’-HA,B), 1.92 – 1.74 (2H, m, 2-HA,B), 1.66 – 1.49 (3H, m, 9-HA, 10-
HA,B), 1.30 (1H, aptd, J = 11.5, 3.5, 1-HA), 1.23 – 1.12 (2H, m, 1-HB, 9-HB), 1.05 (1H, q, J = 11.0, 7-
HB). Signal for minor isomer visible at: 4.15 (0.05H, t, J = 5.0, 6a-H). 13C NMR (Major 
diastereomer, 125 MHz, CDCl3): δ ppm 162.0 (5-C), 156.4 (Ar) 131.5 (Ar), 123.6 (ArH), 114.3 
(ArH), 64.8 (10a-C), 62.5 (8-C), 58.0 (6a-C), 55.5 (ArOCH3), 53.2 (2’/2’’-C), 44.2 (3-C), 35.3 (10-C), 
32.5 (7-C), 29.2 (1-C), 24.3 (9-C), 23.0 (2-C), 17.0 (3’-C). Signals for minor isomer visible at: δ 
ppm 62.3, 58.3, 32.9, 26.9, 23.7. IR νmax (neat)/cm-1: 2932, 2833 (C-H), 1692 (C=O), 1511, 1462, 
1441 (C=C), 1244 (C-O). HRMS (ESI): C20H28N3O2 [M + H+]: calculated 342.2176, found 342.2173. 
 
185 
 
(6aR*,8R*,10aS*)-8-(Cyclopropylamino)-6-tosyloctahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazol-5-one 178 
 
To a solution of the ketone 101c (24.0 mg, 0.07 mmol, 1.0 eq.) in 4 mL THF, cyclopropylamine 
(24.0 µL, 0.34 mmol, 5.0 eq.) and titanium isopropoxide (0.04 mL, 0.14 mmol, 2.0 eq.) were 
added and the mixture was left to stir at room temperature overnight. NaBH4 (3.90 mg, 0.10 
mmol, 1.5 eq.) was then added to the reaction mixture at -78 °C and it was stirred at the same 
temperature for 30 min. It was then allowed to warm up to room temperature for another 30 
min. The reaction mixture was evaporated in vacuo. It was then taken up in 1 mL H2O, diluted 
with 50 mL DCM, dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 – 
4% MeOH in DCM afforded the product as a diastereomeric mixture in the ratio of 87:13 (12.0 
mg, 0.03 mmol, 45% yield). Rf = 0.41 (6% MeOH in DCM). 1H NMR (Major diastereomer, 500 
MHz, CDCl3): δ ppm 7.86 (2H, d, J = 8.5, ArH), 7.24 (2H, d, J = 9.0, ArH), 4.19 (1H, dd, J = 10.3, 
6.4, 6a-H), 3.70 (1H, ddd, J = 12.5, 8.8, 6.0, 3-HA), 2.91 – 2.73 (3H, m, 3-HB, 7-HA, 8-H), 2.35 (3H, 
s, ArCH3), 2.15 (1H, quint, J = 5.0, cyclopropyl CH), 1.87 – 1.69 (5H, m, 2-HA,B; 9-HA; 10-HA,B), 1.52 
(1H, ddd, J = 12.0, 7.2, 2.6, 1-HA), 1.38 – 1.29 (3H, m, 1-HB, 7-HB, 9-HB), 0.65 – 0.40 (4H, m, 
cyclopropyl CH2A,B,C,D). Signals for minor isomer visible at: 7.91 (0.32H, d, J = 8.5, ArH), 4.36 
(0.15H, t, 5.0, 6a-H). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 157.4 (5-C), 143.8 
(Ar), 135.2 (Ar), 128.5 (ArH), 127.2 (ArH), 64.4 (10a-C), 56.6 (6a-C), 52.5 (8-C), 42.9 (3-C), 35.7 
(7-C), 33.4 (1-C), 27.9 (9-C), 26.8 (cyclopropyl CH), 24.9 (10-C), 21.7 (2-C), 20.6 (ArCH3), 5.0 
(cyclopropyl CH2A,B), 4.6 (cyclopropyl CH2C,D). Signals for minor isomer visible at: 64.0, 57.3, 52.4, 
42.6, 34.6, 29.9, 28.6, 27.7. IR νmax (neat)/cm-1: 3274 (N-H), 2939, 2868 (C-H), 1726 (C=O), 1597, 
1494, 1446 (C=C). HRMS (ESI): C20H28N3O3S [M + H+]: calculated 390.1846, found 390.1852. 
186 
 
(6aR*,8aS*,11aR*,11bS*)-10-Benzyl-8-hydroxy-6-isopropyldecahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindol-5(6H)-one 
 
A mixture of the pyrrolidine 109 (17.0 mg, 0.04 mmol, 1.0 eq.) and CeCl3.7H2O (20.7 mg, 0.06 
mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH was allowed to stir at rt for 30 min. The 
temperature was lowered to –78 °C and NaBH4 (2.10 mg, 0.06 mmol, 1.2 eq.) was then added 
and the mixture was left to warm up to room temperature for another 30 min. The reaction 
mixture was evaporated in vacuo. It was then taken up in 1 mL H2O, diluted with 50 mL EtOAc, 
dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 5 – 10% MeOH in DCM 
afforded the product as a 3:2 mixture of diastereomers (10.0 mg, 0.03 mmol, 58% yield). Rf = 
0.26 (10% MeOH in DCM). 1H NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 3.99 (1H, 
hept, J = 7.0, 17-H). 1H NMR (Minor diastereomer, 500 MHz, CDCl3): δ ppm 3.89 (0.7H, hept, J = 
7.0, 17’-H). 13C NMR (125 MHz, CDCl3): δ ppm 163.2, 161.3, 128.3, 127.9, 127.9, 127.8, 127.5, 
127.4, 127.3, 126.3, 65.6, 65.3, 63.1, 62.1, 59.5, 59.3, 59.1, 57.2, 56.7, 53.9, 53.3, 50.8, 47.3, 
44.3, 43.8, 43.4, 43.3, 41.8, 40.2, 39.4, 37.5, 36.1, 35.7, 33.4, 23.9, 23.7, 21.0, 20.4, 18.2, 17.9. 
IR νmax (neat)/cm-1: 3364 (O-H), 2965, 2923 (C-H), 1671 (C=O), 1453, 1418, 1380 (C=C), 1072 (C-
O). HRMS (ESI): C22H32N3O2 [M + H+]: calculated 370.2489, found 370.2485. 
 
 
 
 
187 
 
(6aR*,8S*,8aS*,11aR*,11bS*)-10-Benzyl-8-hydroxy-6-isopropyldecahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindol-5(6H)-one 180 
 
To a solution of the pyrrolidine 110 (16.0 mg, 0.03 mmol, 1.0 eq.) in 4 mL THF at -78 °C, LS-
selectride (37.0 µL, 0.04 mmol, 1.1 eq.) was added and the mixture was allowed to stir for 1 h. 
The reaction mixture was quenched with 0.01 mL of 10% KOH and 0.01 mL H2O. It was then 
diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. Flash chromatography 
with 3 – 7% MeOH in DCM afforded the product as a single diastereomer (6.0 mg, 0.01 mmol, 
37% yield). Rf = 0.37 (8% MeOH in DCM). 1H NMR (500 MHz, CDCl3): δ ppm 7.89 (2H, d, J = 8.3, 
ArH), 7.29 – 7.20 (7H, m, ArH), 4.09 (1H, dd, J = 10.5, 5.4, 6a-H), 3.77 (1H, dt, J = 9.3, 5.6, 8-H), 
3.70 (1H, d, J = 13.5, ArCH2A), 3.65 (1H, ddd, J = 12.5, 6.0, 2.5, 3-HA), 3.62 (1H, d, J = 13.0, 
ArCH2B), 2.96 – 2.89 (1H, m, 11-HA), 2.88 – 2.78 (3H, m, 3-HB, 9-HA,B), 2.44 – 2.38 (1H, m, 7-HA), 
2.36 (3H, s, ArCH3), 2.32 (1H, dd, J = 10.6, 8.5, 11-HB), 2.18 (1H, ddd, J = 14.0, 9.5, 5.5, 7-HB), 
2.16 – 2.11 (1H, m, 8a-H), 1.95 – 1.88 (2H, m, 11a-H, 8-CHOH), 1.78 (1H, ddd, J = 12.2, 7.5, 4.6, 
1-HA), 1.72 – 1.64 (2H, m, 2-HA,B), 1.55 (1H, ddd, J = 12.0, 4.5, 2.0, 1-HB). 13C NMR (125 MHz, 
CDCl3): δ ppm 157.5 (5-C), 143.9 (Ar), 138.0 (Ar, missing – observed through the HMBC of 
ArCH2A,B), 134.2 (Ar), 128.5 (ArH), 127.8 (ArH), 127.5 (ArH), 127.4 (ArH), 126.4 (ArH), 69.5 (8-C), 
65.8 (11b-C), 61.0 (6a-C), 59.8 (ArCH2), 55.0 (9-C), 53.0 (11-C), 46.9 (11a-C), 46.7 (3-C), 43.4 (8a-
C), 36.3 (7-C), 35.5 (1-C), 23.5 (2-C), 20.7 (ArCH3). IR νmax (neat)/cm-1: 3399 (O-H), 3030, 2923 (C-
H), 1729 (C=O), 1596, 1494, 1453 (C=C), 1169 (C-O). HRMS (ESI): C26H32N3O4S [M + H+]: 
calculated 482.2108, found 482.2108. 
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(6aR*,8S*,8aS*,11aR*,11bS*)-10-Benzyl-8-hydroxy-6-(4-methoxyphenyl)decahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindol-5(6H)-one 182 
(6aR*,8R*,8aS*,11aR*,11bS*)-10-Benzyl-8-hydroxy-6-(4-methoxyphenyl)decahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindol-5(6H)-one 183 
 
To a solution of the pyrrolidine 107 (26.0 mg, 0.06 mmol, 1.0 eq.) in 4 mL THF at -78 °C, LS-
selectride (66.0 µL, 0.07 mmol, 1.1 eq.) was added and the mixture was allowed to stir for 1 h. 
The reaction mixture was quenched with 0.01 mL of 10% KOH and 0.01 mL H2O. It was then 
diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. Flash chromatography 
with 1 – 7% MeOH in DCM afforded the products 182 [7.6 mg, 0.02 mmol, 29% yield, Rf = 0.39 
(7% MeOH in DCM)] and 183 [1.7 mg, 3.92 µmol, 7% yield, Rf = 0.42 (7% MeOH in DCM)]. 1H 
NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 7.36 (2H, d, J = 9.0, ArH), 7.34 – 7.27 (5H, 
m, ArH), 6.88 (2H, d, J = 9.0, ArH), 4.30 (1H, t, J = 5.0, 6a-H), 4.24 (1H, ddd, J = 9.6, 5.2, 2.8, 8-H), 
3.89 (1H, ddd, J = 12.4, 9.4, 5.7, 3-HA), 3.79 (3H, s, ArOCH3), 3.73 (1H, d, J = 13.0, ArCH2A), 3.66 
(1H, d, J = 12.5, ArCH2B), 3.09 (1H, ddd, J = 12.5, 8.0, 3.0, 3-HB), 3.00 – 2.81 (2H, m, 9-HA,B), 2.79 
(1H, t, J = 9.0, 11-HA), 2.66 (1H, q, J = 9.0, 11a-H), 2.63 – 2.57 (1H, m, 8a-H), 2.49 – 2.39 (1H, m, 
11-HB), 2.19 (1H, ddd, J = 14.6, 9.8, 5.1, 7-HA), 1.97 – 1.74 (4H, m, 1-HA; 2-HA,B; 8-CHOH), 1.64 – 
1.62 (1H, m, 7-HB), 1.57 – 1.53 (1H, m, 1-HB). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ 
ppm 168.8 (5-C), 160.4 (Ar), 155.3 (Ar), 130.0 (Ar), 127.7 (ArH), 127.5 (ArH), 126.3 (ArH), 122.2 
(ArH), 113.4 (ArH), 64.6 (11b-C), 64.4 (8-C), 59.2 (ArCH2), 55.4 (11-C), 55.2 (9-C), 55.1 (6a-C), 
54.5 (ArOCH3), 43.2 (3-C), 39.0 (11a-C), 38.3 (8a-C), 32.9 (1-C), 31.1 (7-C), 22.2 (2-C). IR νmax 
(neat)/cm-1: 3399 (O-H), 2927, 2834, 2800 (C-H), 1688 (C=O), 1611, 1584, 1511 (C=C), 1245 (C-
O). HRMS (ESI): C26H32N3O3 [M + H+]: calculated 434.2438, found 434.2438. 1H NMR (Minor 
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diastereomer, 500 MHz, CDCl3): δ ppm 7.29 -7.23 (7H, m, ArH), 6.83 (2H, d, J = 9.0, ArH), 4.12 
(1H, dd, J = 5.8, 3.7, 6a-H), 3.87 (1H, ddd, J = 12.3, 9.2, 5.6, 3-HA), 3.73 (3H, s, ArOCH3), 3.66 – 
3.46 (3H, m, 8-H, ArCH2A,B), 3.10 – 3.01 (2H, m, 3-HB, 9-HA), 2.85 (1H, br.s, 8-CHOH), 2.77 (1H, t, J 
= 9.0, 11-HA), 2.64 (1H, q, J = 9.0, 11a-H), 2.45 (1H, q, J = 9.0, 8a-H), 2.30 – 2.09 (2H, m, 9-HB, 11-
HB), 1.98 – 1.71 (5H, m, 1-HA; 2-HA,B; 7-HA,B;), 1.63 – 1.57 (1H, m, 1-HB). No good 13C NMR due to 
sample size but 183 was prepared for biology. IR νmax (neat)/cm-1: 3358 (O-H), 2956, 2922, 
2851 (C-H), 1684 (C=O), 1585, 1513, 1454 (C=C), 1247 (C-O). HRMS (ESI): C26H31N3O3 [M + H+]: 
calculated 434.2438, found 434.2435. 
 
(6aR*,8S*,8aS*,11aR*,11bS*)-8-Hydroxy-6-(4-methoxyphenyl)decahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindol-5(6H)-one 182 
 
To a solution of the pyrrolidine 107 (52.0 mg, 0.12 mmol, 1.0 eq.) in 4 mL THF at -78 °C, LS-
selectride (0.13 mL, 0.13 mmol, 1.1 eq.) was added and the mixture was allowed to stir for 1 h. 
The reaction mixture was quenched with 0.01 mL of 10% KOH and 0.01 mL H2O. It was then 
diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. To a mixture of the 
crude and Pd(OH)2/C (in excess to form a slurry) under nitrogen, 10 mL of HPLC grade MeOH 
was added gently. The reaction mixture was degassed and hydrogen gas was bubbled through it 
with the aid of a balloon, and this procedure was repeated twice. The mixture was then allowed 
to stir under a balloon of hydrogen overnight at room temperature. The reaction mixture was 
then filtered through a plug of Celite washing with 100 mL MeOH and evaporated in vacuo. 
Flash chromatography eluting with 5 - 15% of saturated NH3/MeOH in DCM afforded the 
product 184 as a single diastereomer (11 mg, 0.03 mmol, 27%). Rf = 0.44 (15% of saturated 
NH3/MeOH in DCM). 1H NMR (500 MHz, CDCl3): δ ppm 7.31 (2H, d, J = 9.0, ArH), 6.82 (2H, d, J = 
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9.5, ArH), 4.26 (1H, t, J = 5.3, 6a-H), 4.19 (1H, dt, J = 8.5, 4.5, 8-H), 3.86 (1H, ddd, J = 12.5, 9.5, 
5.8, 3-HA), 3.73 (3H, s, ArOCH3), 3.27 – 3.13 (3H, m, 9-HA,B; 11-HA), 3.06 (1H, ddd, J = 12.0, 4.5, 
3.0, 3-HB), 2.75 (1H, t, J = 9.8, 11-HB), 2.53 – 2.43 (3H, m, 8a-H, 11a-H, 8-CHOH), 2.05 (1H, ddd, J 
= 14.0, 8.5, 5.5, 7-HA), 1.97 – 1.73 (4H, m, 1-HA; 2-HA,B; 10-NH), 1.61 – 1.53 (2H, m, 1-HB, 7-HB). 
13C NMR (125 MHz, CDCl3): δ ppm 160.5 (5-C), 155.4 (Ar), 130.0 (Ar), 122.3 (ArH), 113.4 (ArH), 
64.6 (8-C), 64.4 (11b-C), 54.8 (6a-C), 54.5 (ArOCH3), 48.7 (9-C), 48.2 (11-C), 43.3 (3-C), 40.4 (8a-
C), 38.8 (11a-C), 32.9 (1-C), 31.4 (7-C), 22.2 (2-C). IR νmax (neat)/cm-1: 3294 (O-H, N-H), 3051, 
2927 (C-H), 1687 (C=O), 1611, 1512, 1461 (C=C), 1246 (C-O). HRMS (ESI): C19H26N3O3 [M + H+]: 
calculated 344.1969, found 344.1964. 
 
(6aR*,8R*,8aR*,11aS*,11bS*)-10-Benzyl-8-hydroxy-6-(4-methoxyphenyl)decahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindol-5(6H)-one 185 
 
To a solution of the pyrrolidine 107 (40.0 mg, 0.09 mmol, 1.0 eq.) in 4 mL THF at -78 °C, LS-
selectride (0.10 mL, 0.10 mmol, 1.1 eq.) was added and the mixture was allowed to stir for 1 h. 
The reaction mixture was quenched with 0.01 mL of 10% KOH and 0.01 mL H2O. It was then 
diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. Flash chromatography 
with 3 – 10% MeOH in DCM afforded the product as a 3:1 mixture of diastereomers (16 mg, 
0.04 mmol, 40% yield). Rf = 0.28 (8% MeOH in DCM). 1H NMR (Major diastereomer, 500 MHz, 
CDCl3): δ ppm 7.34 – 7.20 (5H, m, ArH), 7.13 (2H, d, J = 9.0, ArH), 6.83 (2H, d, J = 9.0, ArH), 4.08 
(1H, t, J = 4.3, 6a-H), 3.71 (3H, s, ArOCH3), 3.65 (1H, d, J = 12.9, ArCH2A) No further 
characterisation because of extensive signal overlap. Signal for minor isomer visible at: 4.13 
(0.35H, t, J = 8.5, 6a-H). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ ppm 161.2, 159.3, 
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155.9, 155.6, 129.6, 127.8, 127.4, 123.3, 113.5, 69.8, 64.6, 62.0, 60.0, 55.9, 54.5, 52.7, 46.9, 
46.8, 43.5, 36.8, 32.8, 24.4. Signals for minor isomer visible at: 155.6, 129.8, 128.0, 127.6, 126.2, 
123.2, 113.3, 64.9, 63.2, 61.4, 59.4, 56.8, 54.5, 53.9, 44.6, 43.7, 40.3, 37.9, 31.1, 24.1. IR νmax 
(neat)/cm-1: 3368 (O-H), 2924 (C-H), 1692 (C=O), 1513, 1454, 1427 (C=C), 1246 (C-O). HRMS 
(ESI): C26H32N3O3 [M + H+]: calculated 434.2438, found 434.2435. 
 
(6aR*,8R*,8aR*,11aS*,11bS*)-8-Hydroxy-6-(4-methoxyphenyl)decahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindol-5(6H)-one 186 
(6aR*,8S*,8aR*,11aS*,11bS*)-8-Hydroxy-6-(4-methoxyphenyl)decahydro-1H-
pyrrolo[1’,2’:3,4]imidazo[4,5-e]isoindol-5(6H)-one 187 
 
To a solution of the pyrrolidine 108 (39.0 mg, 0.09 mmol, 1.0 eq.) in 4 mL THF at -78 °C, LS-
selectride (0.10 mL, 0.10 mmol, 1.1 eq.) was added and allowed to stir for 1 h. The reaction 
mixture was quenched with 0.01 mL of 10% KOH and 0.01 mL H2O. It was then diluted with 100 
mL EtOAc, dried over Na2SO4 and evaporated in vacuo. To a mixture of the crude and Pd(OH)2/C 
(in excess to form a slurry) under nitrogen, 10 mL of HPLC grade MeOH was added gently. The 
reaction mixture was degassed and hydrogen gas was bubbled through it with the aid of a 
balloon, and this procedure was repeated twice. The mixture was then allowed to stir under a 
balloon of hydrogen overnight at room temperature. The reaction mixture was then filtered 
through a plug of Celite washing with 100 mL MeOH and evaporated in vacuo. Flash 
chromatography eluting with 10 - 15% of saturated NH3/MeOH in DCM afforded the products 
186 [9.00 mg, 0.03 mmol, 30% yield, Rf = 0.24 (20% of saturated NH3/MeOH in DCM)] and 187 
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[3.0 mg, 0.01 µmol, 7% yield, Rf = 0.51 (20% of saturated NH3/MeOH in DCM)]. 1H NMR (Major 
diastereomer, 500 MHz, CDCl3): δ ppm 7.17 (2H, d, J = 9.0, ArH), 6.83 (2H, d, J = 9.5, ArH), 4.07 
(1H, t, J = 4.7, 6a-H), 3.81 (1H, ddd, J = 10.5, 7.1, 3.4, 3-HA), 3.72 (3H, s, ArOCH3), 3.70 – 3.66 
(1H, m, 8-H), 3.44 (1H, t, J = 10.0, 9-HA), 3.17 – 3.13 (1H, m, 11-HA), 3.04 – 2.92 (2H, m, 3-HB, 8-
CHOH), 2.81 (1H, t, J = 10.2, 11-HB), 2.70 (1H, t, J = 10.5, 9-HB), 2.21 – 2.13 (1H, m, 8a-H), 2.10 
(1H, ddd, J = 15.2, 6.2, 4.5, 7-HA), 1.89 – 1.76 (6H, m, 1-HA,B; 2-HA,B; 7-HB; 11a-H). 13C NMR 
(Major diastereomer, 125 MHz, CDCl3): δ ppm 161.6 (5-C), 156.0 (Ar), 129.6 (Ar), 123.6 (ArH), 
113.5 (ArH), 68.9 (8-C), 64.8 (11b-C), 62.0 (6a-C), 54.5 (ArOCH3), 49.2 (9-C), 47.7 (11a-C), 47.5 (3-
C), 45.2 (11-C), 45.1 (8a-C), 36.8 (1-C), 33.7 (7-C), 24.2 (2-C). IR νmax (neat)/cm-1: 3294 (O-H, N-
H), 3051, 2927 (C-H), 1687 (C=O), 1611, 1512, 1461 (C=C), 1246 (C-O). HRMS (ESI): C19H26N3O3 
[M + H+]: calculated 344.1969, found 344.1964. 1H NMR (Minor diastereomer, 500 MHz, 
CDCl3): δ ppm 7.31 (2H, d, J = 9.0, ArH), 6.82 (2H, d, J = 9.5, ArH), 4.26 (1H, t, J = 5.3, 6a-H), 4.19 
(1H, dt, J = 8.5, 4.5, 8-H), 3.86 (1H, ddd, J = 12.5, 9.5, 5.8, 3-HA), 3.73 (3H, s, ArOCH3), 3.27 – 3.13 
(3H, m, 9-HA,B; 11-HA), 3.06 (1H, ddd, J = 12.0, 4.5, 3.0, 3-HB), 2.75 (1H, t, J = 9.8, 11-HB), 2.53 – 
2.43 (3H, m, 8a-H, 11a-H, 8-CHOH), 2.05 (1H, ddd, J = 14.0, 8.5, 5.5, 7-HA), 1.97 – 1.73 (4H, m, 1-
HA; 2-HA,B; 10-NH), 1.61 – 1.53 (2H, m, 1-HB, 7-HB). 13C NMR (Minor diastereomer, 125 MHz, 
CDCl3): δ ppm 160.5 (5-C), 155.4 (Ar), 130.0 (Ar), 122.3 (ArH), 113.4 (ArH), 64.6 (8-C), 64.4 (11b-
C), 54.8 (6a-C),  54.5 (ArOCH3), 48.7 (9-C), 48.2 (11-C), 43.3 (3-C), 40.4 (8a-C), 38.8 (11a-C), 32.9 
(1-C), 31.4 (7-C), 22.2 (2-C). IR νmax (neat)/cm-1: 3294 (O-H, N-H), 3051, 2927 (C-H), 1687 (C=O), 
1611, 1512, 1461 (C=C), 1246 (C-O). HRMS (ESI): C19H26N3O3 [M + H+]: calculated 344.1969, 
found 344.1964. 
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(6aR*,8S*,8aR*,9aS*, 9bS*)-8-Hydroxy-6-isopropyloctahydro-1H-cyclopropa[5,6]benzo[1,2-
d]pyrrolo[1,2-c]imidazol-5(6H)-one 133a 
 
A mixture of the cyclopropane scaffold 106a (30.0 mg, 0.12 mmol, 1.0 eq.) and CeCl3.7H2O (54.0 
mg, 0.14 mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH was allowed to stir at –78 °C for 30 min. 
NaBH4 (5.48 mg, 0.14 mmol, 1.2 eq.) was then added and the mixture was left to warm up to 
room temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was 
then taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in 
vacuo. Flash chromatography with 1 – 3% MeOH in DCM afforded the product 133a as a 90:10 
mixture of diastereomers (27.0 mg, 0.11 mmol, 90% yield). Rf = 0.29 (4% MeOH in DCM). 1H 
NMR (Major diastereomer, 500 MHz, CDCl3): 4.19 (1H, dt, J = 12.0, 4.5, 8-H), 3.92 (1H, hept, J = 
7.0, isopropyl CH), 3.73 (1H, ddd, J = 12.0, 6.0, 3.5, 3-HA), 3.27 (1H, dd, J = 12.0, 5.5, 6a-H), 2.95 
(1H, ddd, J =12.1, 8.9, 6.1, 3-HB), 1.99 (1H, dtd, J = 12.5, 5.0, 1.0, 7-HA), 1.88 – 1.81 (2H, m, 2-
HA,B), 1.74 – 1.70 (2H, m, 1-HA, 8-CHOH), 1.45 (1H, tt, J = 8.5, 5.0, 8a-H), 1.37 (1H, q, J = 11.0, 1-
HB), 1.21 – 1.13 (1H, m, 7-HB), 1.12 (3H, d, J = 6.5, isopropyl CH3A), 1.10 (3H, d, J = 7.0, isopropyl 
CH3B), 0.92 (1H, td, 8.9, 5.3, 9a-H), 0.75 (1H, q, J = 5.6, 9-HA), 0.52 (1H, td, J = 8.6, 5.7, 9-HB). 
Signal for minor isomer visible at: 4.33 (0.11H, dt, J = 4.0, 2.0, 8-H). 13C NMR (Major 
diastereomer, 125 MHz, CDCl3): δ ppm 162.9 (5-C), 65.6 (8-C), 64.3 (9b-C), 55.5 (6a-C), 44.2 
(isopropyl CH), 43.7 (3-C), 36.8 (1-C), 34.0 (7-C), 22.8 (2-C), 22.4 (isopropyl CH3A), 19.7 (isopropyl 
CH3B), 19.5 (8a-C), 18.9 (9a-C), 4.4 (9-C). Signals for minor isomer visible at: 65.4, 64.5, 50.0, 
43.6. IR νmax (neat)/cm-1: 3378 (O-H), 2967, 2880 (C-H), 1667 (C=O), 1221 (C-O). HRMS (ESI): 
C14H23N2O2 [M + H+]: calculated 251.1754, found 251.1754. 
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(6aR*,8S*,8aR*,9aS*, 9bS*)-8-Hydroxy-6-(4-methoxyphenyl)octahydro-1H-
cyclopropa[5,6]benzo[1,2-d]pyrrolo[1,2-c]imidazol-5(6H)-one 133b 
 
A mixture of the cyclopropane scaffold 106b (15.0 mg, 0.05 mmol, 1.0 eq.) and CeCl3.7H2O (21.5 
mg, 0.06 mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH was allowed to stir at –78 °C for 30 min. 
NaBH4 (2.20 mg, 0.06 mmol, 1.2 eq.) was then added and the mixture was left to warm up to 
room temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was 
then taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in 
vacuo. Flash chromatography with 1 – 4% MeOH in DCM afforded the product 133b as a single 
diastereomer (14.0 mg, 0.04 mmol, 93% yield). Rf = 0.44 (100% EtOAc). 1H NMR (500 MHz, 
CDCl3): 7.21 (2H, d, J = 9.0, ArH), 6.79 (2H, d, J = 9.0, ArH), 4.19 (1H, dt, J = 12.0, 4.5, 8-H), 3.83 
(1H, ddd, J = 14.5, 8.0, 2.5, 3-HA), 3.78 (1H, dd, J = 12.5, 5.5, 6a-H), 3.71 (3H, s, ArOCH3), 3.08 
(1H, ddd, J =14.5, 8.1, 4.3, 3-HB), 1.99 – 1.96 (1H, m, 7-HA), 1.95 – 1.90 (2H, m, 2-HA,B), 1.90 – 
1.84 (1H, m, 1-HA), 1.63 (1H, q, J = 11.0, 1-HB), 1.53 – 1.47 (2H, m, 8a-H, 8-CHOH), 1.04 (1H, q, J 
= 12.5, 7-HB), 1.01 – 0.96 (1H, m, 9a-H), 0.80 (1H, q, J = 5.6, 9-HA), 0.58 (1H, td, J = 8.7, 5.8, 9-
HB). 13C NMR (125 MHz, CDCl3): δ ppm 160.2 (5-C), 155.5 (Ar), 130.0 (Ar), 122.7 (ArH), 113.3 
(ArH), 64.4 (8-C), 62.6 (9b-C), 57.6 (6a-C), 54.5 (ArOCH3), 42.9 (3-C), 36.3 (1-C), 30.0 (7-C), 21.8 
(2-C), 19.1 (8a-C), 18.`1 (9a-C), 3.5 (9-C). IR νmax (neat)/cm-1: 3401 (O-H), 3010, 2954, 2836 (C-H), 
1677 (C=O), 1611, 1511, 1462 (C=C), 1245 (C-O). HRMS (ESI): C18H23N2O3 [M + H+]: calculated 
315.1703, found 315.1699. 
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(6aR*,8S*,8aR*,9aS*, 9bS*)-6-Isopropyl-8-(methylamino)octahydro-1H-
cyclopropa[5,6]benzo[1,2-d]pyrrolo[1,2-c]imidazol-5(6H)-one 190 
 
To a solution of the cyclopropane scaffold 106a (30.0 mg, 0.12 mmol, 1.0 eq.) in 6 mL THF, 2M 
methylamine in MeOH (0.60 mL, 1.21 mmol, 10.0 eq.) and titanium isopropoxide (0.06 mL, 0.24 
mmol, 2.0 eq.) were added and the mixture was left to stir at room temperature overnight. 
NaBH4 (6.90 mg, 0.18 mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was 
stirred at the same temperature for 30 min. It was then allowed to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. To 
a solution of the crude, isonicotinoyl chloride (23.7 mg, 0.13 mmol, 1.1 eq.) and DMAP (14.8 
mg, 0.12 mmol, 1.0 eq.) in 1 mL DMF; TEA (0.10 mL, 0.73 mmol,6.0 eq.) was added. The 
reaction mixture was stirred at room temperature for 16 h and then heated at 100 °C for 6 h. It 
was then evaporated in vacuo. Flash chromatography with 1 - 3% of saturated NH3/MeOH in 
DCM afforded the intermediate amine 190 as a single diastereomer (8.0 mg, 0.030 mmol, 25% 
yield). Rf = 0.37 (6% of saturated NH3/MeOH in DCM). 1H NMR (500 MHz, CDCl3): δ ppm 3.92 
(1H, hept, J = 7.0, isopropyl CH), 3.77 (1H, ddd, J = 11.5, 6.5, 4.0, 3-HA), 3.24 (1H, dd, J = 12.1, 
5.2, 6a-H), 3.00 (1H, dt, J = 12.5, 4.5, 8-H), 2.94 (1H, ddd, J = 11.0, 6.5, 3.0, 3-HB), 2.47 (3H, s, 
NHCH3), 1.92 (1H, dt, J =12.5, 5.0, 7-HA), 1.87 – 1.80 (2H, m, 2-HA,B), 1.72 (1H, ddd, J = 12.0, 6.5, 
3.5, 1-HA), 1.65 (1H, s, NH), 1.47 – 1.41 (1H, m, 8a-H), 1.38 (1H, q, J = 11.5, 1-HB), 1.12 (3H, d, J = 
7.0, isopropyl CH3A), 1.10 (3H, d, J = 7.0, isopropyl CH3B), 0.97 (1H, q, J = 12.5, 7-HB), 0.85 (1H, td, 
J = 8.9, 5.3, 9a-H), 0.60 (1H, q, J = 5.6, 9-HA), 0.45 (1H, td, J = 8.7, 5.6, 9-HB). 13C NMR (125 MHz, 
CDCl3): δ ppm 161.9 (5-C), 63.8 (9b-C), 54.5 (6a-C), 51.6 (8-C), 43.2 (isopropyl CH), 42.6 (3-C), 
35.9 (1-C), 32.3 (NHCH3), 30.6 (7-C), 21.7 (2-C), 21.4 (isopropyl CH3A), 18.5 (isopropyl CH3A), 16.7 
196 
 
(9a-C), 16.1 (8a-C), 3.1 (9-C). IR νmax (neat)/cm-1: 3302 (N-H), 2964, 2933, 2790 (C-H), 1688 
(C=O). HRMS (ESI): C15H26N3O [M + H+]: calculated 264.2070, found 264.2063. 
 
(6aR*,8S*,8aR*,9aS*, 9bS*)-6-(4-Methoxyphenyl)-8-(methylamino)octahydro-1H-
cyclopropa[5,6]benzo[1,2-d]pyrrolo[1,2-c]imidazol-5(6H)-one 191 
 
To a solution of the cyclopropane scaffold 106b (9.00 mg, 0.03 mmol, 1.0 eq.) in 4 mL THF, 2M 
methylamine in MeOH (0.15 mL, 0.29 mmol, 10.0 eq.) and titanium isopropoxide (0.02 mL, 0.06 
mmol, 2.0 eq.) were added and the mixture was left to stir at room temperature overnight. 
NaBH4 (1.60 mg, 0.04 mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was 
stirred at the same temperature for 30 min. It was then allowed to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. 
Flash chromatography with 2 - 3% of saturated NH3/MeOH in DCM afforded the product 191 as 
a 93:7 mixture of diastereomers (5.3 mg, 0.020 mmol, 56% yield). 1H NMR (Major 
diastereomer, 500 MHz, CDCl3): δ ppm 7.21 (2H, d, J = 9.0, ArH), 6.79 (2H, d, J = 9.0, ArH), 3.85 
– 3.79 (1H, m, 3-HA), 3.77 (1H, dd, J = 12.5, 5.5, 6a-H), 3.71 (3H, s, ArOCH3), 3.12 -3.04 (2H, m, 3-
HB, 8-H), 2.40 (3H, s, NHCH3), 1.97 -1.90 (3H, m, 2-HA,B; 7-HA), 1.89 – 1.84 (1H, m, 1-HA), 1.63 
(1H, q, J = 11.0, 1-HB), 1.52 - 1.44 (1H, m, 8a-H), 0.99 – 0.88 (2H, m, 7-HB, 9a-H), 0.71 (1H, q, J = 
5.5, 9-HA), 0.54 (1H, td, J = 8.7, 5.8, 9-HB). Signal for minor isomer visible at: 3.38 (0.07H, dt, J = 
12.7, 3.7, 3-H). 13C NMR (125 MHz, CDCl3): δ ppm 160.2 (5-C), 155.4 (Ar), 130.1 (Ar), 122.6 
(ArH), 113.3 (ArH), 63.0 (9b-C), 57.4 (6a-C), 54.5 (ArOCH3), 51.6 (8-C), 42.8 (3-C), 36.4 (1-C), 31.7 
(NHCH3), 26.8 (7-C), 21.8 (2-C), 16.8 (9a-C), 16.2 (8a-C), 3.5 (9-C). Signals for minor isomer 
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visible at: 63.5, 62.4, 58.0, 57.6, 51.0, 46.6, 24.6, 15.7, 14.4. IR νmax (neat)/cm-1: 3288 (N-H), 
2953, 2790 (C-H), 1693 (C=O), 1512, 1460, 1427 (C=C), 1246 (C-O). HRMS (ESI): C19H26N3O2 [M + 
H+]: calculated 328.2020, found 328.2016. 
 
N-[(6aR*,8S*,8aR*,9aS*,9bS*)-6-(4-Methoxyphenyl)-5-oxodecahydro-1H-
cyclopropa[5,6]benzo[1,2-c]imidazol-8-yl]methanesulfonamide 192 
 
To a solution of the cyclopropane scaffold 106b (23.0 mg, 0.07 mmol, 1.0 eq.) in 4 mL THF, 2M 
methylamine in MeOH (0.37 mL, 0.74 mmol, 10.0 eq.) and titanium isopropoxide (0.04 mL, 0.15 
mmol, 2.0 eq.) were added and the mixture was left to stir at room temperature overnight. 
NaBH4 (4.18 mg, 0.11 mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was 
stirred at the same temperature for 30 min. It was then allowed to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. To 
a solution of the crude and DMAP (1.00 mg, 0.12 mmol, 0.11 eq.) in 5 mL DCM; 
methanesulfonyl chloride (0.01 mL, 0.13 mmol, 1.7 eq.) and TEA (0.02 mL, 0.14 mmol, 1.9 eq.) 
were added. The reaction mixture was then stirred at room temperature overnight. It was 
evaporated in vacuo. Flash chromatography with 1 - 2% MeOH in DCM afforded the product as 
an 89:11 mixture of diastereomers (21.0 mg, 0.05 mmol, 73% yield). Rf = 0.56 (4% MeOH in 
DCM). 1H NMR (Major diastereomer, 500 MHz, CDCl3): δ ppm 7.20 (2H, d, J = 9.0, ArH), 6.80 
(2H, d, J = 9.0, ArH), 4.45 (1H, dt, J = 13.0, 4.0, 8-H), 3.93 (1H, dd, J = 12.0, 5.0, 6a-H), 3.81 (1H, 
ddd, J = 12.5, 6.5, 3.5, 3-HA), 3.72 (3H, s, ArOCH3), 3.06 (1H, ddd, J = 12.0, 5.5, 3.5, 3-HB), 2.77 
(3H, s, SCH3),  2.74 (3H, s, NCH3), 1.97 -1.88 (3H, m, 1-HA, 2-HA,B), 1.72 (1H, dt, J = 13.0, 4.5, 7-
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HA), 1.69 - 1.60 (1H, m, 1-HB), 1.34 (1H, q, J = 12.5, 7-HB), 1.28 – 1.20 (1H, m, 8a-H), 0.94 – 0.86 
(2H, m, 9-HA, 9a-H), 0.80 -0.73 (1H, m, 9-HB). Signal for minor isomer visible at: 4.36 (0.12H, 
br.d, J = 11.2, 6a-H). 13C NMR (Major diastereomer,125 MHz, CDCl3): δ ppm 159.9 (5-C), 155.6 
(Ar), 129.7 (Ar), 122.6 (ArH), 113.4 (ArH), 62.4 (9b-C), 57.8 (6a-C), 54.5 (ArOCH3), 49.8 (8-C), 42.9 
(3-C), 37.8 (SCH3), 36.5 (1-C), 27.9 (NCH3), 25.4 (7-C), 21.8 (2-C), 15.2 (9a-C), 15.0 (8a-C), 5.4 (9-
C). Signals for minor isomer visible at: 159.6, 155.3, 122.0, 113.3, 73.7, 70.0, 62.3, 55.9, 53.4, 
49.3, 48.7, 27.0, 17.7, 15.8, 6.4. IR νmax (neat)/cm-1: 2956 (C-H), 1695 (C=O), 1512, 1464, 1444 
(C=C), 1246 (C-O). HRMS (ESI): C20H28N3O4S [M + H+]: calculated 406.1795, found 406.1794. 
 
(6aR*,8S*,8aR*,9aS*,9bS*)-6-(4-Methoxyphenyl)-8-(2-oxa-6-azaspiro[3.3]heptan-6-
yl)octahydro-1H-cyclopropa[5,6]benzo[1,2-d]imidazol-5(6H)-one 193 
 
To a solution of the cyclopropane scaffold 106b (17.0 mg, 0.05 mmol, 1.0 eq.) in 4 mL THF, 2-
oxa-6-aza-spiro[3.3]heptane (0.01 mL, 0.11 mmol, 2.0 eq.) and titanium isopropoxide (0.03 mL, 
0.11 mmol, 2.0 eq.) were added and the mixture was left to stir at room temperature overnight. 
NaBH4 (3.10 mg, 0.08 mmol, 1.5 eq.) was added to the reaction mixture at -78 °C and it was 
stirred at the same temperature for 30 min. It was then allowed to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. 
Flash chromatography with 1 - 6% MeOH in DCM afforded the product as an 88:12 mixture of 
diastereomers (19.0 mg, 0.05 mmol, 88% yield). Rf = 0.40 (4% MeOH in DCM). 1H NMR (Major 
diastereomer, 500 MHz, CDCl3): δ ppm 7.19 (2H, d, J = 9.0, ArH), 6.80 (2H, d, J = 9.5, ArH), 4.65 
(4H, s, 1’-HA,B; 3’-HA,B), 3.79 (1H, ddd, J = 12.0, 7.5, 4.5, 3-HA), 3.72 (3H, s, ArOCH3), 3.70 (1H, dd, 
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J = 12.0, 5.0, 6a-H), 3.32 (4H, s, 5’-HA,B; 7’-HA,B), 3.06 (1H, dt, J = 12.2, 7.4, 3-HB), 2.54 (1H, br.d, J 
= 12.5, 8-H), 1.96 -1.82 (3H, m, 1-HA, 2-HA,B), 1.66 – 1.56 (2H, m, 1-HB, 7-HA), 1.23 – 1.17 (1H, m, 
8a-H), 0.87 (1H, td, J = 8.9, 5.3, 9a-H), 0.80 (1H, q, J = 12.5, 7-HB), 0.72 (1H, q, J = 5.5, 9-HA), 0.55 
– 0.48 (1H, m, 9-HB). Signal for minor isomer visible at: 4.15 (0.13H, dd, J = 11.2, 6.0, 6a-H). 13C 
NMR (125 MHz, CDCl3): δ ppm 160.1 (5-C), 155.5 (Ar), 130.1 (Ar), 122.7 (ArH), 113.4 (ArH), 80.2 
(1’ or 3’-C), 63.0 (9b-C), 60.7 (5’ or 7’-C), 59.2 (8-C), 57.1 (6a-C), 54.5 (ArOCH3), 42.8 (3-C), 37.7 
(4’-C), 36.5 (1-C), 24.2 (7-C), 21.8 (2-C), 16.0 (9a-C), 14.0 (8a-C), 3.8 (9-C). Signals for minor 
isomer visible at: 121.8, 113.2, 68.8, 65.3, 62.6, 53.6, 38.6, 36.2, 31.1, 28.6, 21.0, 6.4. IR νmax 
(neat)/cm-1: 2936, 2863, 2833 (C-H), 1692 (C=O), 1583, 1511, 1460 (C=C), 1245 (C-O). HRMS 
(ESI): C23H30N3O3 [M + H+]: calculated 396.2282, found 396.2279. 
 
(6aR*,8S*,8aR*,9aS*, 9bS*)-8-Hydroxy-6-isopropyl-8-(thiophen-2-yl)octahydro-1H-
cyclopropa[5,6]benzo[1,2-d]pyrrolo[1,2-d]imidazol-5(6H)-one 195 
 
To a mixture of the cyclopropane scaffold 106a (20.0 mg, 0.08 mmol, 1.0 eq.) and CeCl3 (39.7 
mg, 0.16 mmol, 2.0 eq.) in 4 mL of anhydrous THF at -78 °C, 1M 2-thienylmagnesium bromide in 
THF (0.16 mL, 0.16 mmol, 2.0 eq.) was added and the mixture was stirred at the same 
temperature for 1 h. The reaction mixture was then allowed to warm up to room temperature 
overnight and it was quenched with 1 mL H2O. It was evaporated in vacuo, taken up in 1 mL 
H2O, diluted with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. Flash 
chromatography eluting with 0.5 – 3% MeOH in DCM afforded the product as a 92:8 mixture of 
diastereomers (13.0 mg, 0.04 mmol, 49% yield). 1H NMR (500 MHz, CDCl3): 7.25 (1H, dd, J = 5.1, 
200 
 
1.1, ArH), 7.09 (1H, dd, J = 3.5, 1.2, ArH), 6.95 (1H, dd, J = 5.1, 3.6, ArH), 3.82 (1H, hept, J = 7.0, 
isopropyl CH), 3.73 (1H, dt, J = 12.1, 7.7, 3-HA), 3.03 – 2.95 (2H, m, 3-HB, 6a-H), 2.22 (1H, s, 8-
CHOH), 2.12 (1H, ddd, J = 13.0, 5.2, 1.4, 7-HA), 1.89 – 1.81 (2H, m, 2-HA,B), 1.80 – 1.71 (2H, m, 1-
HA, 8a-H), 1.63 (1H, t, J = 13.0, 7-HB), 1.28 (1H, q, J = 10.5, 1-HB), 1.22 – 1.19 (1H, m, 9a-H), 1.08 
(3H, d, J = 6.8, isopropyl CH3A), 0.94 (3H, d, J = 6.9, isopropyl CH3B), 0.89 (1H, q, J = 5.7, 9-HA), 
0.74 (1H, td, J = 8.8, 6.0, 9-HB). Signal for minor isomer visible at: 4.07 (0.09H, br.d, J = 3.2, 6a-
H). 13C NMR (125 MHz, CDCl3): δ ppm 161.7 (5-C), 150.3 (Ar), 125.7 (ArH), 124.1 (ArH), 122.7 
(ArH), 70.7 (8-C), 63.0 (9b-C), 53.9 (6a-C), 43.2 (isopropyl CH), 42.6 (3-C), 39.4 (7-C), 35.8 (1-C), 
23.4 (8a-C), 21.8 (2-C), 21.3 (isopropyl CH3A), 19.7 (9a-C), 18.3 (isopropyl CH3B), 5.9 (9-C). Signals 
for minor isomer visible at: 126.5, 123.3, 122.4, 55.3, 43.5, 36.8, 23.1, 21.1, 18.6, 18.5, 16.6. IR 
νmax (neat)/cm-1: 3355 (O-H), 2967, 2934 (C-H), 1673 (C=O), 1458, 1420, 1365 (C=C), 1232 (C-O). 
HRMS (ESI): C18H25N2O2S [M + H+]: calculated 333.1631, found 333.1624. 
 
4-Methyl-N-[(5S*,6R*)-1-methyl-8-oxo-1-azaspiro[4.5]decan-6-yl)benzenesulfonamide 197 
 
To a solution of the alcohol 122 (200 mg, 0.59 mmol, 1.0 eq.) in 10.5 mL of acetone; 3.3 M 
Jones reagent [0.31 mL, 1.18 mmol, 2.0 eq.; freshly prepared by slowly adding 0.26 mL of 98% 
sulfuric acid to a stirring solution of chromium (VI) oxide (300 mg, 3.00 mmol) in 0.60 mL of 
water at 0 °C and then leaving the mixture to warm up to room temperature for 30 min] was 
added and the mixture was stirred at room temperature for 1 h 20 min. 5 mL EtOH was added 
to the reaction mixture and it was basified with excess solid Na2CO3 to pH 8 as monitored by a 
strip of pH paper. It was then extracted with DCM (5 × 30 mL), dried over Na2SO4 and 
evaporated in vacuo. Flash chromatography with 1 – 3% MeOH in DCM afforded the product 
197 (60.0 mg, 0.18 mmol, 30% yield). Rf = 0.44 (10% MeOH in DCM). 1H NMR (500 MHz, CDCl3): 
δ ppm 7.67 (2H, d, J = 8.3, ArH), 7.23 (2H, d, J = 8.0, ArH), 3.23 (1H, dd, J = 9.4, 4.9, 6-H), 2.82 
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(1H, ddd, J = 9.0, 7.0, 3.2, 2-HA), 2.52 (1H, dd, J = 16.2, 9.4, 7-HA), 2.49 – 2.43 (2H, m, 2-HB, 7-HB), 
2.42 – 2.37 (1H, m, 9-HA), 2.36 (3H, s, ArCH3), 2.32 (3H, s, 1-CH3), 2.18 (1H, ddd, J = 16.0, 10.5, 
5.5, 9-HB), 2.07 (1H, ddd, J = 15.5, 10.5, 5.0, 10-HA), 1.69 – 1.61 (1H, m, 3-HA), 1.59 – 1.52 (4H, 
m, 3-HB; 4-HA,B; 10-HB). 13C NMR (125 MHz, CDCl3): δ ppm 207.8 (8-C), 142.4 (Ar), 136.3 (Ar), 
128.6 (ArH), 126.1 (ArH), 62.4 (5-C), 54.4 (2-C), 54.2 (6-C), 43.0 (7-C), 36.9 (1-C), 36.6 (9-C), 35.7 
(4-C), 25.2 (10-C), 21.0 (3-C), 20.5 (ArCH3). IR νmax (neat)/cm-1: 3261 (N-H), 2927, 2796 (C-H), 
1672 (C=O), 1598, 1494, 1449 (C=C). HRMS (ESI): C17H25N2O3S [M + H+]: calculated 337.1580, 
found 337.1576. 
 
4-Methyl-N-[(5S*,6R*,8R*)-1-methyl-8-(oxoetan-3-ylamino)-1-azaspiro[4.5]decan-6-
yl)benzenesulfonamide 199 
 
To a solution of the ketone 197 (15.0 mg, 0.04 mmol, 1.0 eq.) in 3 mL MeOH, 3-aminooxetane 
(0.01 mL, 0.14 mmol, 3.2 eq.) and titanium isopropoxide (0.03 mL, 0.09 mmol, 2.0 eq.) were 
added and the mixture was left to stir at room temperature overnight. NaBH4 (2.60 mg, 0.07 
mmol, 1.5 eq.) was then added to the reaction mixture at -78 °C and it was stirred at the same 
temperature for 30 min. It was then allowed to warm up to room temperature for another 30 
min. The reaction mixture was evaporated in vacuo. It was then taken up in 1 mL H2O, diluted 
with 100 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. Flash chromatography with 1 – 
4% MeOH in DCM afforded the product as a 78:22 mixture of diastereomers (3.60 mg, 0.01 
mmol, 21% yield). Rf = 0.42 (5% MeOH in DCM). 1H NMR (Major diastereomer, 500 MHz, CDCl3): 
δ ppm 7.69 (2H, d, J = 8.3, ArH), 7.21 (2H, d, J = 8.1, ArH), 4.71 (1H, t, J = 6.8, 2’-HA), 4.67 (1H, t, J 
= 6.8, 2’’-HA), 4.31 – 4.26 (2H, m, 2’-HB, 2’’-HB), 3.88 (1H, quint, J = 6.6, 3’-H), 3.06 (1H, dd, J = 
9.5, 4.5, 6-H), 2.83 – 2.76 (1H, m, 2-HA), 2.51 (1H, tt, J = 12.5, 4.0, 8-H), 2.44 (1H, dt, J = 16.0, 
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8.0, 2-HB), 2.35 (3H, s, ArCH3), 2.34 (3H, s, 1-CH3), 2.15 (1H, s, 8-TsNH), 1.95 (1H, ddd, J = 14.6, 
5.7, 4.3, 4-HA), 1.69 – 1.66 (1H, m, 7-HA), 1.54 – 1.49 (4H, m, 3-HA, 9-HA, 10-HA,B), 1.40 – 1.38 
(2H, m, 3-HB, 7-HB), 1.34 – 1.30 (1H, m, 9-HB), 1.16 – 1.08 (1H, m, 4-HB). Signal for minor isomer 
visible at: 3.81 (0.29H, quint, J = 6.5, 3’-H). 13C NMR (Major diastereomer, 125 MHz, CDCl3): δ 
ppm 141.8 (Ar), 137.9 (Ar), 128.4 (ArH), 125.8 (ArH), 79.3 (2’-C), 79.1 (2’’-C), 60.7 (5-C), 56.8 (6-
C), 55.7 (2-C), 51.5 (8-C), 50.2 (3’-C), 39.0 (9-C), 37.8 (1-C), 29.9 (7-C), 29.1 (10-C), 27.5 (4-C), 
22.0 (3-C), 20.5 (ArCH3). Signals for minor isomer visible at: 142.3, 140.2, 128.5, 126.4, 66.1, 
31.1. IR νmax (neat)/cm-1: 3294 (N-H), 2951, 2868, 2794 (C-H), 1598, 1513, 1454 (C=C), 1160 (C-
O). HRMS (ESI): C20H32N3O3S [M + H+]: calculated 394.2159, found 394.2139. 
 
4-Methyl-N-[(5S*,6R*,8R*)-1-methyl-8-(methylamino)-1-azaspiro[4.5]decan-6-
yl)benzenesulfonamide 201 
4-Methyl-N-[(5S*,6R*,8S*)-1-methyl-8-(methylamino)-1-azaspiro[4.5]decan-6-
yl)benzenesulfonamide 202 
 
To a mixture of the ketone 197 (20.0 mg, 0.06 mmol, 1.0 eq.) and STAB (19.1 mg, 0.09 mmol, 
1.5 eq.) in 5 mL THF, 2M MeNH2 in MeOH (0.30 mL, 0.60 mmol, 10.0 eq.) and AcOH (0.01 mL, 
0.17 mmol, 2.9 eq.) were added and the mixture was stirred at room temperature overnight. 2 
mL of a saturated aqueous solution of Na2CO3 was then added to the reaction mixture and it 
was evaporated in vacuo. It was then taken up in 1 mL of H2O, diluted with 100 mL DCM, dried 
over Na2SO4, and evaporated in vacuo. To a solution of the crude in 5 mL THF, cyclopropyl 
isocyanate (0.01 mL, 0.12 mmol, 2.0 eq.) was added and the mixture  was refluxed for 30 h. The 
reaction mixture was evaporated in vacuo. Flash chromatography eluting with 2% MeOH in 
DCM followed by 2 – 10% MeOH in DCM afforded the intermediate amines 201 [7 mg, 0.02 
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mmol, 33% yield, Rf = 0.50 (7% of saturated NH3/MeOH in DCM)] and 202 [4 mg, 0.01 mmol, 
19% yield, Rf = 0.41 (7% of saturated NH3/MeOH in DCM)] as products. 1H NMR (Compound 
201, 500 MHz, CDCl3): δ ppm 7.71 (2H, d, J = 8.0, ArH), 7.20 (2H, d, J = 8.0, ArH), 3.14 (1H, dd, J = 
7.6, 4.2, 6-H), 2.84 – 2.76 (1H, m, 2-HA), 2.52 – 2.40 (2H, m, 2-HB, 8-H), 2.35 (3H, s, ArCH3), 2.33 
(3H, s, 1-CH3), 2.26 (3H, s, NHCH3), 1.96 (1H, ddd, J = 13.0, 8.5, 4.0, 4-HA), 1.68 – 1.35 (10H, m, 
TsNH, NHCH3, 3-HA,B; 7-HA,B; 9-HA,B; 10-HA,B), 1.11 (1H, ddd, J = 13.5, 8.0, 4.5, 4-HB). 13C NMR 
(Compound 201, 125 MHz, CDCl3): δ ppm 142.6 (Ar), 139.0 (Ar), 129.3 (ArH), 127.0 (ArH), 62.2 
(5-C), 58.4 (6-C), 56.3 (2-C), 55.5 (8-C), 38.8 (9-C, missing but observed by HMQC) 38.1 (1-C), 
34.1 (7-C, missing but observed by HMQC), 33.9 (NHCH3), 29.2 (10-C), 25.9 (4-C, missing but 
observed by HMQC), 22.6 (3-C), 21.5 (ArCH3). IR νmax (neat)/cm-1: 3324 (N-H), 2941, 2866, 2791 
(C-H), 1598, 1541, 1450 (C=C). HRMS (ESI): C18H30N3O2S [M + H+]: calculated 352.2053, found 
352.2054. 1H NMR (Compound 202, 500 MHz, CDCl3): δ ppm 7.69 (2H, d, J = 8.5, ArH), 7.23 (2H, 
d, J = 8.0, ArH), 2.69 (1H, t, J = 3.0, 6-H), 2.59 (1H, tt, J = 11.0, 4.0, 8-H), 2.35 (3H, s, ArCH3), 2.33 
– 2.25 (3H, m, 2-HA,B; 7-HA), 2.23 (3H, s, NHCH3), 2.17 (3H, s, 1-CH3), 1.84 – 1.78 (1H, m, 9-HA), 
1.75 – 1.64 (3H, m, 3-HA, 4-HA, 10-HA), 1.42 – 1.28 (4H, m, TsNH, 3-HB, 4-HB, 10-HB), 1.16 (1H, 
ddd, J = 14.0, 11.0, 3.1, 7-HB), 1.00 (1H, qd, J = 13.0, 3.5, 9-HB). 13C NMR (Compound 202, 125 
MHz, CDCl3): δ ppm 143.1 (Ar), 136.6 (Ar), 129.5 (ArH), 127.4 (ArH), 67.1 (5-C), 54.0 (6-C), 53.8 
(2-C), 52.2 (8-C), 38.5 (1-C), 33.6 (NHCH3), 32.42 (7-C), 32.38 (10-C), 30.0 (9-C), 28.4 (4-C), 22.3 
(3-C), 21.5 (ArCH3). IR νmax (neat)/cm-1: 3158 (N-H), 2939, 2862, 2792 (C-H), 1598, 1512, 1447 
(C=C). HRMS (ESI): C18H30N3O2S [M + H+]: calculated 352.2053, found 352.2062. 
 
 
 
 
 
 
204 
 
(7aR*,9R*,11aS*)-7-(4-Methoxyphenyl)-6-oxodecahydro-1H-pyrrolo[1,2-d]quinoxalin-9-yl (2-
fluorophenyl)carbamate 209 
 
To a solution of the alcohol 138 (27.0 mg, 0.09 mmol, 1.0 eq.) in 4 mL DCM, 2-
fluorophenylisocyanate (0.01 mL, 0.09 mmol, 1.1 eq.) and TEA (0.04 mL, 0.26 mmol, 3.0 eq.) 
were added and the mixture was stirred at room temperature overnight. The reaction mixture 
was evaporated in vacuo. Flash chromatography with 1 – 8% MeOH in DCM afforded the 
product 210 (33.0 mg, 0.07 mmol, 86% yield) Rf = 0.29 (4% MeOH in DCM). 1H NMR (500 MHz, 
CDCl3): δ ppm 7.93 (1H, t, J = 8.3, ArH), 7.09 (2H, d, J = 9.0, ArH), 7.07 – 6.99 (2H, m, ArH), 6.96 – 
6.91 (1H, m, ArH), 6.80 (2H, d, J = 9.0, ArH), 6.78 (1H, s, NH), 4.70 (1H, tt, J = 8.2, 4.2, 9-H), 3.85 
(1H, d, J = 18.0, 5-HA), 3.72 (1H, dd, J = 8.5, 5.6, 7a-H), 3.70 (3H, s, ArOCH3), 3.38 (1H, d, J = 18.0, 
5-HB), 3.15 – 3.05 (1H, m, 3-HA), 2.97 – 2.85 (1H, m, 3-HB), 2.20 – 2.00 (2H, m, 1-HA, 8-HA), 2.00 – 
1.67 (7H, m,2-HA,B; 8-HB; 10-HA,B; 11-HA,B), 1.30 – 1.20 (1H, m, 1-HB). 13C NMR (125 MHz, CDCl3): 
δ ppm 168.3 (6-C), 157.3 (carbamate C=O), 151.5 (Ar), 151.2 (d, J = 242, ArF), 132.3 (Ar), 126.6 
(ArH), 125.2 (d, J =9.75, Ar), 123.6 (d, J = 3.63, ArH), 122.5 (d, J = 6.38, ArH), 119.2 (ArH), 113.9 
(d, J = 18.8, ArH), 113.5 (ArH), 69.6 (9-C), 61.0 (11a-C), 60.0 (7a-C), 54.4 (ArOCH3), 54.3 (3-C), 
53.0 (5-C), 35.2 (10-C), 32.5 (8-C), 28.2 (1-C), 26.4 (11-C), 21.6 (2-C). IR νmax (neat)/cm-1: 3253 (N-
H); 2955, 2836 (C-H); 1723, 1656 (C=O); 1619, 1536, 1510, 1456 (C=C); 1229 (C-O). HRMS (ESI): 
C25H29FN3O4 [M + H+]: calculated 454.2137, found 454.2145. 
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(7aR*,9R*,11aS*)-7-(4-Methoxyphenyl)-6-oxodecahydro-1H-pyrrolo[1,2-d]quinoxalin-9-yl (3-
fluorophenyl)carbamate 210 
 
To a solution of the alcohol 138 (22.0 mg, 0.07 mmol, 1.0 eq.) in 5 mL DCM, 3-
fluorophenylisocyanate (0.01 mL, 0.09 mmol, 1.3 eq.) and TEA (0.03 mL, 0.21 mmol, 3.0 eq.) 
were added and the mixture was stirred at room temperature overnight. The reaction mixture 
was evaporated in vacuo. Flash chromatography with 1 – 4% MeOH in DCM afforded the 
product 209 (23.0 mg, 0.05 mmol, 73% yield). Rf = 0.37 (4% MeOH in DCM). 1H NMR (500 MHz, 
CDCl3): δ ppm 7.33 (1H, br.s, ArH), 7.15 (1H, dt, J = 11.0, 2.3, ArH), 7.10 (2H, d, J = 9.5, ArH), 6.86 
(1H, dd, J = 8.0, 1.5, ArH), 6.76 (2H, d, J = 9.0, ArH), 6.65 (1H, td, J = 8.3, 2.4, ArH), 4.73 (1H, tt, J 
= 7.0, 4.0, 9-H), 3.86 (1H, d, J = 18.0, 5-HA), 3.75 (1H, dd, J = 8.0, 3.8, 7a-H), 3.66 (3H, s, ArOCH3), 
3.43 (1H, d, J = 17.5, 5-HB), 3.14 – 3.04 (1H, m, 3-HA), 3.00 – 2.90 (1H, m, 3-HB), 2.14 – 2.08 (1H, 
m, 11-HA), 2.07 – 1.84 (8H, m, 1-HA,B; 2-HA,B; 8-HA,B; 10-HA,B), 1.28 (1H, ddd, J = 14.0, 8.5, 3.5, 11-
HB). 13C NMR (125 MHz, CDCl3): δ ppm 167.8 (6-C), 162.1 (d, J = 243, ArF), 157.4 (Ar), 151.6 
(carbamate C=O), 138.7 (d, J = 11.0, Ar), 113.9 (Ar), 129.0 (d, J = 1.88, ArH), 126.8 (ArH), 113.4 
(ArH), 112.9 (ArH), 108.8 (d, J = 21.3, ArH), 105.0 (d, J = 26.4, ArH), 68.7 (9-C), 61.0 (11a-C), 59.5 
(7a-C), 54.3 (ArOCH3), 53.4 (3-C), 52.3 (5-C), 34.9 (10-C), 31.9 (8-C), 26.5 (1-C, 11-C, confirmed 
from HMQC), 21.3 (2-C). IR νmax (neat)/cm-1: 3268 (N-H); 2952 (C-H); 1723, 1642 (C=O); 1605, 
1544, 1510 (C=C); 1223 (C-O). HRMS (ESI): C25H29FN3O4 [M + H+]: calculated 454.2137, found 
454.2141. 
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(6aR*,8R*,10aS*)-8-[(tert-Butyldimethylsilyl)oxy]-6-(4-methoxyphenyl)octahydro-1H,5H-
benzo[d]pyrrolo[1,2-c]imidazole-5-one 213 
 
A mixture of the ketone 101b (36.0 mg, 0.12 mmol, 1.0 eq.) and CeCl3.7H2O (53.7 mg, 0.14 
mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH was allowed to stir at –78 °C for 30 min. NaBH4 (5.4 
mg, 0.14 mmol, 1.2 eq.) was then added and the mixture was left to warm up to room 
temperature for another 30 min. The reaction mixture was evaporated in vacuo. It was then 
taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over Na2SO4 and evaporated in vacuo. To 
a solution of the crude in 2 mL of anhydrous DCM; 2,6-lutidine (0.03 mL, 0.24 mmol, 2.0 eq.) 
and TBSOTf (0.04 mL, 0.18 mmol, 1.5 eq.) were added. The mixture was allowed to stir at room 
temperature overnight and evaporated in vacuo. Flash chromatography with 0 – 30% EtOAc in 
hexane afforded the product as an 81:19 mixture of diastereomers (32.0 mg, 0.23 mmol, 64% 
yield); Rf = 0.28 (30% EtOAc in hexane). 1H NMR (Major diastereomer, 500 MHz, MeOD): δ ppm 
7.36 (2H, d, J = 9.0, ArH), 6.89 (2H, d, J = 9.0, ArH), 4.00 (1H, dd, J = 10.1, 6.3, 6a-H), 3.93 (1H, 
ddd, J = 12.0, 7.0, 3.5, 3-HA), 3.80 (3H, s, ArOCH3), 3.68 (1H, tt, J = 10.0, 4.5, 8-H), 3.06 (1H, ddd, 
J = 12.5, 6.5, 3.0, 3-HB), 2.20 (1H, dddd, J = 12.9, 6.3, 4.6, 1.8, 7-HA), 2.02 – 1.88 (3H, m, 2-HA,B; 
10-HA), 1.76 – 1.62 (4H, m, 1-HA,B; 9-HA,B), 1.47 (1H, dt, J = 13.2, 10.4, 7-HB), 1.39 (1H, ddd, J = 
14.8, 12.3, 3.8, 10-HB), 0.84 (9H, s, tert-butyl CH3), 0.03 (3H, s, SiCH3A), 0.00 (3H, s, SiCH3B). 
Signal for minor isomer visible at: 4.20 (0.24H, dd, J = 7.6, 5.5, 6a-H). 13C NMR (Major 
diastereomer, 125 MHz, MeOD): δ ppm 161.0 (5-C), 155.2 (Ar), 130.6 (Ar), 122.3 (ArH), 113.2 
(ArH), 66.6 (8-C), 63.4 (10a-C), 57.3 (6a-C), 54.4 (ArOCH3), 43.2 (3-C), 37.6 (7-C), 34.3 (9-C), 29.9 
(1-C), 28.1 (10-C), 24.8 (tert-butyl CH3), 22.1 (2-C), 17.0 (tert-butyl C), -5.6 (SiCH3A), -5.7 (SiCH3B). 
Signals for minor isomer visible at: 122.0, 63.7, 63.6, 56.2, 35.1, 34.1, 27.9, 25.3, 22.5. IR νmax 
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(neat)/cm-1: 2951, 2930, 2855 (C-H); 1698 (C=O); 1513, 1462, 1394 (C=C); 1247 (C-O). HRMS 
(ESI): C23H37N2O3Si [M + H+]: calculated 417.2568, found 417.2567. 
 
(6aR*,8R*,10aS*)-8-[(tert-Butyldimethylsilyl)oxy]octahydro-1H,5H-benzo[d]pyrrolo[1,2-
c]imidazole-5-one 214 
 
To a mixure of the urea 213 (20.0 mg, 0.05 mmol, 1.0 eq.) and CAN (105 mg, 0.19, 4.0 eq.) in 1.0 
mL of HPLC grade MeCN, 0.50 mL of H2O was added and the mixture was left to stir for 5 min. 
The reaction mixture was extracted with EtOAc (5 × 20 mL). The combined organic layer was 
washed with brine, dried over Na2SO4, and evaporated in vacuo. Flash chromatography with 0.5 
– 10% MeOH in DCM afforded the product as an 80:20 mixture of diastereomers. (4.00 mg, 0.01 
mmol, 27% yield). Rf = 0.35 (1% MeOH in DCM). 1H NMR (Major diastereomer, 500 MHz, 
MeOD): δ ppm 4.68 (1H, s, NH), 3.73 (1H, ddd, J = 12.3, 9.1, 5.4, 3-HA), 3.64 – 3.57 (1H, m, 8-H), 
3.42 (1H, dd, J = 10.0, 6.0, 6a-H), 2.93 (1H, ddd, J = 12.0, 6.5, 3.0, 3-HB), 2.12 (1H, dddd, J = 11.0, 
6.0, 4.5, 2.0, 7-HA), 1.89 – 1.80 (3H, m, 1-HA, 2-HA,B), 1.66 – 1.61 (2H, m, 9-HA, 10-HA), 1.52 – 1.45 
(3H, m, 7-HB, 9-HB, 10-HB), 1.27 (1H, ddd, J = 14.7, 12.2, 3.9, 1-HB), 0.82 (9H, s, tert-butyl CH3), 
0.00 (3H, s, SiCH3A), -0.003 (3H, s, SiCH3B). Signal for minor isomer visible at: 4.04 (0.25H, ddd, J 
= 11.0, 5.5, 3.0, 3-H). 13C NMR (Major diastereomer, 125 MHz, MeOD): δ ppm 164.6 (5-C), 66.1 
(8-C), 66.0 (10a-C), 51.7 (6a-C), 42.9 (3-C), 40.7 (7-C), 33.6 (9-C), 29.9 (10-C), 28.3 (1-C), 24.8 
(tert-butyl CH3), 22.6 (2-C), 17.1 (tert-butyl C), -5.6 (SiCH3A), -5.7 (SiCH3B). Signals for minor 
isomer visible at: 67.4, 67.1, 52.2, 38.7, 35.4, 29.0, 26.5, 24.1, -4.8, -4.9. IR νmax (neat)/cm-1: 
3274 (N-H); 2951, 2929, 2856 (C-H); 1699 (C=O); 1086 (C-O). HRMS (ESI): C16H31N2O2Si [M + H+]: 
calculated 311.2149, found 311.2145. 
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(6aR*,8R*,10aS*)-8-Hydroxyoctahydro-1H,5H-benzo[d]pyrrolo[1,2-c]imidazole-5-one 215 
 
To a mixture of the ketone 104 (14.0 mg, 0.07 mmol, 1.0 eq.) and CeCl3.7H2O (32.2 mg, 0.09 
mmol, 1.2 eq.) in 3 mL of HPLC grade MeOH at –78 °C, NaBH4 (3.30 mg, 0.09 mmol, 1.2 eq.) was 
added and the reaction mixture was stirred at the same temperature for 30 min. It was then 
allowed to warm up to room temperature for another 30 min. The reaction mixture was 
evaporated in vacuo. It was then taken up in 1 mL H2O, diluted with 50 mL EtOAc, dried over 
Na2SO4 and evaporated in vacuo. Flash chromatography with 3 – 8% MeOH in DCM afforded 
the product as an 85:15 mixture of diastereomers (12.0 mg, 0.06 mmol, 85% yield). Rf = 0.34 
(8% MeOH in DCM). 1H NMR (Major diastereomer, 500 MHz, MeOD): δ ppm 4.81 (1H, s, NH), 
3.73 – 3.65 (2H, m, 3-HA, 8-H), 3.49 (1H, dd, J = 8.5, 6.5, 6a-H), 2.94 (1H, ddd, J = 12.0, 8.8, 6.2, 
3-HB), 2.17 (1H, dt, J = 12.5, 6.5, 7-HA), 1.90 – 1.80 (4H, m, 1-HA; 2-HA,B; 9-HA), 1.66 – 1.61 (1H, 
m, 10-HA), 1.56 – 1.45 (3H, m, 1-HB, 7-HB, 10-HB), 1.31 (1H, qd, J = 11.5, 3.5, 9-HB), 1.18 (1H, s, 8-
CHOH). Signal for minor isomer visible at: 4.12 (0.18H, quint, J = 5.0, 8-H). 13C NMR (Major 
diastereomer, 125 MHz, MeOD): δ ppm 164.5 (5-C), 66.0 (10a-C), 65.4 (8-C), 52.5 (6a-C), 42.9 
(3-C), 39.0 (7-C), 34.0 (10-C), 29.3 (1-C), 28.2 (9-C), 23.0 (2-C). Signals for minor isomer visible at: 
63.1, 52.3, 36.3, 34.7, 27.6, 26.0, 23.3. IR νmax (neat)/cm-1: 3298 (N-H, O-H); 2931, 2855 (C-H); 
1689 (C=O); 1049 (C-O). HRMS (ESI): C10H17N2O2 [M + H+]: calculated 197.1285, found 197.1278. 
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